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ABSTRACT 
PART I: COMPOSITE NANOFORMULATION OF MACROMOLECULES FOR 
BACK OF THE EYE DISEASES 
Pentablock (PB) copolymers have been successfully synthesized for long term delivery in 
the treatment of posterior segment ocular diseases. PB copolymers are comprised of FDA 
approved biodegradable polymer such as polyethylene glycol (PEG), polycaprolactone 
(PCL), polylactic acid (PLA) and polyglycolic acid (PGA). PB copolymers of different 
composition, molecular weights and block arrangements were synthesized by ring 
opening bulk copolymerization method and analyzed by NMR, GPC FT-IR and XRD 
analyses. Further, these PB copolymers have been utilized to develop the macromolecule-
embedded thermosensitive gels or nanoparticles (NPs) or composite nanoformulation 
(NPs suspended in gel) for a sustained drug delivery. PBG (PLA-PCL-PEG-PCL-PLA; 
PBG-1 and PEG-PCL-PLA-PCL-PEG; PBG-2) gelling copolymers were evaluated for 
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their utility as injectable in situ hydrogel forming depot for controlled ocular delivery of 
macromolecules (proteins, peptides and Fab fragments). A wide variety of 
macromolecules (Octreotide, IgG-Fab, IgG-Fab‘ and IgG) with molecular weights 
ranging from 1 - 150 kDa have been used for this purpose. The kinematic viscosity of the 
copolymer solution was studied at different polymer concentration with different block 
arrangment. It was observed that viscosity of hydrophobic polymer (PBG-1) was 
considerably higher relative to PBG-2 copolymer. Sol-gel transition curves for PBG-1 
and PBG-2 copolymer was compared to understand the effect of hydrophobicity and 
effect of block arrangement on the sol-gel behavior of block copolymers. Sol-gel 
transition and rheology revealed that PBG block arrangements were easy to handle at 
room temperature and easy to administer through small gauge needle. Cell viability and 
cytotoxicity studies confirmed that PBG copolymers are superior biomaterials for ocular 
delivery. It was observed that the in vitro release pattern was depended on the molecular 
weight of the macromolecules and amphiphilic nature of the PBG copolymers. It is 
anticipated that much longer release can be obtained by altering block composition or 
change in hydrophobicity and/or hydrophilicity of the gelling polymer. The in vitro 
release pattern was in conjunction with the facts that amorphous and hydrophilic polymer 
degrades fast. CD spectroscopy results revealed no changes in the secondary structure of 
macromoelcules (studied for IgG as a model macromoelcule). The in vitro degradation 
study for PBG-2 copolymer was performed under four different conditions; (i) in pH 7.4 
PBS at 37°C, (ii) in presence of enzymes acetylcholinesterase (14.7 mU/mL) and 
butyrylcholinesterase (5.9 mU/mL), (iii) in pH 9.0 borate buffer at 37°C and (iv) in pH 
7.4 PBS at 40°C. The samples were analyzed by XRD and GPC to determine the weight 
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loss of the PBG-2 copolymer. It was observed that accelerated conditions such as pH 9.0 
(37°C) and high temperature (40°C) exhibited weight loss of ~45% and ~40%, 
respectively which were significantly higher than weight loss observed under normal 
condition (pH - 7.4, 37°C) i.e., ~35%. No significant effect of enzymes was observed on 
polymer degradation. Besides, in vivo assessment of PBG-2 copolymer provided a safe 
environment and was well tolerated in the rabbit eyes analyzed up to 33 weeks.   
Further, PB-NPs were formulated with different molecular weights of PB 
copolymer (PCL-PLA-PEG-PLA-PCL) to study the release pattern of macromolecules 
(lysozyme, IgG-Fab, ranibizumab and IgG). The macromolecules encapsulated in PB-
NPs were prepared by W1/O/W2 double emulsion solvent evaporation method. The 
macromolecules were optimized to achieve a high drug loading (~17%) and entrapment 
efficiency (~66%) in the NPs. PB-NPs alone exhibited significant burst release in the first 
few days however, the dual approach i.e., composite nanoformulations (macromolecules-
encapsulated PB-NPs dispersed in thermosensitive gel) eliminated the burst release effect 
and exhibited nearly zero-order protein release for significantly longer durations (~3-6 
months). In order to compare the duration of in vitro release, PB copolymers with 
different molecular weight have been studied. The enzymatic activity of lysozyme with 
its respective enzymatic assays was used to investigate the activity of released 
macromolecule. Anti-VEGF activity of ranibizumab released from composite 
nanoformulation was analyzed by indirect ELISA. It was observed that macromolecules 
maintained their structural integrity and bioactivity during the preparation of the 
nanoformulation and also during the drug release process. The mean particle size 
distribution of NPs in PBS was found in the range of ~150 nm and was consistent 
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throughout the study in different media analyzed up to 10 days. The results confirmed the 
higher stability of NPs in different cell culture media. In vitro cell viability, cytotoxicity 
and biocompatibility studies performed on various ocular cells, confirmed the safety of 
PB copolymers for ocular applications.  
 
PART II: DEXAMETHASONE NANOPARTICLE TO DEVELOP AN IN VITRO 
MODEL FOR GLAUCOMA   
The aim of the present study was to examine the elevation of myocillin (MYOC); 
one of the extra cellular matrix related proteins whose expression is altered in presence of 
long-term treatment of Glucocorticoids. In this study, dexamethasone (DEX) was 
selected as model drug. The different strains of primary cultures of human trabecular 
meshwork (HTM) cell line (HTM120, 136, 126, 134 and 141) were used to develop the 
in vitro cell culture model of glaucoma. To obtain a long-term delivery of DEX, 
pentablock (PB) copolymer was synthesize using the ring opening bulk copolymerization 
method and characterized by NMR, GPC and XRD analyses. PB copolymer was used to 
formulate the DEX encapsulated nanoparticles (NPs) with entrapment efficiency of ~63% 
and drug loading of ~11% w/w. The mean particle size distribution of NPs was analyzed 
by NTA in PBS was found in the range of ~109 nm. The biomaterial was further studied 
for in vitro cytotoxicity and cell viability. Results showed that neither cell viability nor 
cytotoxicity was affected up to 12 weeks of treatment. DEX-PB-NPs or control NPs 
treatments were given to the HTM cells and cell culture supernatant was 
collected/replaced with fresh 1% DMEM once/week for 12 weeks. DEX or vehicle was 
used as controls to compare MYOC secretion levels by Western blot (WB). Four HTM 
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cell strains tested showed similar MYOC secretion patterns, having robust responses for 
the entire monitoring period.  In contrast, one cell strain responded only for a few weeks. 
Quantitation of WB data from five HTM cell strains showed that MYOC increased by 5.2 
± 1.3, 7.4 ± 4.3, and 2.8 ± 1.1 fold at 4, 8, and 12 weeks in the presence of DEX-PB-NPs 
compared to 9.2 ± 3.8, 2.2 ± 0.5, and 1.5 ± 0.3 fold at 4, 8, and 12 weeks in control DEX 
treatment group. Based on the decline in MYOC levels after withdrawal of DEX from 
control wells, results indicate that DEX-PB-NPs released biologically active DEX for at 
least 10 weeks. By comparison, MYOC levels in vehicle treated control wells remained 
unchanged. Moreover, PB copolymers were biocompatible and didn‘t modifying the 
cellular functions of HTM cells. Although the PB copolymers did not show any sign of 
cytotoxicity to HTM cells in this long-term study, they did modify HTM cell 
morphology. HTM cell elongation was present in all cell strains after both Con-NPs and 
DEX-PB-NPs treatment. Morphological modification of HTM cells by the polymers may 
accompany functional changes those were not measured in the present study, but needs 
further investigations. Meanwhile, this study provides the evidence that our in vitro 
system developed in this study is a valuable tool for analyzing the safety of the polymers 
and biological effects of steroids released from the polymers. In addition, histological 
observations in the C57BL/6 mice showed normal phenomenon in ocular tissue 
morphology.  
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CHAPTER 1  
LITERATURE REVIEW 
(1), (2)
     
 
Introduction 
Ocular diseases pose a major problem and affect quality of life. It is estimated that 
285 million people worldwide are visually impaired, and 39 million are blind 
(http://www.who.int/mediacentre/factsheets/fs282/en/).  In the United States itself, about 
3.4 million people over the age of 40 are blind or have significant visual impairment 
(https://www.cdc.gov/visionhealth/data/national.htm). Normal aging of the eye is 
characterized by a continuous loss of Photoreceptor (PRs), Bruch's membrane (BM) 
thickening, choroidal thinning, scleral stiffening, vitreous degradation and accumulation 
of debris. Among these, age-related macular degeneration (AMD), diabetic retinopathy 
(DR), macular edema (ME), diabetic macular edema (DME), and glaucoma are the 
leading causes of vision loss.   
 
Age-related macular degeneration (AMD)  
Macular degeneration occurs when the small area in the retina (macula) 
deteriorates, and develops as person ages, hence referred to as AMD. It is a degenerative 
disease that damages the retinal pigment epithelium (RPE) and PRs. A total of 8.7% of 
the world population has AMD, and it is projected that the number of people with the 
disease will be at about 196 million in 2020, and 288 million in 2040 (3). About 1.75 
million Americans are affected by AMD, and this number is expected to increase about 3 
million by 2020 (3). As the disease progresses, AMD can be classified into dry and wet 
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forms. Based on the absence or presence of blood vessel growth progressing from the 
choroidal side towards the retina, the disease is broadly subdivided into non-neovascular 
(NNV) and neovascular (NV) AMD (wet AMD). In wet AMD, new blood vessels from 
the choroid may leak, resulting in ME and hemorrhage. Wet AMD accounts for about 
20% of patients, but 90% of AMD patients suffer from severe visual loss. The risk of 
getting advanced AMD increases from 2% for those ages 50-59 years, to nearly 30% for 
those over the age of 75 years (4). Multiple factors such as oxidative stress, lipid 
metabolism, immune system activation, and angiogenesis (5) play a key role in AMD 
pathogenesis. The protein aggregation and immunologic processes are also involved, 
including the inflammatory molecules in BM, recruitment of macrophages/dendritic cells, 
and complement system components in the macula area. In addition, smoking is a major 
oxidative stress factor in the progress of AMD (6). The detailed effects of these factors 
can be explored elsewhere (7, 8).  
RPE performs a variety of complex processes that are essential for proper visual 
functions. RPE plays crucial roles in the retina including formation of blood retinal 
barrier (BRB) by tight junctions, transportation of nutrients from blood to PRs, light 
absorption, secretion of cytokines/growth factors and phagocytosis of outer segments of 
PRs (6, 9). AMD starts with the deposit of drusen between RPE and basal membrane 
(BM) and progresses with the death of RPE and PRs degeneration and eventually loss of 
central vision (6). BM is a thin (2–4 μm) connective tissue located between the RPE and 
the choriocapillaris. It functions as a physical as well as biochemical barrier for normal 
physiological and pathological processes. The primary functions of BM include 
regulating the diffusion of biomolecules, minerals, antioxidants, etc., between the choroid 
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and RPE. BM also provides physical support for migration and differentiation of RPE for 
RPE cell adhesion. 
In case of dry AMD, the gradual deterioration of RPE leads to subsequent PR loss 
at the macula. The vascular endothelial growth factor (VEGF) produced by the basal side 
of the RPE cells is essential to the health of the choriocapillaris. In wet AMD, RPE 
produces excessive amounts of VEGF, and this contributes to the breakdown of the BRB 
and sprouting of fragile blood vessels from the choroid through BM into retina in a 
process called NV. Leakage of blood from these abnormal vessels causes an acute loss of 
vision. Additionally, pigment epithelium-derived factor (PEDF) and transforming growth 
factor-beta (TGF-β), secreted by the apical side of RPE cells provide an 
immunosuppressive microenvironment in the sub-retinal space (6, 10). 
Over the past decade, interesting progress has been made in the treatment of 
AMD owing to an increased understanding of the mechanisms of ocular angiogenesis and 
factors affecting (11). There are several factors involved in angiogenesis in the eye, with 
VEGF playing a central role (12). VEGF-A is a 46 kDa glycoprotein produced by ocular 
cells in response to oxidative stress and has multiple functions in the eye. It stimulates 
endothelial cell growth, promotes vascular permeability and induces dissociation of tight 
junction components. Out of various isoforms of VEGF in humans, VEGF165 is 
primarily responsible for angiogenesis. Currently, no therapy exists for dry AMD and 
only dietary modifications such as increase in intake of antioxidants, cessation of 
smoking, and control of blood pressure slow down disease progression. The approved 
treatment for dry AMD is the use of the Age-Related Eye Disease Study (AREDS)-based 
vitamin supplements that lowers the risk of developing advanced stages of AMD (13).  
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In wet AMD, VEGF has been reported to be present below the RPE cell layer and 
around PRs. VEGF-A is the most potent mediator of both retinal and choroidal 
angiogenesis, and its inhibition via intraocular anti-VEGF treatments to prevent the 
formation of new blood vessels represents the cornerstone of wet AMD therapies. 
However, the primary atrophic component of AMD still progresses despite anti-VEGF 
therapy (6). Recombinant humanized anti-VEGF antibody fragments or soluble receptor 
decoys (e.g., ranibizumab (Lucentis; Genentech/Roche), bevacizumab (off label drug: 
Avastin; Genentech/Roche), pegatanib (Macugen
®
), and aflibercept (Eylea; Regeneron 
Pharmaceuticals) are current FDA approved therapies for wet AMD. The 
physicochemical and pharmacokinetics parameters of anti-VEGF therapeutics for the 
treatment of wet AMD are summarized in Table 1.1. The development of new agents for 
wet AMD has been focused on both improving efficacy and extending the duration of 
action. Other available treatments for wet AMD include photodynamic therapy (PDT) 
with intravenous verteporfin (14). Studies suggested that the combination of PDT with 
angiogenic inhibitors may reduce the frequency of Intravitreal (IVT) injections and the 
risks associated with long-term IVT therapy (15). 
 
Challenges with current intravitreal anti-VEGF treatments 
IVT injections are associated with multiple adverse events including 
subconjunctival hemorrhage, retinal tears, retinal detachments, vitreous hemorrhage, 
intraocular inflammation, tachyphylaxis, retinal vascular occlusion, cataract, and 
endophthalmitis. Furthermore, an increase in IOP has also been observed. Despite the 
facts that effective, IVT anti-VEGF therapies have several drawbacks. 
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 VEGF plays a protective role in the retinal tissue. The knockout of VEGF in retina 
can lead to severe side effects such as defects in the RPE choroid complex or the loss 
of interaction between the RPE and PRs outer segments.  
 Prolonged suppression of the plasma VEGF due to anti-VEGF therapy may lead to an 
increased risk of cardiovascular diseases.  
 The short intraocular retention of anti-VEGF drugs is a major issue due to the high 
clearance rate from the posterior eye, thus requiring frequent administration. 
 Patients suffering from recurrent NV AMD may develop mechanisms of resistance to 
anti-VEGF therapy, which can result in a diminished therapeutic effect(16). 
 An effective and safe anti-VEGF therapy should not damage the normal blood 
vessels; preserve the physiologic functions of the retinal neurons and other cells.  
 IVT injections require a high degree of sterility to prevent infection. 
 The long-term anti-VEGF treatment carries a high financial burden to the patients. 
To improve the safety, cost-effectiveness and impact on patients receiving IVT 
anti-VEGF treatments, a reduction in the drug administration frequency is required. Thus, 
there remains a need for the development of novel strategies for sustained and efficient 
anti-VEGF delivery. Newer agents may offer longer duration and minimize treatment 
burden thus, the overall cost of the therapy (17, 18). However, conventional ocular 
dosage formulations cannot overcome several barriers to ocular delivery and reduce the 
frequency of IVT injections. The uses of nanotechnology based approaches are a possible 
way to overcome these limitations. Thus, there has been considerable effort in the 
development of novel delivery approaches to selectively target and maintain the 
therapeutic drug concentration in the back of the eye for prolonged periods (19, 20).  
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Table 1.1 Characteristics of different anti-VEGF agents used in the clinical management of AMD  
 
Anti-VEGF 
agents 
Structure Biological 
target and 
mechanism 
KD, 
IC50 
for 
VEGF 
Mol 
wt. 
Approvals Vitreous 
half-life 
Intravitreal 
dose  
 
Regimen  Cost 
(Approx.) 
Ref. 
Pegaptanib 
sodium 
(Macugen®) 
Pegylated RNA 
aptamer (28 
base) 
VEGF-A165 200 
pM,  
50 
kDa 
FDA (2004) 
EMA(2005) 
10 days 
(human) 
0.30 mg every 6 
weeks 
US$995 (16, 
21),(22, 
23) 
 
Bevacizumab 
(Avastin®) 
 
Recombinant 
humanized mAb 
lgG1 
 
All 
isoforms of 
VEGF-A 
 
58 
pM, 
423 
pM 
 
149 
kDa 
 
FDA (2004) 
EMA(2005) 
CFDA(2010) 
 
6.7 days 
(human), 
4.32–
6.61 
days (in 
rabbits) 
 
1.25 mg 
 
every 4 
weeks 
 
US$50 
 
(16, 21, 
23) 
 
Ranibizumab 
(Lucentis®) 
 
Recombinant 
humanized 
lgG1-κ 
isotypemAb 
fragment 
 
All 
isoforms of 
VEGF-A 
 
46 
pM, 
343 
 
48 
kDa 
 
FDA (2006) 
EMA (2007) 
CFDA 
(2012) 
 
9 days 
(human), 
2.88-
2.89 
days (in 
rabbits 
 
0.50 mg 
 
every 4 
weeks 
 
US$2000 
 
(16, 21, 
23) 
 
Aflibercept 
(Eylea®) 
 
Fusion protein: 
domain 2 of 
VEGFR-1 and 
domain 3 of 
VEGFR-2 fused 
with lgG1 Fc 
 
All 
isoforms of 
VEGF-A, 
VEGF-B, 
and PIGF 
 
0.50 
pM, 8 
pM 
 
115 
kDa 
 
FDA (2011) 
EMA (2012) 
 
7 days 
 
2.0 mg 
 
every 4 
weeks 
for 3 
months 
and then 
once 
every 8 
weeks  
 
US$1850 
 
(16, 21, 
23) 
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Anti-VEGF 
agents 
Structure Biological 
target and 
mechanism 
KD, 
IC50 
for 
VEGF 
Mol 
wt. 
Approvals Vitreous 
half-life 
Intravitreal 
dose  
 
Regimen  Cost 
(Approx.) 
Ref. 
Conbercept Fusion protein: 
domain 2 of 
VEGFR-1 and 
domains 3 & 4 
of VEGFR-2 
fused with lgG1 
Fc 
All 
isoforms of 
VEGF-A, 
VEGF-B, 
VEGF-C, 
and PIGF 
0.50 
pM, 
10 pM 
143 
kDa 
CFDA 
(2013) 
4.2 days 
(in 
rabbits)  
0.50 or 2.0 
mg 
every 4 
weeks 
* (23) 
Brolucizumab Immunoglobulin 
Fv fragments; 
mAb. 
Humanized, 
single-chain Ab 
fragment 
inhibitor of 
VEGF-A.  
binds all 
isoforms of 
VEGF-A 
* 26 
kDa 
Phase III 4.9 days 1.25 mg every 4 
weeks 
* (17, 24) 
Abicipar Small molecule: 
(DARPins) 
inhibits all 
subtypes of 
VEGF-A  
* 34 
kDa 
Phase II 6 days 1 or 2.0 mg every 4 
weeks 
* (17, 25) 
Tanibirumab hlgG from a 
fully human 
naive single-
chain phage 
library 
VEGFR-2 
receptor Ab 
* * Preclinical * * * * (26, 27) 
 No information could be found. 
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Diabetic retinopathy (DR) 
Patients with diabetes (whether Type 1 or Type 2 diabetes) develop ‗macrovascular‘ 
complications which affect the kidneys (nephropathy), eyes (retinopathy) and peripheral nerves 
(neuropathy) (28). Among people with diabetes, the overall prevalence of DR worldwide is 
about one third, with increasing risk associated with longer disease duration, and presence of 
hypertension. It is the leading cause of vision loss in adults aged 20–64 years in developed 
countries. Recent estimates suggest that the number of people with DR will increase from 127 
million in 2010 to 191 million by 2030 (29). Primary cause of DR is diabetes—a condition in 
which the levels of glucose (sugar) in the blood are too high. Elevated sugar levels from diabetes 
can damage the small blood vessels that nourish the retina and in some cases, block them 
completely. When damaged blood vessels leak fluid into the retina it results in a condition 
known as diabetic macular edema which causes swelling in the center part of the eye (macula) 
that provides the sharp vision needed for reading and recognizing faces (30). Prolonged damage 
to the small blood vessels in the retina results in poor circulation to it and macula. This leads to 
the development of growth factors that cause generation of new abnormal blood vessels 
(neovascularization) and scar tissue to grow on the surface of the retina. This stage of the disease 
is known as proliferative diabetic retinopathy (PDR) (31). New vessels may bleed into the 
middle of the eye, cause scar tissue formation, pull on the retina, cause retinal detachment, or 
may cause high pressure and pain if the blood vessels grow on the iris, clogging the drainage 
system of the eye leads to vision loss (30).  
DR can be very broadly classified into two stages based on the level of microvascular 
degeneration and related ischemic damage: non-proliferative DR and advanced, proliferative DR 
(32). The progression of  DR is related to abnormalities of the vasculature including permeability 
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of the BRB, progressive microvascular damage with vascular endothelial cell and pericyte loss, 
subsequent occlusion of capillaries, thickening of vascular BM, and retinal neuronal and glial 
abnormalities (29). The alteration of the BRB is the hallmark of the pathogenesis of diabetic 
retinopathy. In diabetes, three changes happen at the BRB: (i) loss of endothelial cell–cell 
junctions; (ii) thickening of the basement membrane; and (iii) selective loss of pericytes. The 
breakdown of the BRB leads to intraretinal haemorrhages, hard exudates and macular oedema 
(33). At present there are few measures available to prevent DR beyond regulating 
hyperglycaemia, preventing dyslipidemia, controlling hypertension and cessation of tobacco 
smoking. The laser photocoagulation therapy has been the mainstay of management therapy in 
addition to the use of IVT anti-VEGF agents & steroids (34, 35).  
 
Diabetic macular edema (DME) 
Diabetic macular edema is the common cause of vision loss from diabetic retinopathy, 
typically presenting as a varying degree of central blurring. DME is defined as a thickening and 
cystoid edema of the macula, often with exudate deposition, attributable to DR (36). Pathology 
in the retinal microvasculature is an early indicator of the vasculopathy: microaneurysms, 
capillary dropout, and blood–retinal barrier dysfunction leads to DME (37). The resultant 
anatomical alterations (loss of retinal capillary pericytes and endothelial cells, dilated capillaries, 
and retinal microaneurysms) and chemical induction of hyperpermeability (via cytokines, 
including VEGF) leads to breakdown of the blood–retinal barrier, resulting in fluid leakage into 
the extracellular space: in the macular region, leading to DME (36) (38). Diabetes and 
hyperglycaemia have obvious effects on intraocular vascular endothelial cell permeability, 
adhesion to leukocytes, as well as angiogenesis. These alterations result in increased vascular 
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leakage (increased permeability), vascular occlusions, ischemia, and angiogenesis (39). The 
pathogenesis of DME is believed to be secondary chronic hyperglycemia. Chronic 
hyperglycemia causes systemic small vessel vasculopathy (capillary endothelial damage) related 
to factors that lead to retinal capillary hyperpermeability: hyperglycemic toxicity, inflammation, 
oxidative stress, and angiogenesis (39) (40). Chronically elevated serum glucose leads to a 
breakdown of the inner and outer retinal blood barrier. Hypoxia, oxygen-free radical 
accumulation, and inflammatory mediators result in VEGF-A expression (41).    
VEGF plays a critical role in DME development. VEGF is implicated in NV and 
increased vascular permeability (42). VEGF levels in both the anterior and vitreous chambers 
correlate with DME severity. These observations made VEGF a distinct target in the treatment of 
DME (39). IVT pharmacologic agents have demonstrated superior efficacy in clinical trials 
compared to laser for treatment of DME. However, laser photocoagulation has largely been 
replaced by IVT pharmacologic injections over the past decade as a principal therapy for DME 
(43).  
 
Glaucoma 
Glaucoma is the second leading cause of irreversible vision loss and blindness 
worldwide. Approximately 60 million people worldwide are afflicted with glaucoma. This 
number is expected to increase to 80 million in 2020 because of both demographic expansion 
and population aging (44). Glaucoma is a group of progressive optic neuropathies characterized 
by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. Loss of 
ganglion cells is related to the level of intraocular pressure, but other factors may also play a 
role. The death of retinal ganglion cells is accompanied by morphologic changes of the retina. 
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These are central nervous system neurons that have their cell bodies in the inner retina and axons 
in the optic nerve. Degeneration of these nerves results in cupping, a characteristic appearance of 
the optic disc and visual loss (45) (44). The biological basis of glaucoma is poorly understood 
and the factors contributing to its progression have not been fully characterized. The two main 
types of glaucoma are open-angle and angle-closure. These are marked by an increase in 
intraocular pressure. Well-marked symptoms are observed only in acute angle-closure glaucoma. 
All other forms of chronic glaucoma are largely asymptomatic. Normal-tension glaucoma is a 
form of glaucoma in which damage occurs to the optic nerve without eye pressure exceeding the 
normal range (12-22 mm Hg). Secondary glaucoma refers to any form of glaucoma in which 
there is an identifiable cause of increased eye pressure (traumatic glaucoma, uveitis glaucoma, 
drug induced glaucoma, advanced cases of cataract or diabetes, and others) (46). The only signs 
are gradually progressive visual field loss and optic nerve changes. Unfortunately, because of the 
asymptomatic nature of chronic glaucoma, upto 50% of people are unaware of their diagnosis 
and not receiving treatment. Management of glaucoma focuses on lowering intraocular pressure, 
which remains the principal proven method of treatment initiated with ocular hypotensive drops, 
laser trabeculoplasty or surgery may also be used to slow disease progression (47).  
 
Ocular drug delivery to back of the eye 
The major diseases that significantly impact vision problems are AMD, DR, ME, DME, 
uveitis, and glaucoma. The treatment of these diseases, especially those associated with the retina 
requires a direct and local application of the therapeutic molecules since there are several 
anatomical and physiological barriers present in the eye (48). Due to these barriers, the drug 
delivery to the intraocular tissues especially to the posterior of the eye is significantly limited, 
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especially via the topical and systemic routes (19, 20). However, with a better understanding of 
the anatomy of the eye, and pathophysiology of these diseases, several effective treatment 
options are now being offered. In addition, the uses of nanotechnology based delivery systems 
and availability of different routes of drug administration have been shown to overcome several 
ocular barriers and target specific tissues, including the retina (49). Current treatments for 
posterior eye diseases suffer from significant disadvantages including frequent intraocular 
injections and related adverse events, in addition to the high cost of the treatment (17).  
 
Barriers and various routes of drug delivery to the posterior segment of the eye 
The interior of the human eye is subdivided into anterior and posterior segments. The 
anterior segment is filled with aqueous humor which provides nourishment to the lens and cornea 
and removes degradation products. The iris (colored part of the eye), separates the anterior 
segment from the posterior segment. The ciliary body, located behind the iris, produces the 
aqueous humor, which fills the two chambers. The posterior segment consists of the vitreous 
humor, retina, choroid, and sclera (50). The retina is consist of the inner limiting membrane, 
nerve fiber layer, ganglion cell layer, inner and outer plexiform layers, inner and outer nuclear 
layers, external limiting membrane; PR layer; and RPE. The choroid is the vascular cover of the 
eye lying between the retina and the sclera, which provide nourishment to the PRs.   
The regular routes to target back of the eye are topical (51), systemic, intraocular 
(suprachoroidal, IVT), and periocular (subconjunctival, subtenon, retrobulbar). These routes are 
briefly discussed along with their advantages and limitations in Table 1.2 and a schematic 
representation is provided in Figure 1.1. The drug bioavailability in the eye is limited by several 
anatomical/static (conjunctiva, cornea, sclera, blood aqueous and retinal barriers) and 
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physiological/dynamic (choroidal blood flow, efflux transporters, tear washing, nasolacrimal 
drainage) barriers (48). These barriers effectively limit the drug access to the back of the eye as 
shown in schematic representation in Figure 1.2.  
 
 
 
 
 
 
 
 
Figure 1.1 Schematic representation of routes of administration (Reproduced from permission (1) 
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Table 1.2 Characteristics of various routes of administration for posterior eye delivery 
 
Route Comments 
Topical 
Drug entry pathways Corneal, conjunctival, and scleral pathways. 
Delivery barriers Membrane barriers and elimination pathways on the eye surface, cornea, 
BRB, and tight junctions. 
Elimination pathway Tear wash out, nasolacrimal drainage, choroid, conjunctiva blood flow, 
and lachrymation, blinking. 
Advantages  High patient compliance. 
 Less systemic side effects. 
 Relatively easy to administer. 
Limitations  Small retention time of drug or dosage forms. 
 Blurring of vision, irritation. 
 Precorneal drug losses, drainage through the nasolacrimal duct. 
 Low bioavailability. 
 Limited volume of administration (approx. 30 μL). 
 Fast clearance from ocular surface. 
 Metabolism by tear enzymes. 
 Nonproductive uptake into systemic circulation via highly 
vascularized conjunctiva, choroid, uveal tract and inner retina. 
 Aqueous humor outflow gradient. 
Approaches for 
improvement in 
therapeutic efficacy 
 Bioadhesive formulations may be employed to reduce precorneal 
clearance and increase corneal surface contact time. 
 Positive charge of formulations may enhance the contact time with 
cornea to interact with negatively charged mucosa. 
 Nanowafers approach may be beneficial for long-term and sustained 
drug release. 
 
Systemic  
Drug entry pathways Choroid, conjunctiva 
Delivery barriers Choroid; efflux transporters, BRB (selectively permeable to highly 
lipophilic molecules). 
Elimination pathway Hepatic clearance, conjunctival and choroid capillaries, phagocytic 
clearance. 
Advantages  Better patient compliant than intraocular injection. 
 Comparatively safer to eye since not a direct administration. 
Limitations  Low bioavailability due to the BRB, hence high doses required which 
produce systemic side effects. 
Approaches for 
improvement in 
therapeutic efficacy 
Large molecules and/or hydrophilic drugs are able to penetrate the 
choroid from the systemic circulation, but are unable to cross the inner 
BRB into the retina. Thus, drugs must exit the choroidal circulation and 
permeate the outer BRB. 
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Routes                        Comments 
Intravitreal 
Drug entry pathways Directly to the vitreous chamber 
Delivery barriers Diffusion through the vitreous chamber, neural retina, and BRB. 
Elimination pathway  Movement to aqueous chamber and retina. 
 Dynamic clearance mechanisms, such as anterior bulk aqueous flow 
or posterior vitreoretinal-choroidal flow, eliminate drugs from the site 
of deposition.  
Advantages  Local and direct delivery. 
 High therapeutic concentration. 
 No barrier to reaching macula. 
Limitations  It is necessary to administer the drug frequently to maintain adequate 
intraocular concentrations. Frequent injections have been associated 
with adverse events especially retinal detachment, vitreous 
hemorrhage and endophthalmitis. 
 Linked to degeneration of PRs and cataracts. 
 Only about 50–100 μl being administrable in human via IVT route 
 High cost of administration and drugs (anti-VEGF). 
Approaches for 
improvement in 
therapeutic efficacy 
Changes in the drug's formulation to release the drug for longer duration 
or modify specific properties of the drug, such as size, charge, and 
lipophilicity. 
Stimuli-responsive approach may be beneficial to release the drug when 
required. 
Periocular 
Drug entry pathways Majorly via the transscleral pathway to effectively deliver drugs next to 
the choroid. 
Delivery barriers Scleral thickness, choroidal blood circulation and BRBs [21]. 
Elimination pathway  Conjunctival and choroidal blood and lymphatic flow. 
 Losses from the periocular space, BRB, choroidal circulation. 
 Binding of drugs to tissue proteins; efflux transporters. 
Advantages  Less invasive. 
 High therapeutic drug levels. 
 Repetitive periocular administration under local anesthesia is possible 
without direct interference with the vision. 
 High volumes of drug solution can be administered in humans. 
 Can bypass the BRB without intraocular penetration.  
Limitations  Low retinal bioavailability compared to IVT injections. 
 The injected drug still has to traverse the sclera, which is less 
permeable to larger molecules.  
 
 
 
 
 
 The drug has to pass through several layers-including the episclera, 
sclera, choroid, BM, and RPE-while overcoming choroid circulatory 
clearance, delivery is not as effective as intraocular injections in 
targeting retinal targeting. 
 Rapid drug clearance, systemic side effects, tissue hemorrhage. 
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Routes 
Approaches for 
improvement in 
therapeutic efficacy 
Comments 
Improvements to formulations that either increase residence time or 
promote diffusion from the middle coat may be effective ways to 
overcome the barriers to periocular delivery. 
Nano-size formulations with small size may provide superior diffusion. 
Negative charge or positive charge of formulations depends if interaction 
or diffusion required. 
Suprachoroidal  
Drug entry pathways Across the sclera to flow quickly along the inner surface of the eye and 
subsequently into the posterior chamber. 
Delivery barriers Choroid-BM. 
Elimination pathway High blood flow in the choriocapillaries washes away therapeutic 
molecules deposited in the suprachoroidal (SCS). 
Advantages  Preferred site for drug delivery to the posterior tissues such as 
choroid, RPE and macula, due to its non-interference with the optical 
pathways and improved diffusional access to the choroid. 
 Allow for larger volumes of drugs with a safer procedure. 
 Drugs injected into the SCS are less likely to reach the RPE, interact 
with the rods and cones of the PR cells and ultimately to trigger 
immunologic responses. 
 SCS can accommodate up to 1 mL of fluid, which rapidly diffused 
into the posterior segment. 
 Injections of 10–50 µL into the SCS have been demonstrated to be 
well tolerated with a low risk of ocular complications.  
Limitations  Injection of a drug solution into the SCS can result in rapid drug 
diffusion to cover the entire SC surface; this could potentially induce 
drug-related toxicities of the surrounding tissues.  
 Rapid clearance of macromolecules following suprachoroidal route. 
 Postoperative inflammation and choroidal hemorrhage remain a 
concern and needs to be overcome when injecting into the SCS. 
Approaches for 
improvement in 
therapeutic efficacy 
 Diffusion kinetics from the SCS could be optimized using sustained 
release formulations such as nanoparticles and microparticles. 
 Drug delivery systems that can provide controlled and continuous 
drug release are likely to minimize such side-effects. 
 Microneedles appear to offer a viable option to deliver drugs to the 
back of the eye, especially through the SCS route. These needles help 
to deposit drug or carrier system into sclera or into the SCS which 
may facilitate diffusion of drug into deeper ocular tissues, choroid 
and neural retina. 
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Figure 1.2: Schematic representation of drug disposition in eye following various routes of ocular administration. (Reproduced with 
permission from (1)  
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Biodegradable polymers for ocular drug delivery  
 Many approaches have been evaluated to improve ophthalmic drug delivery. 
Applications of controlled drug delivery systems have been anticipated as an effective 
approach to circumvent all these limitations. Controlled drug delivery systems release the 
drug in a sustained and controlled manner by which the therapeutic concentration is 
maintained for the prolonged period of time (52). These systems provide many practical 
advantages such as avoid frequent administration, which is a major non-compliance with 
many chronic eye disorders. The delivery of emerging therapeutic macromolecule 
therapeutics having short biological half-lives could be possible with polymeric delivery 
(53). These systems protect the protein drugs in situ and have an ability to deliver them at 
desire rate by overcoming anatomical and biochemical barriers (54). For such purpose, 
biodegradable polymers are of enormous importance. Biodegradable polymers are 
generally divided into two groups, natural and synthetic based on their origin. Natural 
biodegradable polymers such as gelatin, albumin, chitosan, hyaluronic acid and synthetic 
biodegradable polymers such as polyethylene glycol (PEG), polyglycolic acid (PGA) and 
polylactic acid (PLA), polyvinyl alcohol (PVP) have been thoroughly explored for ocular 
delivery systems. These polymers are approved by FDA for human applications (55). 
Synthetic origin polymers offer advantages over natural polymers by being versatile with 
a wide spectrum of applications, having a capability to tailor mechanical properties and 
altering the rate of degradation according to the need.     
 In the past two decades the development and application of synthetic 
biodegradable polymers for ocular drug delivery have gained significant momentum.  
(52). Polymeric delivery approaches such as micro and nanoparticles (NPs), 
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microspheres, liposomes, hydrogels and ocular implants have been designed to deliver 
the therapeutic agents in the controlled manner for long duration (56). The release rate of 
the drug molecules from these polymeric system depends on many factors such as, 
molecular weight (MW) and degradation mechanisms, physicochemical properties of the 
drug, interaction between the drug and polymer (1).  
The natural and synthetic biodegradable polymers have many favorable properties 
such as biocompatibility with ocular tissues, biodegradability and mechanical strength 
(57). They provide negligible toxicity and also their degradation products are non-toxic in 
terms of both local and systemic response. In addition, the inability of a single 
biodegradable polymer to meet all the requirements leads to the development of the block 
copolymers strategy.   
PLA, PGA and their copolymers polylactide-co- glycolide (PLGA) (58, 59) are 
the most promising biodegradable polymers. PLGA copolymers of different MWs widely 
used for opthalmic applications. PGA alone is highly prone to hydrolysis and remains 
insoluble in common organic solvents therefore it is not widely acceptable for the 
fabrication of controlled drug delivery systems (60). PLA offers unique features of 
biodegradability, biocompatibility, thermoplastic processability and eco-friendliness that 
offer potential and being a bioresorbable polymer that play an increasingly important role 
in biomedical applications due to their unique ability to be completely resorbed in pre-
designed time frames ranging from months to a few years (61). PLA alone and in 
combination with PGA with different ratios are mostly utilized in the formulations. These 
polymers upon non-enzymatic or enzymatic hydrolysis produce water soluble metabolic 
products, which are not harmful to living tissues. These polymers belong to polyester 
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class and degrade mainly through bulk erosion (61). In vitro degradation of polyesters 
primarily occurs through hydrolytic cleavage. However, in vivo, enzymes play an 
important role to initiate the degradation process (62). The degradation products lactic 
acid and glycolic acid are nontoxic and eliminate in the form of CO2 and water via Krebs 
cycle (63). (64). PLA and PLGA are widely utilized in ocular drug delivery systems such 
as implants, injectable microspheres and NPs (65).   
Poly- ε-caprolactone (PCL) is an aliphatic polyester synthesized form monomer 
ε-caprolactone through ring opening polymerization. It is a tough semi crystalline 
polymer having the melting point in the range of 59 and 64 °C (66). Permeability and 
crystallinity of the PCL can be modified by copolymerization with PLA or PGA. PCL is 
utilized for sustained drug delivery due to its higher permeability to various drug 
molecules and slower degradation in comparison to other polymers (67). Degradation rate 
of PCL can be improved by copolymerizing with other fast degrading polymers (68).  
 
Nanotechnology based delivery systems for the posterior segment of eye diseases 
There are several novel delivery technologies that are designed to serve as drug 
delivery systems in ocular and other applications (19, 20, 48, 69, 70). Among these, 
nanocarrier (NC)-based delivery systems are extensively studied (19, 20, 71). NCs are 
colloidal systems in the nano-scale size range and capable of loading the lipophilic and 
hydrophilic as well as small and macromolecule drugs. Because of the small size and use 
of biodegradable materials in the formulation development, NCs offer various significant 
advantages such as, small size avoids irritation considering the highly sensitive nature of 
ocular tissue (20, 72), improved drug bioavailability and ocular tissues biocompatibility, 
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provide stability to drug from in vivo/in vitro degradation, reduction of drug clearance 
and increase of the in vivo half-life, sustain or controlled drug release profile, site-specific 
delivery by targeting ligand, and potential to combine diagnosis and therapy. In the 
following sub-sections, several types of NCs systems, their advantages and limitations 
are discussed. The therapeutic potential of these carriers in the posterior segment eye 
diseases is summarized in Table 1.3. 
Liposomes 
Liposomes are lipid vesicles in the size range from 0.1 to 10μm. They are made of 
amphiphilic phospholipids bilayers (to encapsulate hydrophobic drugs) surrounding an 
aqueous core (to encapsulate hydrophilic drugs) (48, 73). Liposomes have been 
comprehensively used in ocular therapeutics due to several advantages such as high 
versatility of surface chemical modification, specific targeting, drug release can be 
controlled depending on the number of bilayers number and composition, and potential of 
stimuli-sensitive delivery system (73). Also, the physiochemical properties of liposomes 
(size, surface charge, and functional chemistry) can be modified by mixing different 
lipids during their formulation development. However, liposomes present certain 
limitations, such as low reproducibility, instability of macromolecules during the 
formulation process, manufacturing cost and scale up issues, difficulties in sterilization, 
immunotoxicity, variable size distribution, and instability in biological environment (74). 
Polymeric nanoparticles (NPs) and microparticles (MPs) 
Polymeric NPs are biodegradable and biocompatible colloidal systems in the size 
range of 10-1000nm (48). MPs are delivery systems having the micrometer size range of 
about 1 to 1000µm (75). In addition the above advantages as of liposomes, NPs and MPs 
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provide flexibility in various routes of administration, stimuli-responsive system, 
encapsulation and delivery of multiple drugs in a single particle, and flexibility in 
modifying size, shape, and surface functionality in ocular drug delivery (20, 76). They 
can also achieve cellular drug delivery either via endocytosis or phagocytosis. However, 
these particles have several drawbacks, such as burst release which may lead to drug 
toxicity, rapid phagocytic clearance in systemic circulation, immunogenicity, scale-up 
issues, particle aggregation due to large surface area, and non-uniformity in size 
distribution.  
Nanomicelles 
Nanomicelles are self-assembled systems from biodegradable and biocompatible 
amphiphilic block polymers in the size range of ~10-100nm. They can encapsulate poorly 
or highly-water soluble drugs in the core or outer hydrophilic shell, respectively (77, 78). 
Nanomicelles have wide advantages in ocular and other drug delivery applications, such 
as easy and reproducible formulation, easy sterilization by filtration, ability to enhance 
solubility of hydrophobic drugs, prevention or minimization of drug degradation, 
possibilities of changing polymer block arrangements as needed, and improved drug 
permeation through ocular epithelia with minimal or no irritation, ultimately leading to 
enhanced ocular bioavailability (20, 79). Drawbacks of nanomicelles include instability 
in biological/physiological environment, immunogenicity and toxicity, premature drug 
release, and lack of formulation scale-up methods. 
Dendrimers 
Dendrimers are branched polymeric systems in the size range of 10-100nm. Drugs 
can be either entrapped in the dendrimers network through hydrogen bonds, hydrophobic 
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and ionic interactions or conjugated through covalent bonds (80, 81). These systems have 
terminal end groups of amine/hydroxyl/carboxyl functionality which may be utilized to 
conjugate targeting ligand or therapeutic molecules. Due to their unique structure, 
dendrimers exhibit improved physicochemical properties, uniform size distribution, and 
higher biocompatibility. However, the complexity and multistep in formulation process 
and, toxicity issues limit their applicability. 
Nanowafers 
Nanowafers are tiny disc-like or rectangular membrane that contains drug loaded 
nano-reservoirs. Nanowafers can be readily applied on the eye and release the drug for a 
longer duration, thus improving the overall therapeutic efficacy. During the course of the 
drug release, nanowafer slowly dissolves and fades away. Recently, topically applied 
nanowafers with extended drug release attributes and enhanced efficacy has been 
developed to treat dry eye diseases (82, 83). The slow drug release from the nanowafer 
increases the ocular surface drug residence time and subsequent absorption into the 
surrounding tissue. Although, nanowafers are in early development phases, they have the 
potential for treating posterior eye diseases. 
Nanocrystals 
Nanocrystals are drug particles stabilized by the surfactant or polymeric 
stabilizers and have a size range between 10 and 1000 nm. Nanocrystals possess 
outstanding features enabling to overcome the solubility problems of poorly soluble 
drugs and provide an enhanced bioavailability, high drug load, low side effects, fast onset 
of action and an overall improved efficiency and safety (84). Nanocrystals have been 
explored for the delivery of antiglaucoma drugs forskolin (85) and brinzolamide (86). 
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Thus, it can be postulated as future choice for the treatment of various posterior ocular 
diseases. 
Hydrogels 
Hydrogels have several potential applications in ophthalmology and delivery 
systems (87). Porous, soft nature and high water content of hydrogels are suitable for 
higher encapsulation of water soluble drugs including proteins and peptides. The 
processing of hydrogels usually occurs at ambient temperatures and organic solvents are 
rarely used, thus, they are excellent for encapsulating biomacromolecules (87, 88). 
Hydrogels can be made from natural or synthetic polymers. Natural polymers provide 
biocompatibility, and biodegradability however, may suffer from weak mechanical 
strength, high batch-to-batch variability, and immunogenicity. Synthetic polymers 
provide tunable mechanical properties and prolonged stability. Hydrogels permit various 
mechanisms (diffusion/swelling/chemically controlled and stimuli-responsive) of drug 
release. However, the high water content and soft nature of hydrogels may result in 
relatively rapid release of biomolecules from the gel matrix. The low mechanical strength 
represents a major limitation and the degradation of the polymers during the sterilization 
processes may affect the gel properties of the hydrogel (48, 87, 88). Moreover, the 
rapidly gelling formulations may clog the needle and affect the injectability of the 
hydrogel (88). 
Composite nanosystems 
Composite nanosystems (NPs suspended in a gel matrix) are made of 
biodegradable, FDA approved block copolymers and emerging as a versatile platform in 
ocular drug delivery applications (89, 90). The suspended NPs in the thermo-responsive 
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gel matrix encounter an additional diffusion barrier which in turn provides the long-term 
release especially for macromolecules. Similarly, it minimizes burst effect, and follows 
long-term zero order kinetics. In addition, composite nanosystems provide stability to 
macromolecules from enzymatic degradation and helps in improving the biological half-
life. The physicochemical characteristic of composite nanosystems can be modified by 
varying the chemistry, MW, and block arrangements of the polymers. However, 
premature drug release from the NPs and drug accumulation in the gel matrix could give 
burst effect and needs further evaluation. 
Ocular implants 
Intraocular implants are designed to provide localized controlled drug release over 
an extended period of time. Implants are placed intravitreally by making an incision 
through minor surgery located posterior to the lens and anterior to the retina (87, 91). 
Though implantation is invasive, these devices are gaining interest due to their several 
advantages such as sustained and local drug release to diseased ocular tissues at 
therapeutic levels, reduced side effects and ability to circumvent BRB (50, 92). Ocular 
implants are available as biodegradable and non-biodegradable devices. Biodegradable 
implants of PLA, polyglycolic acid PGA, PLGA, and PCL are gaining attention due to 
their biocompatibility and sustained drug release properties (92, 93). Drug release can 
vary depending on the surface area, rate of polymer degradation, polymer swelling, MW 
and nature of the encapsulated drug molecule (91). 
Non-biodegradable implants using the polymers such as polyvinyl alcohol (PVA), 
ethylene vinyl acetate (EVA), and polysulfone capillary fiber (PCF) offer long-lasting 
release by achieving near zero order release kinetics (92). However, these devices have to 
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be surgery implanted and removed after drug depletion, which makes the treatment 
expensive and patient non-compliance. Also, adverse events such as endophthalmitis, 
pseudoendophthalmitis, vitreous haze, hemorrhage, cataract development and retinal 
detachment limit their applications. In general, non-biodegradable polymers are preferred 
for implant fabrication to release the drug in a more controlled manner over long-time, 
while they can be easily removed in case of adverse reactions.  
Stimuli-responsive nanosystems for the posterior segment of eye diseases 
Developing a stimuli-responsive NC system is an attractive area for drug delivery 
to the posterior segment of the eye diseases since variable drug concentrations may be 
required at various time points depending on the individual‘s and the disease state (91, 
94, 95). These novel systems are able to enhance/trigger the release of therapeutic 
molecules within a particular site in response to a number of intrinsic (pH, temperature, 
enzymes, oxidative stress) (96-98) and external (magnetic field, light, and heat) stimuli to 
control the release of therapeutic molecules in a spatial and temporal manner. In the 
following sub-sections several stimuli-responsive delivery approaches are briefly 
discussed.  
Light-activated systems 
The transparent nature of the cornea and the lens makes the eye an organ of 
choice for light activated drug delivery system (91, 99). These systems have incorporated 
light sensitive materials into the formulation which respond to a specific wavelength. 
However, UV irradiation will likely raise the safety issue as UV light causes adverse 
effects in the cornea, lens and retina. The NPs drug delivery depot formulated for on-
demand light-triggered release of drugs post-implantation has been developed (100). 
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These NPs rapidly release encapsulated small molecules upon exposure to 365 nm light. 
One implant system has been developed by On Demand Therapeutics (ODTx), which 
contains several drug reservoirs that can be activated individually by laser light (91). This 
implantable light activated system provides a platform for controlled delivery of many 
types of drugs in the treatment of posterior eye diseases. Recently, suprachoroidal 
delivery of bevacizumab was demonstrated using a light-activated in situ gel (101).  
Thermo-responsive systems 
Thermosensitive polymers undergo abrupt change in their solubility in response to 
a small change in temperature (102). This can cause conformational changes in the 
polymer material that triggers the drug release. An injectable PLGA-PEG-PLGA-based 
thermo-responsive hydrogel for IVT sustained release of bevacizumab has been designed 
(103). Results entail an initial burst release of bevacizumab followed by a sustained 
release of hydrogel. The hydrogel showed higher intraocular biocompatibility and 
extended drug release. 
Ultrasound-responsive systems 
Recent advances demonstrate the significant potential of ultrasound mediated 
drug release for ocular applications (104, 105). Ultrasound is an exogenous stimulus 
which employs pressure waves with frequency of ≥20 kHz. Ocular formulations have the 
potential be combined with ultrasound method to increase the drug permeability of the 
ocular barriers (106). Ultrasound-responsive drug delivery systems have been used with 
several NCs formulations (104, 107). Ultrasound application has shown to enhance the 
delivery of dexamethasone sodium phosphate, through the cornea in vivo (108). 
However, the physical effect of ultrasound on the stability of the NCs formulations is yet 
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to be evaluated in addition to risk of sonication side effects, patient‘s compliance and cost 
issues.  
Micro Electro Mechanical (MEM) systems 
MEM systems consist of one or more drug reservoirs and actuators which are 
responsible to push the drug out of the reservoir by mechanical means in response to the 
stimulus including temperature, electrical stimulus, magnetic field, and osmotic pressure 
(91). A MEM based ocular implant has been studies for phenylephrine delivery (109). 
The approach has been later modified using a mini drug pump (hydrolysis based 
actuation) (110) to provide a precise control over the amount of drug released in response 
to the stimulus, exhibiting more accurate drug delivery. Another MEMS based magnetic 
responsive drug release ocular implant is investigated to provide a precise control over 
docetaxel release intended for the treatment of PVR (111).  
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Table 1.3 Nanocarriers (NCs) drug delivery systems in posterior segment of eye diseases 
 
Delivery 
system/Stimuli 
Therapeutics Polymer Route of 
administration 
Target disease Ref. 
Liposomes pDNA, and PEI Topical AMD (112) 
 bevacizumab Annexin A5-associated 
Liposomes 
Topical Posterior eye 
diseases 
(113) 
 SU5416: angigenesis 
inhibitor 
Ala-Pro-Arg-Pro-Gly-
modified liposomes 
Intravitreal CNV (114) 
 Bevacizumab Phospholipid (egg 
phosphatidylcholine or 1,2-
dipalmitoyl-sn-glycero-3-
phosphocholine) and 
cholesterol 
Intravitreal Posterior eye 
diseases 
(115) 
Nanoparticles 
UV light Nintedanib Light-sensitive polymer Intravitreal Macular 
degeneration and 
DR 
(100) 
 Ranibizumab PLGA MPs entrapping 
chitosan NPs 
 
Intravitreal AMD (116) 
Temperature Triamcinolone 
acetonide 
PEGylated PLGA NPs 
incorporated into PLGA-PEG-
PLGA thermo-reversible gel 
Intravitreal AMD (117) 
 Triamcinolone 
acetonide 
Folate-PEG-b-PCL  AMD (118) 
 Bevacizumab PLGA  Intravitreal AMD (119) 
 Brimonidine tartrate  Alkoxylphenacyl-based 
polycarbonates copolymer 
with PCL 
 
Intravitreal glaucoma (120) 
Ultrasound FITC-BSA Silk fibroin Transscleral Posterior eye 
diseases 
(104) 
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Delivery 
system/Stimuli 
Therapeutics Polymer Route of 
administration 
Target disease Ref. 
 Coumairn-6 Chitosan and poloxamer 407 Topical Posterior eye 
diseases 
(121) 
Microparticles/ 
Microspheres 
Ranibizumab PLGA Intravitreal AMD (122) 
 Bevacizumab PLA NPs encapsulated into 
PLGA MPs 
Intravitreal Posterior eye 
diseases 
(123) 
 Bevacizumab PLGA  Intravitreal Posterior eye 
diseases 
(124) 
Temperature Ovalbumin PLGA MPs suspended in poly 
(N-isopropyl acrylamide)-
based hydrogel 
Intravitreal Posterior eye 
diseases 
(125) 
Nanomicelles Dexamethasone  
 
Polyoxyl 40 stearate and 
polysorbate 80 
Topical Posterior uveitis (126) 
 Cidofovir Hexadecyloxypropyl-cidofovir Intravitreal Chronic retinal 
diseases 
(127) 
Dendrimers Dexamethasone  Poly (amidoamine) Topical and 
Subconjunctival 
DR (128) 
 Brimonidine and 
timolol maleate 
Polyamidoamine   (129) 
Light 5-Aminosalicylic acid G2 lysine dendrimers with a 
silsesquioxane core 
Intraperitoneal Retinal 
degeneration 
(130) 
Nanowafers Dexamethasone  Carboxymethyl cellulose 
polymer 
Topical Dry eye (82) 
 Axitinib PVA, polyvinylpyrrolidone, 
(hydroxypropyl) methyl 
cellulose, and carboxymethyl 
cellulose 
 CNV (83) 
Nanocrystals Brinzolamide  Different polymer stabilizers Topical Prolonged 
reduction of IOP 
(86) 
Temperature Forskolin  Poloxamer 407 and 
polycarbophil 
Topical Glaucoma (85) 
  
 
 
3
1
 
Delivery 
system/Stimuli 
Therapeutics Polymer Route of 
administration 
Target disease Ref. 
Hydrogels Bevacizumab Oxidized alginate and glycol 
chitosan 
Intravitreal AMD (131) 
UV light Bevacizumab PCL dimethacrylate and 
hydroxyethyl methacrylate 
Suprachoroidal CNV (101) 
Temperature Bevacizumab PEG-poly-
(serinolhexamethylene 
urethane) 
Intravitreal Posterior eye 
diseases 
(132) 
Temperature Bevacizumab poly(2-ethyl-2-oxazoline)-b-
poly(ε-caprolactone)-b-poly(2-
ethyl-2-oxazoline) 
Intraocular Posterior eye 
diseases 
(133) 
 Bevacizumab Vinyl sulfone functionalized 
hyaluronic acid and thiolated 
dextran 
Intravitreal Posterior eye 
diseases 
(134) 
 Bevacizumab PLGA-PEG-PLGA Intravitreal Posterior eye 
diseases 
(103) 
Composite Nanosystems 
Temperature IgG-Fab PCL-PLA-PEG-PLA-PCL) 
based NPs suspended in a 
thermo-sensitive gelling 
copolymer (mPEG-PCL-PLA-
PCL-PEGm) 
Intravitreal Posterior eye 
diseases 
(89) 
Temperature Octreotide, insulin, 
lysozyme, IgG-Fab, 
IgG, and catalase 
 Intravitreal Posterior eye 
diseases 
(90) 
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Macromolecule drug delivery nanocarrier fabrication 
Macromolecule drugs have shown great promise as a novel therapeutics in the 
treatment of ocular diseases. These large molecule drugs offer many advantages 
compared to small molecule drugs with respect to high potency, activity, low unspecific 
binding, less toxicity, minimization of drug-drug interaction, biological and chemical 
diversity. The chemical structure of macromolecules enables them to perform several 
specific functions in the body. However, these macromolecules are subjected to the 
physical and chemical degradation, short in vivo circulation half-life and biodistribution, 
lack of an efficient, safe, and specific delivery. In addition, clearance by the mononuclear 
phagocytes of the reticuloendothelial system, risk of immunogenic effect, solubility 
challenges, high MW, structural complexity, and failure to permeate cell membranes 
further reduce their therapeutic efficacy. In general, systemically delivered formulations 
either for small or macromolecule drugs faces several barriers before reaching the target 
cell/organs. Hence, there is a requirement to develop new methods and formulation 
strategies to deliver these highly potent macromolecule drugs for ocular treatment. 
However, due to several physiochemical instability and enzymatic barriers of 
macromolecules delivery, it is very difficult to develop a suitable formulation for these 
drugs. Several novel delivery technologies have been designed for ocular applications. 
The ideal characteristics and therapeutic potential of these carriers are summarized in 
Table 1.4 and Table 1.5 respectively. 
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Table 1.4 Ideal characteristics of an ocular drug delivery formulation for macromolecules 
 
Property Description 
Features of 
drug delivery 
system  
 Should allow a high drug loading to reduce the instilled volume. 
 Appropriate size to facilitate corneal uptake and passage. 
 Isotonic and close to physiological pH with physiological fluids to 
avoid irritation and lacrimation. 
 Product should provide a controlled, sustained or stimuli-sensitive 
drug release as required. 
 High specificity to the ocular tissues. 
 Possess more local activity than systemic effects. 
 Dosage forms should allow the active drug to distribute through the 
target site for adequate time. 
 Proper syringeability and injectability to assure the administration 
of the prescribed dose of therapeutics. 
 The physical properties (size, shape and the charge), of the delivery 
system are among the key attributes that can influence the 
performance of a formulation of ocular drug delivery system. 
 It is essential that the product is not inducing any drug resistance. 
 In general, for vision to be unaffected, ocular delivery systems 
should be smaller than 50 μm in order to decrease the light-
scattering effects associated with larger particles. 
Active agents 
attributes 
 Preferentially lipophilic since non-ionizable lipophilic compounds 
will concentrate into the corneal epithelium, while ionizable 
lipophilic ones will partition into the aqueous humor. 
 Should provide a long-term efficacy. 
 Drugs should have an amphipathic nature in order to pass through 
these different layers of cornea. 
 Compatibility with other drugs having different physicochemical 
properties. 
Stability 
concern and 
adverse-effects  
 Limited side effects associated with systemic, topical 
administration and frequent intraocular injections. 
 Products should be safe, with no localized/systemic toxicity.  
 Must be inert towards the ocular tissues. 
 The products should be stable under diverse environmental 
conditions, possess adequate shelf-life and proper storage stability. 
Process 
parameters, 
manufacturing 
and cost 
effectiveness 
 Formulation and manufacturing of dosage forms must be feasible.  
 Allowing for the production in the amounts needed to meet the 
projected needs. 
 Product must be economically feasible, cost benefits to the patients 
as well as easy to use.   
Patient 
Acceptance 
 Products should be simple, acceptable, easy to self-administer,  and 
have a convenient dosage regimen.   
 Products must be non-irritating, with a long-lasting action. 
 Minimal number of surgical interventions is required.  
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Table 1.5 Macromolecules Delivery Systems: Advantages and Limitations 
 
Delivery 
systems 
Advantages Limitations 
Micro and 
Nanoparticle  
 Controlled and long-term drug 
release is possible using various 
routes of administration 
 Small size allows enhanced 
permeation in to various organs  
 Greater flexibility of surface 
modification ligands molecule 
 High adjuvancy for vaccine 
 Encapsulation and delivery of 
various drugs on one nanocarrier. 
 Adjustable physicochemical 
properties (size, shape, surface 
functionality). 
 Higher possibility of stimuli 
sensitive delivery. 
 Targeted delivery system 
 Burst release of drug can 
produce potential toxicity. 
 Non-specific uptake in RES 
system and phagocytic 
clearance 
 Challenges include the 
biocompatibility, toxicity, 
safety, stability, and 
immunotoxicity. 
 Polymer has strong influence 
on drug release and stability. 
 Various factors (size, shape, 
surface properties of carriers) 
affect their release behavior, 
stability and targeting 
efficiency. 
 Scale-up of 
nanoformulations. 
 Small size and large surface 
area can leads to particle 
aggregation. 
 Non-uniformity of particle 
size distribution. 
 Polymers hydrophobicity and 
acidic microenvironment by 
degradation leads to protein 
denaturation/aggregation. 
 Chemical reactions between 
macromolecules and 
polymers. 
Solid Lipid 
NPs (135-
137) 
 Large scale and effective 
production. 
 Small size, large surface area, 
high drug loading. 
 Improved drug stability. 
 Avoidance of organic solvents in 
the production can avoid the 
stability problems of 
macromolecules. 
 Potential of carrying both 
lipophilic and hydrophilic drugs. 
 Complexity of the physical 
state of the lipid. 
 Phagocytic uptake and 
clearance. 
 Lipid particle growth and 
tendency to gelation. 
 Sometimes low drug loading 
capacity due to the formation 
of a lipid crystal matrix. 
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Delivery 
systems 
Advantages Limitations 
Liposomes  Versatility of surface chemical 
modification and specific 
targeting. 
 Delivery to CNS through blood-
brain barrier due to their 
lipophilic nature of liposomes. 
 Entrapment of hydrophilic and 
hydrophobic drugs to aqueous 
and lipid phases, respectively. 
 Can provide a sustained and 
controlled release. 
 Drug release can be controlled, 
depending on the bilayers number 
and composition. 
 Possibility of stimuli sensitive 
delivery system. 
 Higher biocompatibility and non-
immunogenicity. 
 Instability in biological 
media. 
 Phagocytic uptake. 
 Process of the formation of 
liposomes has stability issues 
on macromolecules. 
 Manufacturing cost, scale up, 
batch-to-batch 
reproducibility. 
 The production of sterile 
liposomes is expensive which 
reduces their applicability. 
 Interactions of phospholipids 
with protein drugs. 
 Heterogeneous particle size 
distribution. 
Hydrogels  The porous nature of hydrogels 
can be finely tuned to allow for 
drug loading. 
 Pharmacokinetic properties for 
release of the loaded therapeutic 
molecule can be easily adjusted 
to the requirements of individual 
molecule. 
 Biocompatible materials because 
their high water content and soft 
nature. 
 Unlike other delivery systems, 
organic solvents and protein 
denaturing processes are not used 
in hydrogel preparation 
procedures. This is beneficial in 
preserving protein stability, as 
very mild conditions (aqueous 
environment, room temperature) 
are normally used. 
 Proteins have a limited mobility 
or are immobilized in the 
hydrogel network, which is 
favorable for preservation of their 
fragile 3D structure.  
 
 High water content and soft 
nature of hydrogels typically 
results in relatively rapid 
release of proteins from the 
gel matrix. 
 Burst release, low 
mechanical strength, and 
short durability. 
 Protein damage due to 
encapsulation. 
 Stability of hydrogels is poor 
in most cases and represents 
a major limitation. 
 The low tensile strength of 
many hydrogels limits their 
use in load-bearing 
applications and can result in 
the premature dissolution or 
flow away of the hydrogel 
from a targeted local site. 
 The quantity and 
homogeneity of drug loading 
into hydrogels may be 
limited, particularly in the 
case of hydrophobic drugs. 
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Delivery 
systems 
Advantages Limitations 
  Hydrogel‘s soft and hydrophilic 
nature and mild preparation 
methods are well-suited to 
enhance efficacy, reduce dosing 
interval, and provide a more 
convenient dosage route of large 
and labile protein 
 Stimuli sensitive hydrogel 
delivery is feasible. 
 Sometimes, hydrogels are not 
sufficiently deformable to be 
injectable, necessitating 
surgical implantation.  
 Each of the above issues 
significantly restricts the 
practical use of hydrogel-
based drug delivery therapies 
in the clinic. 
Micelles   High diversity of polymers. 
 Suitable for intravenous 
administration. 
 Easy of sterilization by simple 
filtration process for safe 
administration. 
 High biocompatibility, 
biodegradability, and the 
multiplicity of functional groups. 
 Possibilities of different polymer 
block arrangements based on the 
requirements. 
 The hydrophobic core serves as a 
solubilization depot for drugs 
with poor aqueous solubility. 
 Hydrophilic shell limits the 
opsonin adsorption, contributes 
towards longer blood circulation  
 The small size of polymeric 
micelles contributes towards 
longer blood circulation time by 
evading scavenging by the MPS 
system in the liver and bypassing 
the filtration of inter-endothelial 
cells in the spleen. 
 Longer circulation time leads to 
improved accumulation at tissue 
sites with vascular abnormalities. 
 Toxicity and immunogenicity 
concern. 
 Lack of suitable formulation 
methods for scale-up. 
 Formulation instability. 
 Low cellular uptake and 
tissue accumulation. 
 Self-assembled polymeric 
micelles are not stable and 
may dissociate upon dilution 
however, lipid-core micelles 
demonstrate high stability, 
biocompatibility, and 
prolonged blood circulation 
time. 
 Potential use in gene delivery 
is small and not well 
evaluated. 
 Instability in the 
physiological environment. 
 Micelles are liable to 
dissociate, especially upon 
administration when they are 
diluted to a concentration 
below the CMC. 
 Limitations in entrapping 
hydrophilic small as well as 
macromolecule drugs. 
Dendrimers  Can be tailored by manipulating 
the structure/composition or 
number of surface functional 
groups. 
 
 
 Toxicological issues are 
major limitations of the 
dendrimers in their clinical 
application. 
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Delivery 
systems 
Advantages Limitations 
  Thermodynamically stable 
system. 
 Uniform size distribution 
 Drug molecules can be loaded 
both in the interior as well as 
attached to the surface groups. 
 High transfection efficiency not 
only due to their well-defined 
shape, but may also be caused by 
the amine functionality. 
 Complexity of 
formulation methods  
 Core of structure is 
difficult to access as the 
complexity of the system 
increases with multiple 
generation structures. 
Composite 
formulations 
(NPs-in-gel) 
 Minimizes the burst effect (dose 
dumping) effect of 
nanoformulations which may 
result in severe dose related 
toxicity. 
 Exhibit nearly zero order release 
for longer period of time. 
  This novel system provides 
stable environment for 
macromolecules against catalytic 
enzyme. 
 NPs can be suspended to the 
gel at the time of delivery 
only otherwise drug will be 
released from the NPs and 
accumulate in the gel which 
could give burst effect. 
Therefore, this novel 
approach require dual 
chamber mixing device.  
 Storage at cool temperature.  
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PART I: COMPOSITE NANOFORMULATIONS OF MACROMOLECULE FOR 
BACK OF THE EYE DISEASES 
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CHAPTER 2 
  INTRODUCTION 
 
Overview 
Ever since the emergence of the first US Food and Drug Administration (FDA)-
approved recombinant protein, human insulin, in 1982, there has been a tremendous 
surge in the development of commercial protein therapeutics for applications in various 
fields of medicine (138). Ophthalmology is one such field that has benefited greatly from 
the advent of commercial therapeutic proteins. The role of therapeutic proteins used in 
the eye ranges from the neutralization of biomolecules, such as cytokines and growth 
factors, to protection of photoreceptors and prevention of angiogenesis (139). Among 
these, many proteins are used for the treatment of diseases affecting the back of the eye 
diseases such as age-related macular degeneration (AMD), retinal vein occlusion with 
cystoid macular edema (CME), posterior uveitis, glaucoma, diabetic retinopathy (DR), 
and retinitis pigmentosa (1). Of these, the most common ones are AMD, glaucoma, and 
DR, which accounts for nearly 26% of the cases of blindness worldwide and a staggering 
85% of all cases of blindness in the developed world (139). Hence, a huge amount of 
research time and money has been spent on the development of drugs and treatment 
modalities in this area. The disease progression in DR involves neovascularization of the 
retina and choroidal neovascularization (CNV) in the case of AMD, which is responsible 
for the loss of vision.     
The gold-standard treatment for retinal/ choroidal neovascularization involves 
ablation of CNV or laser-assisted thermal photocoagulation to make the retina anoxic 
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(140). However, these approaches are gradually being replaced by intravitreal injections 
of anti-vascular endothelial growth factor (anti-VEGF) agents (141). Anti-VEGF agents 
are essentially antibodies or fragments thereof that can bind to and block VEGF, thereby 
inhibiting neovascularization (142). In a land-mark study conducted in 2006, it was 
shown that repeated injections of ranibizumab (Lucentis
TM
), a recombinant antibody 
fragment developed by Genentech and Novartis, prevented vision loss in nearly 95% of 
patients, and significantly improved vision in 40%. Ranibizumab was designed such that 
it contained only the Fab portion of the anti-VEGF antibody bevacizumab (Avastin
TM
), 
which is used off label to treat AMD/DR (143), (144). Compared with bevacizumab, 
ranibizumab is one-third the size, has higher binding affinity for VEGF, is cleared from 
the circulatory system 100-fold faster, and is expected to be able to penetrate better into 
the retina because of its small size (145). Biological advantages of aflibercept include its 
greater binding affinity for VEGF, a longer intravitreal half-life relative to other anti-
VEGF agents, and the capacity to antagonize growth factors other than VEGF (146). 
Currently, recombinant humanized anti-VEGF antibody fragments or soluble receptor 
decoys (e.g., ranibizumab (Lucentis; Genentech/Roche), bevacizumab (off label drug: 
Avastin; Genentech/Roche), pegatanib (Macugen
®
), and aflibercept (Eylea; Regeneron 
Pharmaceuticals) are current FDA approved therapies for wet AMD (1).  
Conventional drugs failed to achieve required therapeutic levels of drugs in the 
posterior eye segment owing to the presence of several ocular barriers. Intravitreal 
injection is currently the only approved mode of administration, although it is suboptimal 
because of repeated injection every 1–2 months due to high protein clearance rates from 
the vitreous humor (147), (148). In addition, the associated side effects includes the 
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blurred vision, increase in intraocular pressure, cataract and risk of retinal detachment 
(149). Moreover, current intravitreal therapies are available at high cost and brand drugs 
like Avastin
TM
 and Lucentis
TM
 have the treatment cost of around $590 and $23,400 per 
month, respectively (http://www.allaboutvision.com/conditions/lucentis-vs-avastin.htm). 
Therefore, development of a cost effective, long term efficient therapy which can also 
reduce the frequency of intra-vitreal injection is needed. In this regard, the full clinical 
potential of many novel therapeutic proteins designed for posterior segment of the eye 
diseases has often been limited because of their inherent instability and difficulty in 
overcoming various ocular barriers.     
To reduce the need for repeated intraocular injections and to maintain a constant 
and safer level of therapeutic proteins, different drug delivery systems have been 
designed (93). However, one of the major problems when designing such technologies is 
to maintain the therapeutic compounds without their degradation during the preparation, 
sterilization, and drug release processes. Optimally, the drug delivery system should be 
injectable and biodegradable to limit the potential side effects. To make them injectable, 
proteins, peptides or vaccines are encapsulated in particulate systems, mostly composed 
of poly-lactic acid (PLA), poly-glycolic acid (PGA) and poly (D, L-lactide-co-glycolide) 
(PLGA) (65), (150), (151). However, these polymers produce a high molar mass of lactic 
acid and glycolic acid upon degradation under physiological conditions in the body, 
which causes the tissue irritation and toxicity. Moreover, degradation products of PLGA 
drastically reduces the pH in the microenvironment which directly affects the stability of 
protein drugs (152) (153). Thus, there is a need to develop a polymer and its delivery 
system which ensure the stability and sustain release of large molecules, often called 
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macromolecule or biologics (protein, peptide and antibodies) for longer duration of time, 
thus eliminating the repeated injections.    
Recent years have seen the emergence of protein delivery systems specifically 
developed for applications to the back of the eye. These systems can be broadly classified 
as injectable colloidal particles and injectable hydrogels. Injectable colloidal particles 
such as nanoparticles (NPs) may offer an advantage of providing long term release and 
higher residence time for large molecules. In this regard, the formulation of NP 
encapsulated with drug can be achieved by using FDA approved biodegradable and 
biocompatible polymers such as PCL (polycaprolactone), PLA, PGA and PEG 
(polyethylene glycol). 
 
Rationale for investigation 
 
The rationale behind developing novel biodegradable and biocompatible PB 
based biomaterial is to achieve controlled drug delivery over a period of several weeks 
from a single IVT injection that can provide a cost effective, long term and efficient 
therapy. Therefore, pentablock (PB) copolymers are introduced to fabricate such delivery 
system. PB copolymers are composed of FDA approved polymer blocks such as PEG, 
PCL, and PLA /PGA with different block ratios. The focus of this work is to utilize the 
polymeric biomaterials to design the constructs which can modulate the release for longer 
duration by using their inherent properties. PB copolymers have been utilized for the 
preparation of NPs and thermosensitive gel. Each block plays an important role such as 
the presence of PEG helps to improve stability of NPs to escape phagocytosis by 
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macrophages resulting in improved circulation half-life. PCL is a slow degrading highly 
crystalline polymer which improves macromolecule encapsulation of NPs and also 
sustains drug release for longer duration of time (90), (154). Moreover, these tailor-made 
polymers are designed in a manner which releases lower amount of lactic and glycolic 
acid comparison to PLGA (155). Based on previous studies, existing PCL or PLA based 
block polymers primarily showed diffusion mediated drug release due to their extremely 
slow degradation (156). Therefore, tailor-made PB copolymers are designed to overcome 
the aforementioned problems. It is anticipated that reduction of the PLA molar mass in 
PB copolymers will improve the stability of encapsulated protein molecules, in addition 
to reduction in possible tissue irritation and toxicity. This novel approach will provide the 
entire range of polymers with different hydrophilicity-hydrophobicity index. This 
enormous advantage will allow us to select a unique composition of the polymer which is 
suitable for a respective therapeutic agent. Furthermore, reduction in the MW and/or 
change in the polymer block arrangement allow us to prepare PB copolymer with 
different physicochemical property. Besides, PB copolymers may be utilized to prepare 
thermosensitive gel and NPs both.   
The thermosensitive gelling polymer will remain in liquid aqueous state at room 
temperature (25 °C) and form a thin transparent film upon contact with eye temperature 
i.e. 34 °C. It has been reported in earlier studies that NPs alone causes burst effect (157), 
(158). Therefore, the dual approach of NPs suspended in a thermogelling system could 
minimize burst release due to longer diffusion pathway of entrapped molecules from the 
system. This technology is termed as composite nanoformulation (Fig 2.1) which in turn 
results into a prolonged duration of action. The purpose of this study is to prepare 
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injectable composite nanoformulations comprised of macromolecule encapsulated NPs 
suspended in thermosensitive gel that can act as depots for sustained release without 
disturbing the stability.     
 
 
Figure 2.1 Composite nanoformulation approach acts as depots for sustained release  
 
Subconjunctival/IVT administration of such a novel formulation may result in a 
prolong duration of action (~3-6 months) and thereby eliminate the need for repeated 
administration. It is anticipated that this formulation may provide higher patient 
compliance with reduced side effects. This approach may act as a platform for ocular 
delivery of other macromolecules such as siRNA, aptamers, peptides and large proteins. 
Therefore, the broad objective of this work is to develop novel PB copolymer based 
sustained delivery systems of macromolecules for posterior eye diseases. 
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Objectives 
In this study, macromolecules such as IgG, IgG-Fab‘, IgG-Fab, lysozyme, 
ranibizumab, and octreotide were loaded in PB copolymers based thermosensitive gels 
and/or NPs. The macromolecule encapsulated NPs were suspended in a thermosensitive 
gel to formulate the composite nanoformulations. The composite nanoformulation was 
investigated to study the effect of new polymeric compositions from low to high MWs. A 
major focus was given to optimize the formulation parameters to achieve a higher drug 
loading and to examine the effect of different MW of PB copolymer on drug release 
profile. In addition, the effect of hydrodynamic behavior of different MW 
macromolecules on in vitro release was studied. To test this, following specific aims are 
proposed.   
Aim 1: Synthesis of PB thermosensitive gelling (PBG) copolymers and comparative 
in vitro release study of different MW of macromolecules: PBG copolymers with 
various MW ratios and block arrangement were synthesized by ring opening 
polymerization method. The effects of block arrangement on sol-gel transition, viscosity 
and in vitro drug release of different MW of macromolecules (IgG, IgG-Fab‘, IgG-Fab, 
octreotide) was investigated. The aim 1 is subdivided into the following sections;  
(A) Characterization of PBG copolymers: The synthesized copolymers were 
characterized for their structure, purity, MW, PDI and crystallinity, using various 
analytical methods such as nuclear magnetic resonance (NMR), X-ray diffraction 
analysis (XRD) and gel permeation chromatography (GPC). 
(B) Rheology study of PBG copolymers: Viscosity measurement by Ubbelohde 
viscometer and sol-gel transition curve by tube inverting method.  
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(C) Cytotoxicity evaluation of PBG copolymers: In vitro cytotoxicity (LDH assay) and 
cell viability (MTS assay) was performed on ocular cells.  
(D) Biocompatibility evaluation of PBG copolymers: In vitro biocompatibility study 
was performed on macrophage (RAW 264.7) cells. The release of various inflammatory 
mediators such as TNFα, IL-6 and IL-1β was evaluated.     
(E) In vitro release study and kinetic mechanisms PBG copolymers: In vitro drug 
release from hydrophilic and hydrophobic thermosensitive gels was quantified by the 
Bradford assay. The release kinetic model was applied to study the release mechanism.  
(F) Stability studies of macromolecule: The stability of released protein was 
investigated by circular dichroism (CD) spectroscopy.        
(G) In vitro degradation of PBG copolymer: The study was performed under four 
conditions; (i) in pH 7.4 PBS at 37°C, (ii) in presence of enzymes acetylcholinesterase 
(14.7 mU/mL) and butyrylcholinesterase (5.9 mU/mL), (iii) in pH 9.0 borate buffer at 
37°C and (iv) in pH 7.4 PBS at 40°C. The samples were analyzed by XRD and GPC. 
(H) In vivo histology of PBG copolymer: Histology study was performed in New 
Zealand White Rabbit to examine the changes in the tissue morphology of the eye.   
 Aim 2: Synthesis of PB copolymers for NP preparation and comparative in vitro 
release study of different MW of macromolecules from composite 
nanoformulations: The synthesis of PB copolymers with various MW ratios was carried 
out by the ring opening bulk polymerization method. The effects of in vitro drug release 
of different MW of macromolecules were investigated.  
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(A) Characterization of PB copolymers: The synthesized copolymers were 
characterized for their structure, purity, MW, PDI, and crystallinity using various 
analytical methods such as NMR, XRD and GPC.  
(B) Biocompatibility evaluation of PB copolymers: In vitro biocompatibility study was 
performed on macrophage (RAW 264.7) cells. The release of various inflammatory 
mediators such as TNFα, IL-6 and IL-1β was evaluated.     
(D) NP preparation, optimization and characterization: The PB copolymers were 
utilized to encapsulate macromolecules (IgG, IgG-Fab, lysozyme) in NPs using Water-in-
oil-in-water (W1/O/W2) double emulsion solvent evaporation method. The NPs were 
characterized for Particle mean diameter (PMD), Size distribution and PDI using 
dynamic light scattering (DLS) method with Zetasizer Nano ZS. The drug encapsulation 
and loading efficiency of NPs was assessed by Micro-BCA
TM 
assay.  
(C) In vitro release study and kinetic mechanisms: In vitro drug release from 
composite nanoformulation (NPs suspended in a thermosensitive gel) was quantified by 
Micro-BCA
TM
. The release kinetic models were applied to study the release mechanism.  
(D) Enzymatic activity of released macromolecule: Lysozyme released from 
composite nanoformulation was analyzed by enzyme assay. 
Aim 3: Development, optimization and evaluation of PB copolymer based IgG-Fab 
and Ranibizumab-encapsulated composite nanoformulation: To synthesize and 
characterize PB copolymers for the preparation of IgG-Fab and ranibizumab-
encapsulated NPs. Composite nanoformulations (NP suspended in a thermosensitive gel) 
were investigated to achieve zero order drug release. In addition, formulation parameters 
were optimized to achieve higher drug loading.        
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(A) Characterization of PB copolymers: The synthesized copolymers were 
characterized for their structure, purity, MW, PDI and crystallinity, using NMR, XRD 
GPC and Fourier-transform infrared spectroscopy (FT-IR).  
(B) Cytotoxicity evaluation of PB copolymers: In vitro cytotoxicity (LDH assay) and 
cell viability (MTS assay) was performed on ocular cells. 
(C) Biocompatibility evaluation of PB copolymers: In vitro biocompatibility study was 
performed on macrophage (RAW 264.7) cells. The release of various inflammatory 
mediators such as TNFα, IL-6 and IL-1β was evaluated.        
(D) NP preparation, optimization and characterization: IgG-Fab and ranibizumab 
were used as therapeutic drug for the optimization of NP formulation. Water-in-oil-in-
water (W1/O/W2) double emulsion solvent evaporation method was used to formulate the 
NPs. In order to improve drug loading, encapsulation efficiency and sustained release 
profile of NPs, various process parameters such as drug: polymer ratio, amount of 
emulsifier and stabilizer, types of PB copolymer and its polymer blend ratio, aqueous: 
non-aqueous phase ratio, and sonication time were optimized. The NPs were 
characterized for Size distribution and PDI by DLS method. The drug encapsulation and 
loading efficiency of NPs was assessed by Micro-BCA
TM 
assay. 
(E) In vitro release study and release kinetic mechanisms: In vitro drug release from 
composite nanoformulation (NPs suspended in a thermosensitive gel) was quantified by 
Micro-BCA
TM 
assay. The kinetic models were applied to study the release mechanisms.  
(F) Stability studies of released macromolecule: Indirect ELISA was performed to 
determine the activity of released drugs from the composite nanoformulations.     
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CHAPTER 3 
BIODEGRADABLE AND BIOCOMPATIBLE THERMOSENSITIVE GELLING 
PENTABLOCK COPOLYMERS FOR LONG TERM OCULAR DELIVERY OF 
MACROMOLECULES 
 
Rationale 
Increase in the use of macromolecules, often called biologics has occurred over 
the past decade for the treatment, prevention, or cure of a variety of ocular diseases (159). 
Biological products include vaccines, immunoglobulins, cells or microorganisms, other 
proteins and peptides (160). Among several biologics, anti-Vascular Endothelial Growth 
Factor (VEGF) agents are administered for back of the eye diseases, usually by monthly 
intravitreal injection (161). A controlled, sustained release therapeutic would decrease the 
frequency of injections, leading to increased patient compliance and therapeutic efficacy 
especially for the sensitive organ like eye.   
FDA approved biodegradable polymers such as polycaprolactone (PCL), 
polylactic acid (PLA), polyglycolic acid (PGA) and polyethylene glycol (PEG) have been 
comprehensively studied for the sustained delivery of the macromolecules (152). These 
polymers are widely explored to prepare various diblock, triblock and PB copolymers in 
drug delivery approaches. Recently, many investigators have applied various block 
copolymers combinations such as poly lactide-co-glycolide (PLGA) (119), PLGA-PEG-
PLGA (162), PEG-PCL-PEG (163), (164), and PEG-PLA  (165) for the development of 
sustained release formulations. PLGA based hydrogels exhibit better biodegradability, 
higher gelation temperatures and longer periods of sustained drug release compared to 
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poloxamer systems (166). However, degradation of copolymers produces lactic acid and 
glycolic acid, which reduces local pH substantially and may degrade macromolecules. 
Furthermore, local tissue reaction to the PLGA may reduce tolerability and 
biocompatibility (152). Other types of multiblock amphiphilic polymer (i.e., with both 
hydrophilic and hydrophobic domains) have been synthesized using a wide range of 
gelling polymers. Some of these gelling polymers are sufficiently deformable to be 
injectable, but many are not, necessitating surgical implantation for drug delivery (103). 
In either case, a high initial burst and lack of sustained drug release limit the clinical 
utility of these gels. Hydrogels provide a deformable drug depot that slowly elutes a high 
concentration of drug to surrounding tissue for an extended period of time (167), (168). 
However, because most hydrogels only physically incorporate to the drugs, a rapid drug 
release occurs over a few hours to days, limiting their value for sustained drug delivery. 
Therefore, an injectable and biocompatible hydrogel that provides a sustained release of 
biologically active protein therapeutic remains to be developed.   
 Considering these facts, comparative studies have been done to develop PB 
thermosensitive gelling (PBG) copolymer to achieve long term delivery. PBG 
copolymers are composed of biodegradable or biocompatible polymer blocks of PEG, 
PCL, PGA, and PLA. The in vitro drug release profile of macromolecules can be 
optimized by adjusting the block length, arrangement and ratio of the PCL/PLA/PGA 
with PEG. The arrangements may be further optimized by changing the MW of each 
polymeric block. PBG copolymers have different MW, ratios and arrangement, which 
can influence the drug release profile.   
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 The relative block arrangement and MW of PBG copolymers affect the solution-
gelation (sol-gel) transition behavior, viscosity, degradation, and in vitro release 
characteristics of the macromolecule. PBG can be injected through a small-gauge needle 
to form a firm, in situ, hydrogel depot. Therefore, the potential advantages of PBG as 
carriers for sustained delivery of macromolecule/biologic therapeutics include 
biodegradation, biocompatibility, long-term release, ease of injectability, and stability of 
the therapeutic being delivered.   
Biodegradable polymers generally undergo homogenous or heterogeneous erosion 
(169). Homogenous erosion, commonly referred as bulk erosion, involves hydrolytic 
cleavage of the complete cross-section of polymer matrix. The degradation rate of bulk 
eroding polymers is slower and varies from several weeks to years (170). Heterogeneous 
degradation generally referred as surface erosion. Heterogeneous degradation take place 
at faster rate compared to homogeneous degradation because slower diffusion of water 
molecules inside the polymer matrix (171). Drug release from a bulk eroding polymer 
matrix depends upon swelling, diffusion, and hydrolytic degradation in contrast to 
surface eroding polymers, where it primarily depends on hydrolytic degradation (170), 
(169). The hydrolytic degradation rate of polyesters depends on their MW and 
crystallinity. Low MW PLGA degrades faster than high MW PLGA (65) (172).  
 In the present study, we have synthesized and evaluated various novel 
thermosensitive hydrogels composed of FDA approved polymer. This study has 
addressed five important aspects; (i) synthesis and characterization of PBG copolymers; 
(ii) effect of hydrophilic and hydrophobic block copolymers on sol-gel transition 
behavior; (iii) in vitro cytotoxicity/biocompatibility; (iv) in vitro release study and 
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hydrodynamic behavior of different MW of the macromolecule drugs (IgG, 150 kD; IgG 
Fab‘, 110 kD; IgG-Fab, 50 kD; and Octreotide 1 kD); (v) release kinetic mechanism (vi) 
in vitro degradation studies of hydrophilic gelling polymer (vii) in vivo ocular histology. 
 
Materials and methods 
Materials 
Poly (ethylene glycol), monomethoxy PEG, poly (vinyl alcohol) (PVA), stannous 
octoacte were obtained from Sigma Aldrich, USA. ε-caprolactone, and L-lactide were 
obtained from Acros organics, USA. Lactate dehydrogenase estimation kit and CellTiter 
96® AQueous non-radioactive cell proliferation assay (MTS) kit were obtained from 
Takara Bio Inc. and Promega Corp., respectively. All other reagents utilized in this study 
were of analytical grade.  
 
Methods 
Synthesis of PB copolymers   
Synthesis of hydrophobic PBG-1 copolymer (PLA-PCL-PEG-PCL-PLA)  
PCL-PEG-PCL; TB copolymer was synthesized by ring-opening bulk 
copolymerization of ε-caprolactone. PEG was utilized as macro-initiator whereas 
stannous octoate as a catalyst. Briefly, PEG was vacuum dried for 4 h before 
polymerization. Predetermined amount of PEG and ε-caprolactone were added in the 
round bottom flask. Polymer melt was degassed under vacuum for 30 min at 130°C 
followed by addition of stannous octoate (0.5 wt%) and purged with nitrogen gas. 
Reaction was carried out for 24 h at 130°C. The resulting polymer was then dissolved in 
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dichloromethane and precipitated by addition of cold diethyl ether. Precipitates were 
centrifuged and sediments were vacuum-dried to remove any residual solvents. Purified 
polymers were stored at -20°C. To synthesize PBG-1, predetermined amount of TB and 
L-lactide were added in a round bottom flask and degassed under vacuum for 30 min at 
130°C. Flask was then purged with nitrogen gas and followed by addition of stannous 
octoate (0.5 wt%). Reaction was carried out at 130°C for 24 h. The resulting polymers 
were purified and stored at -20 °C. A schematic synthesis raection of PBG-1 is 
represented in Figure 3.1.  
 
 
Figure 3.1 Synthesis of hydrophobic PBG-1 copolymers (PLA-PCL-PEG-PCL-PLA) 
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Synthesis of hydrophilic PBG-2 copolymer (PEG-PCL-PLA-PCL-PEG)  
To synthesize the thermosensitive gelling copolymer (PBG-2; PEG-PCL-PLA-
PCL-PEG), intermediate copolymer (mPEG-PCL-PLA) was synthesized by ring-opening 
bulk copolymerization. ε-caprolactone was polymerized at the hydroxyl terminal of 
mPEG (550 Da) followed by second polymerization with L-lactide. The resulting 
intermediate copolymer was coupled using HMDI as a linker. The coupling reaction was 
continued for 8 h at 70°C. The synthesized PBG-2 copolymers was purified by cold ether 
precipitation followed by drying under vacuum and stored at -20°C until further uses. A 
schematic synthesis reaction of PBG-2 is depicted in Figure 3.2.  
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Figure 3.2 Synthesis of hydrophilic PBG-2 copolymers (PEG-PCL-PLA-PCL-PEG) 
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Characterization of PBG copolymers 
PBG-1 and PBG-2 copolymers were characterized for their MWs and purity by 
(
1
H) nuclear magnetic resonance (
1
H-NMR) spectroscopy, gel permeation 
chromatography (GPC), X-ray diffraction (XRD). The structures and MWs of PBG-1 and 
PBG-2 copolymers are described based on 
1
H-NMR and GPC.   
Proton (
1
H) nuclear magnetic resonance (NMR) spectroscopy 
The 
1
H-NMR spectra of PBG-1 and PBG-2 copolymers were acquired on a 400 
MHz NMR instrument (Varian Inc., Palo Alto, CA). The chemical shift values were 
reported as δ in parts per million (ppm). The NMR samples were prepared by dissolving 
each copolymer in deuterated chloroform as solvent in a 5-mm outer diameter NMR 
tubes (Wilmad-LabGlass, Vineland, NJ).   
Gel permeation chromatography (GPC) analysis   
The purity, MWs and PDI of PBG-1 and PBG-2 copolymers were further 
confirmed by GPC analysis. Polymeric samples were analyzed with Waters 410 
refractive index detector (Waters, Milford, MA). Briefly, samples were prepared by 
dissolving 5 mg of polymeric material in tetrahydrofuran (THF) whereas THF was 
utilized as eluting agent at the flow rate of 1 mL/min. Separation was carried out on 
Styragel HR-3 column (Waters, Milford, MA). Polystyrene samples with narrow MW 
distribution were considered as standards.  
X-ray diffraction (XRD) analysis  
 To analyze the crystallinity of copolymers, XRD analysis was performed using 
Rigaku MiniFlex automated X-ray diffractometer (Rigaku, The Woodland, TX) equipped 
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with Ni-filtered Cu-Kα radiation (30 kV and 15 mA). The analysis was performed at 
room temperature at the scanning rate of 5°/min.  
Thermosensitive PB copolymer characterization  
Sol-gel transition 
The sol (flow)-gel (no flow) transition of block copolymers was examined by 
following a previously published protocol with minor modifications. Briefly, block 
copolymers ranging from 15-30 wt% were dissolved in distilled deionized water followed 
by 12 h of incubation at 4°C. After equilibration, 1 mL of aqueous polymeric solution 
was transferred in 4 mL glass vial and placed in water bath. The temperature of the water 
bath was raised gradually from 10°C to 50°C at an increment of 1°C. Vials were kept for 
5 min at each temperature. Gel formation was observed visually by inverting the tubes. A 
physical state with no fluidity for 1 min was considered as gel phase. The temperature at 
which the solution transforms to gel phase was considered as critical gelling temperature 
(CGT) and the temperature where polymer starts to precipitate (phase separation) was 
described as critical precipitation temperature (CPT). 
Viscosity measurements 
The change in the viscosity of the PBG-1 and PBG-2 copolymer solution as a 
function of temperature may also be employed to gain an understanding of the phase 
transitions. A viscosity change may suggest the formation or destruction of a structured 
network, implying a sol or gel state. Rheological properties of 20 wt% aqueous solution 
of PBG-1 and PBG-2 copolymers were estimated with an Ubbelohde capillary 
viscometer at temperatures ranging from 5±1°C to 25±1°C. Temperature of the 
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viscometer was maintained with a temperature controlled water bath. Viscosity values are 
represented as an average of triplicates (kinematic viscosity, cP± standard deviation). 
 
In Vitro cytotoxicity of gelling polymers  
To analyze the cytotoxic effects of PBG-1 and PBG-2 gelling copolymers Lactate 
Dehydrogenase (LDH) assay (Takara Bio Inc.) and cell viability (MTT) assay Promega 
Corp) were performed according to the supplier‘s instructions. Retinal Pigment 
Epithelium (D407) cells are immortalized and can be sub-cultured many times, while 
maintaining their physiological properties. Cells were cultured at 37°C, humidified 5% 
CO2/95% air atmosphere in a culture medium containing DMEM/F-12 supplemented 
with 15% (v/v) FBS (heat inactivated), 15 mM HEPES, 22 mM NaHCO3, 100 mg of 
penicillin and streptomycin each, 5 μg/mL insulin, and 10 ng/mL of human epidermal 
growth factor. Cells of passage numbers between 62 and 65 were utilized for all the 
experiments. The growth medium was changed every other day. A D407 cell was 
cultured in flasks, harvested at 80–90% confluency with TrypLE™ Express (a superior 
replacement for trypsin).  
Lactate dehydrogenase (LDH) assay  
LDH assay was performed using previously published protocol with minor 
modifications to evaluate the cytotoxicity of both PBG copolymers. Briefly, 5, 25 and 50 
mg/mL of PBG-1 and PBG-2 copolymers were dissolved in acetonitrile (ACN) and 
hundred microliter solutions were aliquoted in each of the 96-well. Plates were exposed 
overnight under UV light (laminar flow) for polymer sterilization as well as evaporation 
of ACN. D407 cells at the density of 1.0 x 10
4
 were seeded in each well and incubated at 
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37°C, 5% CO2 in humidified atmosphere for 48 h. After completion of incubation period, 
cell supernatants were analyzed for quantification of LDH using LDH assay kit. 
Absorbance of each well was measured at 450 nm using a DTX 800 multimode 
microplate reader (Beckman Coulter, Brea, CA). More than 10% of LDH release was 
considered as cytotoxic. The LDH release (%) was calculated according to Eq. 3.1,  
 
    … Eq. 3.1 
MTS assay  
The safety and biocompatibility of PBG copolymers was further established by 
performing an in vitro cell viability assay (MTS; (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) tetrazolium reduction). MTS assay was performed 
according to previously reported protocol with minor modifications (89). As described 
earlier, PBG-1 and PBG-2 copolymer solutions at the concentration of 5, 25 and 50 
mg/mL were prepared, aliquoted and sterilized. After sterilization, D407 cells were 
seeded in each well of 96-well plate at a cell density of 1.0 x 10
4
, and incubated at 37°C 
and 5% CO2 in humidified atmosphere for 48 h. At the end of incubation period, cell 
culture medium was aspirated and cells were incubated for 4 h (37°C and 5% CO2) in 
presence of hundred microliter of serum free medium containing twenty microliter of 
MTS solution. The fluorescence was measured at the excitation and emission 
wavelengths of 560 nm and 590 nm, respectively, using the above microplate reader. 
Percent cell viability was calculated according to Eq. 3. 2. In this study, PBG copolymers 
exhibiting more than 90% of cell viability were considered non-toxic and suitable for 
ocular applications. 
 59 
 
 
             Eq. 3.2 
 
In vitro drug release studies of macromolecule drug  
For the in vitro release experiments, one hundred µL of 20 wt% aqueous block 
copolymer solutions were added to 1 mL Eppendorf tubes. Solutions were gently mixed 
(~30 sec) at 4°C until drugs (Octreotide, IgG Fab, IgG-Fab‘ and IgG) was dissolved in 
respective vials. Eppendorf tubes were incubated at 37°C for 5 min followed by addition 
of 1 mL phosphate buffer saline (PBS, pH 7.4). Throughout the release period, Eppendorf 
tubes were kept in a water bath maintained at 37°C. At predetermined time intervals, two 
hundred µL of release samples were collected and replaced with fresh PBS (pre-
incubated at 37°C). The amount of released macromolecule drugs was estimated by 
Bradford assay (Thermo Fischer Scientific, USA).  
Release kinetics 
In order to investigate release mechanisms, release data were fitted to various 
kinetic models i.e., Zero-order (C = K0t), First-order (LogC = LogC0 – Kt/2.303), 
Higuchi (Qt = Kt
1/2
), and Korsmeyer-Peppas (Mt/M∞ = kt
n
).  Based on the R
2 
value, best 
fit model was identified. Diffusion exponent (n) of Korsmeyer-Peppas equation was 
utilized to understand the mechanism of release.    
 
Stability analysis of IgG by ultraviolet circular dichroism spectroscopy  
Circular dichroism (CD) spectroscopy was performed to evaluate effect on 
secondary structure of IgG from the released sample. Consequently, released sample was 
diluted using 10 mM phosphate buffer. IgG freshly prepared standard solution was used 
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as control. Concentration was adjusted to 0.05mg/mL for both sample and control. CD 
spectra was collected over a range of 200-250 nm using Jasco 720 spectropolarimeter at 
room temperature at a scan speed of 20 nm/min. Cuvette of 0.01 cm path length was 
employed for all measurement. An average of three signals was recorded and 
measurements were reported as ellipticity (θ, mdeg). 
 
In vitro degradation study of PBG-2 copolymer 
 In Vitro degradation studies were performed by taking approximately 20 wt% 
gelling solution (100 μL, n=3) in phosphate buffered saline (PBS), pH 7.4. PBG-2 
copolymer was incubated under various conditions. These conditions are; (i) gel in pH 
7.4 PBS at 37°C, (ii) gel in presence of enzymes acetylcholinesterase (14.7 mU/mL) and 
butyrylcholinesterase (5.9 mU/mL), (iii) gel in pH 9.0 borate buffer at 37°C and (iv) gel 
incubated in pH 7.4 PBS at 40°C. Buffer volume was kept constant at 4mL under all four 
conditions. Solutions were replaced every 5 day. Samples were withdrawn after 0, 5, 15, 
30, and 45 days, centrifuged to collect sediment and freeze-dried further subjected to 
GPC and XRD analyses.   
 
In vivo safety assessment 
Use of animals in this study adhered to the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. It was approved and monitored by the 
North Carolina State University Institutional Animal Care and Use Committee. In vivo 
ocular histology studies were performed in New Zealand White Rabbits to evaluate 
intravitreal toxicity after injecting 100µl of filter sterilized low endotoxin thermosensitive 
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gel. Rabbits from each group were euthanized at 1, 4, 16 and 33 weeks after injection. 
Euthanasia was performed by intravenous injection of a barbiturate based agent. 
Immediately after euthanasia, eyes were enucleated and placed in Davidson‘s solution for 
24 hours, followed by alcohol. Central sections of each globe, including the optic nerve, 
were stained with H&E and examined using light microscopy.   
 
Result and discussion  
 
Synthesis and characterization 
PBG-1 and PBG-2 copolymers were synthesized successfully by ring opening 
bulk copolymerization method. The process of block copolymerization of ε-caprolactone 
initiated by dihydroxyl PEG involved two steps. In the first step, ring-opening 
polymerization of ε-caprolactone initiated by dihydroxyl PEG formed a TB copolymer 
with a central PEG block and two lateral PCL blocks. The TB copolymer served as 
macroinitiator and opened the ring of L-lactide in the second step. The resulting polymer 
presented a chain structure of PLA-PCL-PEG-PCL-PLA. On the other hand, 
copolymerization initiated by PEG propagated at one end only.  
Proton NMR showed all the characteristic peaks for the polycaprolactone, 
polylactide and mPEG residues. 
1
H NMR spectrum of PBG-1 and PBG-2 copolymer in 
deuterated chloroform was observed in Figure 3.3 A and Figure 3.3 B respectively. 
Typical signals of PLA, PCL and PEG components were observed; Signals at 1.5 (–
CH3;g) and 5.1 ppm (–CH;f) were assigned to PLA blocks, 1.3 (a), 1.6 (b), 2.3 (c) and 
4.0 (d) ppm to the different methylene protons (–CH2–) of PCL blocks, and 3.6 ppm (–
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CH2–) to PEG blocks, respectively. A peak at 3.38 δ ppm was denoted to terminal 
methyl of (-OCH3-; e) of PEG.    
Molecular weights (Mw and Mn) and PDI of PBG copolymers were determined 
by GPC. A unimodal distribution of MW was observed (not shown here). The MWs of 
block copolymers were very close to feed ratio. PDI was also below 2.0 describing 
narrow distribution of MWs. 
1
H-NMR and GPC were applied to calculate the MW of 
block copolymers. As summarized in Table 3.1, experimental values were consistent 
with theoretical values derived from feed ratio. Hence for simplicity, theoretical values 
are mentioned in the following text.  
 
Table 3.1 Characterization of PBG Copolymers  
Name Structure Total Mn
a
 
(theoretical) 
Total Mn
b
 
(calculated) 
Total Mn
c
 
(calculated) 
Mw
c
 
(GPC) 
PBG-
1 
PLA250-PCL850-PEG1050-
PCL850-PLA250   
3250  2890 3085 3108 
PBG-
2 
PEG550-PCL825-PLA500-
PCL825-PEG550  
3300 2910 3020 3120 
a: Theoretical value, calculated according to the feed ratio.  
b: Calculated from 
1
H-NMR. 
c: Determined by GPC analysis.    
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Figure 3.3 Proton (
1
H) Nuclear magnetic resonance (NMR) spectroscopy (A) PLA-PCL-
PEG-PCL-PLA (PBG-1); (B) PEG-PCL-PLA-PCL-PEG (PBG-2)  
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In order to evaluate crystallinity, PBG-1 and PBG-2 copolymers were analyzed 
for XRD patterns (Figure 3.4A and 3.4B). Interestingly, PBG-1 exhibited crystalline 
peaks of PCL at 2θ = 21.5° and 23.9°, whereas PBG-2 was devoid of any such peaks.  
  
 
Figure 3.4 X-ray diffraction (XRD) analysis (A) PLA-PCL-PEG-PCL-PLA (PBG-1); (B) 
PEG-PCL-PLA-PCL-PEG (PBG-2) 
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Sol-gel transition 
PBG copolymers reported in this study are amphiphilic in nature containing 
hydrophilic block (PEG) and hydrophobic block(s) (PCL and/or PLA). Synthesized PBG 
copolymers exhibited a temperature-dependent reversible sol-to-gel transition in water: a 
sol-to-gel transition (at the lower transition temperature) and a gel-to-precipitate 
transition (at the upper transition temperature). PBG-1 and PBG-2 copolymers 
(approximately similar MW but different arrangement) did not significantly alter the 
thermosensitive behavior. Change in block arrangement may enhance intermolecular and 
intramolecular hydrophobic interactions of the polymers. Both PBG copolymers are 
soluble in water and exhibit sol-gel transition behavior. However, PEG at the terminal 
(PB) exhibited good aqueous solubility. For both copolymers, rise in aqueous polymer 
concentration from 15 to 30 wt% significantly shifted CGT to lower and CPT to higher 
values. The polymer solutions formed translucent sol at room temperature.  
Sol-gel transition curves for PBG-1 and PBG-2 (Figure 3.5), was compared to 
understand the effect of hydrophobicity on the sol-gel behavior of block copolymers. 
Increased hydrophobicity of PBG-1 has reduced the CGT and shifted the value of CPT at 
higher temperature. Higher hydrophobicity of polymers may enhance the intramolecular 
and intermolecular hydrophobic interactions even at lower temperature compared to the 
hydrophilic copolymers which lead to lower CGT. Additionally, these hydrophobic 
interactions allow more rigid gel matrix and hence delay polymer precipitation at higher 
temperature (CPT).      
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Figure 3.5 Sol-Gel transition of (A) PLA-PCL-PEG-PCL-PLA (PBG-1); (B) PEG-PCL-
PLA-PCL-PEG (PBG-2) 
 
In order to understand the effect of block arrangement on thermogelling behavior, 
sol-gel transition curves of PBG-1 and PBG-2 was compared. Interestingly, CGT and 
CPT for PBG-1 copolymer were significantly lower than PBG-2 copolymer at any 
respective concentration. This behavior may be attributed to the different mechanism of 
gelation of these block copolymers.  Effects of arrangement of blocks and hydrophobicity 
of PBG on sol-gel transition behavior are in agreement with previously published reports 
of PLGA-PEG-PLGA (173) and PEG-PLGA-PEG (174) copolymer hydrogels.  
Both types of copolymers (i) hydrophobic segments at the terminals PBG-1 and 
(ii) hydrophilic segments at the terminals PBG-2 can be dissolved via micellization where 
the core is composed of hydrophobic segments and shell is made up of hydrophilic 
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segment. Therefore, interaction of PEG with water molecules was dominated at low 
temperature (4°C) allowing polymer to solubilize. In contrast, elevation in temperature 
may cause polymer aggregation and initiate the process of micellization. PBG-1 
copolymers possess hydrophobic terminals and hence may possibly behave differently in 
aqueous solution relative to PBG-2 copolymers. It might be due to strong hydrophobic 
interactions between PCL or PCL-PLA chains which can significantly overcome weak 
hydrophilic interactions (hydrogen bonds) between PEG and water molecules.  
 
Viscosity measurement 
Table 3.2 describes the kinematic viscosity of 15 wt% aqueous gelling solutions 
of different block copolymers at various temperatures ranging from 5°C to 25°C. 
Kinematic viscosities of PBG copolymer solutions accelerated with rise in temperature. 
Interestingly, at any given temperature, increase in MW of block copolymers exhibited 
higher viscosity. Also, viscosity of hydrophobic polymer was considerably higher relative 
to PBG-2 as shown in Figure 3.6. It is speculated that hydrophobic interactions exerted 
by PCL or PCL-PLA blocks (hydrophobic copolymers) are significantly stronger at any 
given temperature relative to hydrophilic copolymers, irrespective of approximately 
similar MW. In addition, as temperature of the solution rises, these hydrophobic 
interactions also begin to dominate which eventually improve the viscosity of aqueous 
polymer solution. Interestingly, polymer arrangement also exhibited noticeable effect on 
viscosity. Hence, kinematic viscosity of PBG-2 solution was significantly lower 
compared to PBG-1 aqueous solution.  
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Table 3.2 Viscosity of thermosensitive gelling solutions (20 wt %) at various 
temperatures  
 
Block 
copolymers 
Viscosity (cp) at various temperature 
5ºC 10ºC 15ºC 20ºC 25ºC 30ºC 
PBG-1 3.06 ± 0.05  3.32 ± 0.11  3.62 ± 0.07  4.15 ± 0.12  4.87± 0.11   - 
PBG-2 2.18 ± 0.11  2.37 ± 0.09  2.63 ± 0.06  3.02 ± 0.08  3.39± 0.14   4.08 
 
 
Figure 3.6 Kinematic viscosity of (A) PLA-PCL-PEG-PCL-PLA (PBG-1); (B) PEG-
PCL-PLA-PCL-PEG (PBG-2) 
 
At low temperature, the viscosity of the PBG copolymers solution remains close 
to that of water. This fluid-like zone corresponds to a homogeneous solution in which the 
block copolymers could be completely dissolved in water. At intermediate temperatures, 
the solution viscosity increases as the system enters a gel-like zone. On further increase 
of the temperature, the viscosity goes through a sharp maximum and then drops rapidly. 
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At higher temperatures, the viscosity returns to a value close to that of water, and then 
increases on entering a fluid-gel transition zone or precipitation zone. This last effect is 
presumably associated with phase separation of the solution. The transition from the sol 
state to a structured network gel caused a viscosity change because of the aggregation of 
the PCL hydrophobic segments. The maximum viscosity of the copolymer solution 
increased with increasing hydrophobicity of the copolymer and with increasing 
copolymer concentration.  
 
In vitro cytotoxicity and cell culture study 
In vitro cell culture model has been utilized to study the compatibility between the 
PBG copolymer and biological system. PBG-1 and PBG-2 copolymers at various 
concentrations were exposed to D407 cells for 48 h. LDH is the cytosolic enzyme, which 
is secreted into the cell supernatant following membrane damage. Concentration of 
released LDH provides a direct estimation of polymer toxicity. Results (Figures 3.7) 
indicate less than 10% of LDH release at any given concentration for both the cell types. 
The results were not significantly different than negative controls i.e., cells without 
treatment.   
 Results observed in LDH assay were further confirmed by employing MTS cell 
viability study. In order to study metabolic response, D407 cells were incubated with 
PBG-1 and PBG-2 block copolymers at various concentrations. Results indicated in 
Figure 3.8 demonstrate that more than 90% of cells are viable even after 48 h of polymer 
exposure. No significant difference in cell viability is observed relative to negative 
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control. Results obtained from LDH and MTS assay indicated negligible toxicity 
suggesting excellent safety profile of block copolymers for back of the eye applications. 
 
 
Figure 3.7 LDH assay of (A) PLA-PCL-PEG-PCL-PLA (PBG-1); (B) PEG-PCL-PLA-
PCL-PEG (PBG-2). Results are given as mean ± SD, n = 5. 
  
Figure 3.8 MTT assay of (A) PLA-PCL-PEG-PCL-PLA (PBG-1); (B) PEG-PCL-PLA-
PCL-PEG (PBG-2). Results are given as mean ± SD, n = 5. 
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In vitro release study of macromolecules  
The model macromolecule [(IgG, 150 kD), (IgG Fab‘, 110 kD), (IgG-Fab 50 kD) and 
(Octreotide, 1 kD)] drugs were utilized to evaluate the suitability of PBG copolymers as 
controlled release delivery systems. In vitro release studies were performed by adding the 
above mentioned model drugs in 20 wt% aqueous solution of respective PBG-1 and 
PBG-2 copolymers. To estimate the concentration of all model drugs, release samples 
were analyzed by Bradford Assay (Thermo Fisher scientific).   
In vitro release behavior of different MW of model drugs from PBG-1 and PBG-2 
thermosensitive gels was compared and represented in Figures 3.9 and 3.10. Release of 
these model drugs was noticeably affected by the block arrangements of the copolymers. 
Hydrophilic gelling polymer (PBG-2) exhibited faster release relative to hydrophobic 
gelling polymer (PBG-1) noticed in all macromolecule model drugs. Therefore, in vitro 
release profile of these drugs was sustained for longer duration in case of PBG-1 
compared to PBG-2. It is anticipated that PLA block at the terminal may have prolonged 
the release of macromolecule drugs due to hydrophobic nature relative to PBG-2 
copolymers. PBG-1 gelling polymer may form compact structure with smaller porosity of 
gel matrix relative to PBG-2 polymer. This structural difference may lower the diffusion 
of the macromolecule drugs across gel matrix resulting in prolong duration of release. 
This study also supports that decrease in crystallinity increase the drug release. 
According to XRD spectra, amorphous nature of PBG-2 gelling polymer exhibit faster 
drug release. 
In vitro release of lowest MW octreotide showed burst release of 35% and 30% 
with PBG-2 and PBG-1 respectively. Approximately, 90% cumulative release released 
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was observed in three days with PBG-2 and four days in case of PBG-1. Similarly, due to 
loose matrix of the thermosensitive gelling copolymer burst release was observed in all 
model drugs with both PBG-1 and PBG-2. Approximately, 90% cumulative drug release 
of IgG, IgG Fab‘, IgG-Fab was observed 19 days, 16 days, 10 days, in case of PBG-1 and 
14 days, 9 days, 7 days in case of PBG-2, respectively.   
 
Figures 3.9 In vitro drug release studies from PBG-1 copolymer. Results are given 
as mean ± SD, n = 3 
 
Figures 3.10 In vitro drug release studies from PBG-2 copolymer. Results are given as 
mean ± SD, n = 3 
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In vitro release kinetics 
Table 3.3 Coefficient of determination (R
2
) for various kinetic models for in vitro release 
of octreotide, IgG Fab, IgG Fab‘ and IgG from PBG-1 
 
Block 
copolymers 
Korsmeyer-
Peppas 
Higuchi First-
Order 
Zero-
Order 
Best fit model 
R
2
 n R
2
 R
2
 R
2
 
Octreotide 0.993 0.301 0.964 0.982 0.866 Korsmeyer-
Peppas 
IgG-Fab 0.995 0.318 0.984 0.964 0.933 Korsmeyer-
Peppas 
IgG-Fab’ 0.997 0.360 0.994 0.979 0.951 Korsmeyer-
Peppas 
IgG 0.991 0.414 0.993 0.980 0.971 Korsmeyer-
Peppas 
 
 
 
Table 3.4 Coefficient of determination (R
2
) for various kinetic models for in vitro release 
of octreotide, IgG Fab, IgG Fab‘ and IgG from PBG-2 
 
Block 
copolymers 
Korsmeyer-
Peppas 
Higuchi First-
Order 
Zero-
Order 
Best fit model 
R
2
 n R
2
 R
2
 R
2
 
Octreotide 0.997 0.346 0.979 0.985 0.873 Korsmeyer-
Peppas 
IgG-Fab 0.995 0.293 0.976 0.954 0.922 Korsmeyer-
Peppas 
IgG-Fab’ 0.990 0.347 0.987 0.961 0.950 Korsmeyer-
Peppas 
IgG 0.994 0.367 0.992 0.977 0.957 Korsmeyer-
Peppas 
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Stability analysis of IgG by ultraviolet circular dichroism spectroscopy  
 In CD spectra, negative band near 218 nm that corresponds to presence of β-
sheets in IgG structure have been observed. There was no difference in peak maxima 
observed between standard and sample (Figure 3.11). Results indicated that secondary 
structure of IgG was not destabilized by PBG-2 polymer.  
 
Figure 3.11 Circular dichroism spectroscopy of IgG from PBG-2 copolymer (A) Standard 
IgG; (B) Sample IgG 
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In vitro degradation studies 
 Weight loss of PBG-2 copolymer: Similar degradation pattern was observed 
under all four conditions as shown in Figure 3.12. Total weight loss after 45 day was 
31% with PBS pH 7.4 and 34% with PBS pH 7.4 with acetylcholinesterase and 
butylcholinesterase at 37
o
C. In addition, higher weight loss was observed at accelerated 
conditions, 44%, borate buffer pH 9.0 at 37
 o
C and 39% with PBS pH 7.4 at 40
o
C. The 
rate of degradation was most rapid in borate buffer (pH 9.0) incubated at 37°C. 
Accelerated conditions such as pH 9.0 (37°C) and high temperature (40°C) exhibited 
weight loss of ~45% and ~40%, respectively which were significantly higher than weight 
loss observed under normal condition (pH - 7.4, 37°C) i.e., ~35%. No significant effect of 
enzymes was observed on polymer degradation relative to other conditions without using 
enzyme.  
 
 
Figure 3.12 Degradation of PBG-2 (PEG-PCL-PLA-PCL-PEG) gelling polymer at 
different conditions (Weight loss Vs time). Results are given as mean ± SD, n = 3.    
 76 
 
 
GPC analysis of PBG-2 copolymer: The gelling polymer was degraded at a 
faster rate due to its amorphous and hydrophilic nature (Figure 3.13). Approximately 
50% MW loss was noticed in 5 days. Similar pattern of degradation was observed under 
all four conditions. After hydrolytic degradation of PEG, PCL was present at the 
terminal. Therefore, degradation is slow and MW was fairly constant till 45 days. 
 
 
 
Figure 3.13 Molecular weight (MW) loss estimated by GPC of PBG-2 
(PEG-PCL-PLA-PCL-PEG) gelling polymer. Results are given as mean ± SD, n = 
3.   
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XRD analyses of PBG-2 copolymer: In order to evaluate crystallinity of gelling 
polymer, X-ray diffraction studies were conducted. Figures 3.14, 3.15, 3.16, and 3.17 
illustrate XRD patterns of gelling polymer at 0, 5, 15, 30, and 45 days incubated under 
four different conditions. Gelling polymer exhibited three characteristic crystalline peaks 
of PCL blocks at diffraction angles (2θ) of 21.5°, 24°, and 28°. In case of group A 
(Fig.3.14) and group B (Fig.3.15) crystallinity was observed after 30 days. However, 
crystallinity was observed at 5 day onwards for group C (Fig.3.16) and 15 days onwards 
with group D (Fig. 3.17). The rate of degradation was more rapid under accelerated 
condition relative to normal condition. Rapid degradation of gelling polymer may be due 
to amorphous nature and hydrophilicity of PEG at the terminal. The degradation is 
primarily caused by ester hydrolysis. No significant effect of enzymes was observed on 
degradation.   
The fast degradation of gelling polymer was found more due to amorphous and 
hydrophilic nature of gelling polymer. However, degradation rate was reduced after 5 
days as observed by MW loss analyzed by GPC. It could be due to exposure of PCL flank 
after the degradation of PEG flank presented at the terminal end.  However, at accelerated 
condition the rate of degradation of polymer was found more as compare to normal 
condition. Conversely, no significant effect of enzyme degradation was observed. 
Further, XRD results indicate increase of crystallinity with progress of degradation time. 
This could be due to increase of PCL component after degradation of PEG. 
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Figures 3.14 XRD patterns for Group - A  (PBS pH – 7.4, 37⁰ C) 
 
 
Figures 3.15 XRD patterns for Group - B (Enzymes, PBS pH – 7.4, 37⁰ C) 
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Figures 3.16 XRD patterns for Group - C (Borate buffer, pH – 9.0, 37⁰ C) 
 
 
Figures 3.17 XRD patterns for Group – D (PBS, pH – 7.4, 40⁰ C) 
 
 80 
 
 
In vivo safety assessment 
Ocular histopathology was performed at weeks 1, 4, 16 and 33 after intravitreal 
injection to New Zealand white Rabbit (Table 3.5). Results reported in Figures 3.18 (A)  
1 week control (B) 1 week (C) 4 week (D) 16 week  and (E) 33 week indicated no 
evidence of inflammation or toxicity associated with PBG-2 copolymer. Some rabbit eyes 
exhibited mild inflammation which may be injection procedure associated lens trauma. 
Based on these findings, it appears that the test articles are well tolerated by the rabbit 
eyes, without evidence of overt inflammation. Moreover, histopathological evidence of 
tissue damage indicated excellent biocompatibility of PBG copolymer. However, changes 
associated with injection procedure are relatively common and may cause most of the 
inflammatory and tissue damage observed in histology study.  
 
Table 3.5 Histology study of PBG-2 copolymer in New Zealand white rabbit 
 
Rabbit Number Treatment Euthanasia 
No. 10 IVT saline 1 week 
No. 12 IVT PB Gel  1 week 
No. 21 IVT PB Gel  4 weeks 
No. 19 IVT PB Gel  16 weeks 
No. 20 IVT PB Gel  33 weeks 
  
 
 
8
1
 
 
Figure 3.18 Ocular histopathology after intravitreal injection of PBG-2 using light microscopy after (A) 1 week Control; (B) 1 week; 
(C) 4 week (D) 16 week (E) 33 week     
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Conclusion 
Compositions of PLA-PCL-PEG-PCL-PLA and PEG-PCL-PLA-PCL-PEG block 
copolymers were successfully synthesized and evaluated for their utility as injectable in 
situ hydrogel forming depot for controlled ocular delivery of macromolecules. Sol-gel 
transition and rheology revealed that PBG-2 block arrangements were easy to handle at 
room temperature and easy to administer through small gauge needle. In vitro cell 
cytotoxicity studies confirmed that PBG copolymers were superior biomaterials for 
ocular delivery. PBG copolymers also exhibited sustained release and the release pattern 
was dependent on the hydrophobicity and hydrophilicity of the PBG copolymers. It is 
anticipated that much longer release can be obtained by altering block composition or 
change in hydrophobicity and/or hydrophilicity of the gelling polymer. In vitro release 
pattern were in conjunction with approved facts that amorphous and hydrophilic polymer 
degrade fast. CD spectroscopy results revealed that no changes in the secondary structure 
of IgG. In vivo assessment of PBG-2 copolymer confirmed that it was well tolerated in 
the rabbit eyes studied up to 33 weeks. These outcomes clearly suggested that PBG based 
delivery systems may serve as a promising platform not only for back of the eye 
complications but also for the treatment of anterior segment diseases. 
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CHAPTER 4 
COMPOSITE NANOFORMULATION FOR LONG TERM OCULAR DELIVERY OF 
MACROMOLECULES: EFFECT OF MOLECULAR WEIGHT ON DRUG RELEASE  
 
Rationale 
Normal aging process of the eye is characterized by a continuous loss of 
photoreceptor (PR), Bruch‘s membrane thickening, choroid thinning, scleral stiffening, 
vitreous degradation, and accumulation of debris. Among the posterior segment diseases 
diabetic retinopathy, macular edema, and macular degeneration are the leading causes of 
age-related vision loss. It represents 14% of the total causes of blindness globally (175) 
(176). Macular degeneration ensures when a small area in the retina (macula) 
deteriorates. It develops with age; hence it is referred as age-related macular degeneration 
(AMD). It is a degenerative process that damages the retinal pigment epithelium (RPE) 
and PR (1). With progression, AMD can be classified into the dry and wet forms. This 
classification is based on the absence or presence of vascular growth progression from 
the choroidal side toward the retina. It is subdivided into non-neovascular (NNV) and 
neovascular (NV) AMD. NNV is known as dry AMD and NV is called wet-AMD (177). 
In wet-AMD, new blood vessels from the choroid may leak, leading to macular edema. If 
left untreated, the progression may cause a centrally blinding disciform scar. Multiple 
factors such as oxidative stress, lipid metabolism, immune system activation, and 
angiogenesis play a key role in AMD pathogenesis (8). 
    Over the past decade, significant progress has been made in the treatment of 
AMD owing to an increased understanding of the mechanisms of ocular angiogenesis. 
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Several factors are associated with ocular angiogenesis, with vascular endothelial growth 
factor (VEGF) playing a central role (11). VEGF-A is a 46 kDa glycoprotein produced by 
ocular cells in response to oxidative stress. VEGF-A is the most potent mediator of both 
retinal and choroidal angiogenesis (178), (12). It stimulates endothelial cell growth, 
promotes vascular permeability and induces dissociation of tight junction components. In 
wet-AMD, a high level of VEGF is present below the RPE cell layer and around PR. 
VEGF inhibition via intraocular anti-VEGF to prevent the formation of new blood 
vessels represents the cornerstone of wet-AMD therapies (12). Recombinant humanized 
anti-VEGF antibody fragments or soluble receptor decoys (e.g. ranibizumab: Lucentis®; 
Genentech/Roche), pegaptanib (Macugen®), aflibercept (Eylea®; Regeneron 
Pharmaceuticals), and bevacizumab (off label drug: Avastin®; Genentech/Roche), are 
currently Food and Drug Administration (FDA) approved therapies for wet-AMD (1). 
Current treatments for posterior eye diseases suffer from various challenges including 
frequent intraocular injections, related adverse effects, and high cost of the treatment. 
Because of several anatomical/physiological barriers present in the eye, drug delivery to 
the posterior ocular segment is significantly impaired (48). However, the application of 
nanotechnology has been shown improvement in ocular drug delivery and offers 
numerous treatment options (2).  
    Various FDA approved biodegradable polymers such as polycaprolactone (PCL), 
polylactic acid (PLA), polyglycolic acid (PGA) and polyethylene glycol (PEG) have been 
extensively investigated for controlled delivery of macromolecules as matrices of NP 
formulations (154) (90). Several investigators have applied block copolymers such as 
polylactide-co-glycolide (PLGA) (179), PEG-PLGA (180), PCL-PEG-PCL (181), for the 
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development of controlled release of macromolecules or biologics (protein, peptide, 
antibody, Fab, Fc fragments) formulations. As a result, there is a need to develop 
biocompatible polymeric system which provides controlled release of macromolecule 
drugs for longer periods of time. In order to overcome this problem, various sequences of 
block copolymers can be tailor-made by considering physical chemical properties of 
FDA approved polymers. Among those, PEG provides hydrophilicity to copolymer 
which helps to degrade the matrix. PCL is another polymer which possesses crystallinity 
and hydrophobic in nature. This enhances the drug entrapment efficiency. PLA and PGA 
are other polymers; more hydrophilic relative to PCL. This polymer contributes to rapid 
degradation (182), (183). Based on the properties of these polymers, various tailor made 
combinations on the basis of different MW, ratios and arrangements can be designed to 
achieve a particular release rate. Moreover, block copolymers are amphiphilic in nature 
rendering these materials suitable for macromolecule delivery.    
   Therefore, the objective of this work is to synthesize the pentablock (PB) 
copolymers of a unique ratios and MWs consisting each block (PEG, PLA and PCL) for 
controlled long term delivery of macromolecules for the treatment of AMD. In this study, 
PB copolymers have been synthesized by sequential ring-opening bulk copolymerization 
method to achieve the long term release of lysozyme (14.3 kDa; Lyz), IgG-Fab (50 kDa; 
Fab) and IgG (150 kDA). The hypothesis of this project is centered on the release of the 
macromolecules encapsulated in NPs based on different molecular weight. The study has 
been designed to examine the effect of hydrodynamic diameter of molecules on the in 
vitro drug release profile as a function of MWs of macromolecule drugs. NPs have been 
characterized for particle size, PDI, entrapment efficiency, drug loading and in vitro 
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release profiles. Furthermore, in order to minimize burst release and to achieve 
continuous zero-order drug release, the experiments designed towards a novel composite 
formulation comprising drug loaded NPs suspended in thermosensitive gelling aqueous 
solutions. In addition, biocompatibility studies have been performed in order to ensure 
the safety of PB copolymers.   
 
Materials and methods 
Materials 
Poly (ethylene glycol) (PEG, 4 kDa), methoxy-PEG (550 Da), stannous octoate, 
ε-caprolactone, poly (vinyl alcohol) (PVA), lipopolysaccharide, and Micrococcus luteus 
were procured from Sigma-Aldarich (St. Louis, MO). L-lactide and 
hexamethylenediisocynate (HMDI) were purchased from Acros organics (Morris Plains, 
NJ). Micro-BCA
TM
 assay kit was obtained from Fisher scientific Inc., (Rockford, IL). 
Mouse tumor necrosis factor alpha (TNF-α), Interleukin 6 (IL-6), Interleukin 1 beta (IL-
1β), and enzyme-linked immunosorbent assay (ELISA) kit were purchased from e-
Bioscience Inc., (San Diego, CA). All other reagents used in this study were of analytical 
grade. 
 
Methods  
Synthesis of PB copolymers  
PB copolymers i.e, poly(caprolactone)-poly(lactic acid)-poly(ethylene glycol)-
poly(lactic acid)- poly(caprolactone) (PCL-PLA-PEG-PLA-PCL i.e., PB-A and PB-B) 
and poly(ethylene glycol) -poly(caprolactone) -poly(lactic acid) -poly(caprolactone)-
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poly(ethylene glycol) (PEG-PCL-PLA-PCL-PEG i.e., PBG-2) were synthesized by ring-
opening bulk polymerization method (154), (90). PB-A copolymer was synthesized by 
two steps sequential ring-opening polymerization for NP preparation. PEG (4 kDa) was 
utilized as macroinitiator and stannous octoate served as catalyst. In the first step, triblock 
(TB) copolymer PLA-PEG-PLA (Figure 4.1, step 1) was synthesized by polymerization 
of PLA at two open hydroxyl ends of PEG. Lactic acid and stannous octoate (0.5% w/w) 
were added to anhydrous PEG with temperature raised to 150°C. After 24 h the reaction 
mixture was dissolved in dichloromethane (DCM) followed by precipitation in cold 
petroleum ether. The precipitated TB copolymers were filtered and dried overnight by 
using high speed under vacuum at room temperature. In a second step, PLA-PEG-PLA 
(TB) copolymers were added to ε-caprolactone to prepare PB-A and PB-B (Figure 4.1, 
step 2). TB copolymer and e-caprolactone were placed in round bottom flask under inert 
condition and temperature was raised to 150°C. To this reaction mixture, stannous 
octoate (0.5% w/w) was added and the reaction was allowed to run for 24 h. 
Subsequently, PB copolymer was purified by cold ether precipitation method. The 
product was dried under vacuum and stored at -20°C until further use.   
The thermosensitive gelling polymer (PBG-2) was synthesized by ring-opening 
bulk copolymerization as described previously in chapter 3, Figure 3.2. 
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Figure 4.1 Synthesis scheme for PB-A and PB-B (PCL-PLA-PEG-PLA-PCL) copolymer 
  
Characterization of PB copolymers 
The copolymers were characterized for MW and purity by 
1
H NMR spectroscopy 
and crystallinity by XRD analysis.  
Proton nuclear magnetic resonance (
1
H-NMR) spectroscopy 
1
H-NMR spectra of TB and PB copolymers were acquired on a 400 MHz NMR 
instrument (Varian Inc., Palo Alto, CA). The chemical shift values were reported as δ in 
parts per million (ppm). NMR samples were prepared by dissolving each copolymer in 
deuterated chloroform in a 5-mm outer diameter NMR tubes (Wilmad-Lab Glass, 
Vineland, NJ). 
X-ray diffraction (PXRD) analysis 
The crystallinity of PB copolymers was determined by XRD analysis with Rigaku 
MiniFlex automated X-ray diffractometer (Rigaku, The Woodland, TX). It was equipped 
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with Ni-filtered Cu-Kα radiation (30 kV and 15 mA). The analysis was performed at 
room temperature at a scanning rate of 5°/min. 
Phase transition (gelation) study of PBG-2 thermosensitive gelling copolymer 
The sol-gel transition behavior of PBG-2 copolymer was examined by test tube 
inverting method as mentioned in chapter-3, Figure 3.5. 
 
 In Vitro biocompatibility studies 
 Mouse macrophage cells (RAW-264.7) cells were maintained according to ATCC 
guidelines at 37°C, 5% CO2 and 95% humidified atmosphere for 48 h. PB copolymers 
(PB-A, PB-B, and PBG-2) were dissolved in ACN at a concentration of 25 mg/mL. Two 
hundred microliters of this solution were aliquoted in 48-well cell culture plates and 
incubated for overnight under UV lights (laminar flow). The process continued with the 
ACN evaporation and sterilization of resulting polymer film. After the sterilization, 
RAW-264.7 cells (5.0 x 10
4
) were seeded in each well of the cell culture plate and 
incubated for 24 h at 37°C and 5% CO2. After completion of the incubation period, cell 
supernatants were analyzed for the presence of cytokines i.e., TNF-α, IL-6 and IL-1β. 
Lipopolysaccharide (LPS) was selected as positive control whereas, cells without any 
treatment were considered as negative control. Cytokines level (in pg/mL) was measured 
by ELISA method according to manufacturer‘s protocol (e-Biosciences, San Diego, CA). 
Standard calibration curves for TNF-α, IL-6 and IL-1β were prepared in the concentration 
ranges of 10-750 pg/mL, 5-500 pg/mL and 10-500 pg/mL, respectively (154).  
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Preparation of NPs     
Lyz, Fab and IgG-encapsulated NPs were prepared by water in oil in water 
(W1/O/W2) double emulsion solvent evaporation method using PB-A and PB-B 
copolymers (154), (90). Briefly, Fab containing aqueous solution (W1 phase) was 
emulsified in the organic phase (dichloromethane: DCM) comprising PB-A or PB-B 
copolymer by drop-wise addition to the aqueous phase containing 2% w/v polyvinyl 
alcohol (PVA). This was subjected to probe sonication for 30 sec at 2W output to form a 
W1/O primary emulsion. The resulting primary emulsion was then added drop-wise to 5 
ml of 2% w/v PVA solution (W2 phase) under constant sonication for 60 sec at 2W 
output to prepare a W1/O/W2 double emulsion. To avoid the excessive heating and any 
possible degradation of macromolecule, emulsion preparation was carried out in ice-bath. 
The double emulsion was stirred at room temperature for 30 min followed by evaporation 
of DCM under vacuum using a rotatory evaporator to formulate the NPs. The emulsion 
containing NPs was centrifuged for 30 min at 20,000 rpm and 4°C followed by two 
washing cycles with distilled deionized water (DDW). The Lyz-loaded PB-A based NPs 
and IgG loaded PB-B based NPs were formulated according to the similar protocol. 
Finally, the Lyz, Fab and IgG-loaded NPs were freeze-dried in the presence of 5% w/w 
mannitol (as a cryoprotectant) and stored at -20°C until further use.  
 
Characterization of NPs 
Particle size and PDI 
Freeze-dried NPs were dispersed in DDW (1 mg/mL) and analyzed for size and 
distribution. Particle size was determined by Zetasizer (Zetasizer Nano ZS, Malvern 
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Instruments Ltd, Worcestershire, UK) at 90° scattering angel. All the NP samples were 
analyzed in triplicate. 
Percent entrapment efficiency (EE %) and drug loading (DL %) 
Lyz, Fab and IgG encapsulated freeze-dried NPs were examined for their 
entrapment EE and DL by estimating the amount of protein in the supernatant obtained 
from NPs preparation. Micro BCA
TM
 protein estimation kit was employed for the 
estimation of total protein. The samples were analyzed by a DTX 800 Multimode 
microplate reader (Beckman Coulter, Brea, CA). The standard curves of respective 
macromolecules (Lyz, Fab and IgG) ranging from 3.125 to 200 µg/ml were prepared in 
DDW. The following equations 1 and 2 were applied for the calculation of EE (%) and 
DL (%). 
  
% Encapsulation efficiency = (Initial amount of drug – Amount of drug in supernatant) *100    …Eq. 4.1   
     Initial amount of drug 
 
 
 % Drug loading =  Amount of drug in nanoparticle     * 100                      …Eq. 4.2 
    Total amount of drug and polymer 
 
In vitro release studies     
The PB copolymer based NPs were characterized for their ability to release the 
Lyz, Fab and IgG from native NPs and NPs suspended in thermosensitive gelling 
copolymer (composite nanosystem). In order to conduct the in vitro drug release studies, 
1 mg of each of Lyz, Fab and IgG equivalent freeze-dried NPs was suspended in 1 ml of 
Phosphate Buffer Saline (PBS; pH 7.4). The resulting NP suspension was then incubated 
in a water bath equilibrated at 37°C. At predefined time intervals, the suspension was 
centrifuged at 12,000 rpm for 30 min. Two hundred microliters of supernatant was 
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collected and replaced with the same volume of PBS. NPs were then resuspended and the 
release study was continued at 37°C. In a second set (composite nanosystem) of in vitro 
release studies, 1 mg equivalent of Lyz, Fab and IgG containing NPs was suspended in 
100 µl of an aqueous solution of thermosensitive gelling copolymer (PB-C; 15 wt%). The 
resulting suspension was incubated in an Eppendorf tube at 37°C for 30 min. Once the 
gel was formed, an aliquot (1 ml) of PBS (pre-incubated at 37°C) was slowly added. At 
predetermined time intervals, 200 µl of supernatant was collected and replaced with the 
same volume of fresh PBS (pre-incubated at 37°C). The drug release samples were 
analyzed by Micro BCA
TM
 assay for total protein content according to the supplier‘s 
instructions (Fisher scientific, Rockford, IL). In vitro release experiments were performed 
in triplicate (n = 3) and expressed as percent cumulative drug release with time.    
Release kinetics  
In order to delineate the release kinetics mechanisms of Lyz, Fab and IgG from 
NPs and composite nanosystem, release data were fitted to first-order, Higuchi, Hixon 
Crowell, and Korsmeyer-Peppas models as given by Eqs. (3), (4), (5), and (6), 
respectively. 
 t/2.303K+loglog 10QQt        ...Eq. 4.3 
5.0
HK tQt         …Eq. 4.4 
(Q0
1/3
 – Qt
1/3
 = Khct)       …Eq. 4.5 
nkt/QQ t        …Eq. 4.6 
 In these Equations, Qt is the amount of drug released at time t, Q0 is the initial 
amount of drug in solution, K1 is first order release constant, KH is the Higuchi release 
rate constant, Khc is Hixon Crowell release rate constant, Qt/Q∞ is the fraction of drug 
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released at time t, Q∞ is the total amount of drug released, and k is a kinetic constant. The 
constant n is the release exponent explaining the drug release mechanisms and classified 
as Fickian diffusion (n ≤ 0.5), case-II transport (n = 1), anomalous transport (0.5 < n < 
1), and super case-II transport (n > 1) (184).   
 
Estimation of enzymatic activity of lysozyme 
The enzymatic activity of Lyz in the released samples was estimated by comparing with 
freshly prepared Lyz solutions and/or control samples. The controls were prepared with 
Lyz solution incubated at 37°C in PBS (pH 7.4). These solutions were parallel to the in 
vitro release study from composite nanosystem. In order to determine the enzymatic 
activity of Lyz, a stock solution of Micrococcus luteus (0.01% w/v) was prepared with 
phosphate buffer (66 mM, pH 6.15) and diluted to achieve the absorbance between 0.2 - 
0.6 at 450 nm. One hundred microliters of samples, standards, and controls were mixed 
with 2.5 ml of Micrococcus luteus suspension. The absorbance was measured at 450 nm 
over a period of 4 min at room temperature. Data were plotted for absorbance against 
time and slope was calculated to quantify the amount of Lyz in enzyme unit (EU). The 
EU units of Lyz (active) per mg of protein were calculated from the following equations 
4.7 and 4.8 (185).  
 
(0.1) (0.001)
(df) Blank)450nm/min A  -Test 450nm/min A (
sample of ml onein  Lyz of Units

  Eq. 4.7  
 sample ml onein  Lyz of mg
 sample of ml onein  Lyz of Units
sample of mg
Lyz of Units
            …Eq. 4.8 
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As per the definition of Lyz, one EU of enzyme is able to produce ΔAbs450nm of 
0.001 per minute at pH 6.15 and 25°C utilizing Micrococcus luteus suspension. The 
number 0.1 represented the volume of release samples, standards, or controls and df 
depicts the dilution factor. The biological activity observed for the release samples were 
compared with the respective controls at the same time points.  
 
Results and discussion 
 
Synthesis and characterization of PB copolymers  
PB-A, PB-B and PBG-2 (Chapter 3; Figure 3.2) were successfully synthesized by 
ring-opening bulk copolymerization of ε-caprolactone, and L-lactide. In the first step, TB 
copolymers were synthesized, purified and characterized as mentioned in the method 
section. The resulting TB A and B copolymers were composed of a PEG central block 
bearing two PLA sequences at both ends. Purified TB-A and TB-B copolymers were then 
utilized for the synthesis of the respective PB copolymers A and B respectively. 
Purity and molecular weight (Mn) of PB copolymers were calculated by 
1
H-NMR 
spectroscopy. As showed in Figure 4.2, typical 
1
H-NMR signal of a sharp peak at 3.65 δ 
ppm could be attributed to methylene protons (−CH2CH2O−) of PEG in TB-A 
copolymer (Figure 4.2A). PB-A was observed at 1.40, 1.65, 2.30 and 4.06 δ ppm 
representing the methylene (–CH2–) protons of - (CH2)5-, -OCO-CH2-, and -CH2OOC- of 
PCL units, respectively, (Figure 4.2B). Typical signals at 1.50 (-CH3) and 5.17 (-CH) 
ppm were assigned to PLA blocks. Figure 3C represents 
1
H-NMR spectra of PBG-2 
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copolymers (thermosensitive gel) represented in chapter 3; Figure 3.3B. Molecular 
weight (Mn) of PB copolymers was very similar to theoretical MWs (Table 4.1).  
 
 
Figure 4.2 
1
H-Nuclear Magnetic Resonance (
1
H-NMR) spectrogram of (A) TB-A and 
PB-A in CDCl3 
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Table 4.1 Characterization of PB copolymers  
 
Code Structure Total Mn
a
 
(theoretical) 
Total Mn
b
 
(calculated) 
PB-A PCL7000-PLA3000-PEG4000-PLA3000-PCL7000  22000 21034 
PB-B PCL7000-PLA6000-PEG4000-PLA6000-PCL7000  30000 27653 
a Theoretical value, calculated according to the feed ratio. 
b Calculated from 1H NMR    
 
 
Interestingly, TB-1 and TB-2 (PLA-PEG-PLA) copolymer exhibited a crystalline 
peak at 2θ = 16°, 19°, and 23° but, in PB-A and PB-B crystalline peaks of PCL shifted to 
2θ = 20.5° and 2θ = 21.5° represented in Figures 4.3 A and 4.3 B, respectively. XRD 
patterns of TB-A and TB-B indicated that PLA blocks retained their crystalline structure. 
Conjugation of PCL blocks at the terminals of TB-A and TB-B copolymers exhibited 
shift in the intensity of the crystalline peak showing the semi-crystalline structures of PB-
A and PB-B copolymers. Thus, the crystallinity of copolymers was easily controlled by 
the arrangement of polymer blocks in structural backbone. PBG-2 (Chapter 3; Figure) 
copolymer was devoid of any crystalline peak suggesting its amorphous nature. 
Previously published reports (186) suggested that a decrease in crystallinity enhanced the 
degradation of block copolymers. 
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Figure 4.3 X-Ray diffraction analyses of (A) TB-A and PB-A (B) TB- B and PB-B 
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Phase transition (gelation) of PBG-2 thermosensitive gel 
The thermosensitive gelling copolymers were amphiphilic in nature, containing 
hydrophilic block (PEG) and hydrophobic block(s) of PCL and/or PLA. The aqueous 
solution of PB-C was observed clear due to the self-assembly of polymeric chains into 
micellar structure which showed aggregation upon increasing the temperature and 
resulted in the gel formation. However, upper gel-sol conversion was due to an increased 
molecular motion of the hydrophobic chain of PCL and PLA. The aqueous solution of PB 
copolymers exhibited a sol-gel transition response upon increasing the temperature in the 
concentration range of 10wt-30wt%. The phase diagram (Chapter 3; Figure 3.5) revealed 
the critical gel concentration (CGC) from the solution to gel state conversion at 37°C. 
 
In vitro biocompatibility studies   
The release of various cytokines releases such as TNF-α, IL-6 and IL-1β in 
culture supernatant following 24 h exposure to PB-A, PB-B and PB-C copolymers were 
examined. The samples were analyzed via sandwich ELISA method. Results depicted in 
Figure 4.4 indicated the release of TNF-α (~200 pg/ml) in both groups, i.e., PB-A, PB-B 
and PB-C. However, the values were comparable to the negative control (cells without 
treatment) with no significant differences. Similarly, a negligible release of IL-6 and IL-
1β was observed, suggesting that these copolymers are safe for use.    
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Figure 4.4 In vitro biocompatibility of PB-A, PB-B and PBG-2 copolymers on RAW 
264.7 cells estimating the levels of TNF-α, IL-6 and IL-1β in the supernatants of PB 
copolymers. Results are given as mean ± SD, n = 5. 
 
Characterization of NPs 
Particle size and PDI 
Lyz, Fab and IgG were encapsulated in PB-A and/or PB-B copolymers by W1/O/W2 
double emulsion solvent evaporation method. NPs are ranging in diameter from 200-250 
nm (Table 4.2). Unimodal size distribution with narrow PDI was observed. These results 
suggested that the hydrodynamic diameter of macromolecules had no significant effect 
on the particle size distribution of NPs. 
  
Entrapment efficiency (EE) and drug loading (DL)    
  As presented in Table 4.2, the EE of Lyz, and Fab in PB-A NPs were ~42% and 
~45%, respectively. The low EE of NPs may be due to hydrophilicity of macromolecules 
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escaping from primary emulsion phase to the large volume of the external phase. 
However NPs prepared from PB-B copolymer exhibited a slightly higher EE ~49% for 
Fab. This could be due to the reason that the high hydrophobicity of PB-B copolymer 
relative to PB-A may have produced a rapid polymer precipitation to form the NPs during 
the solvent evaporation step and provided a slightly higher EE. It is also plausible that EE 
and DL were affected by the increased ratio of lactide during the NP preparation. The 
hydrophobic segment of PLA-PCL chain and the hydrophilic drug were associated with 
the PEG core which reduced the escape to the outer aqueous phase. Also, the EE and DL 
of IgG (molecular weight ~150 kDa) encapsulated in PB-B NPs was calculated to 
determine the effect of molecular weight in EE and DL of PB copolymers. Results 
showed that due to the high molecular weight and hydrophobicity of PB-B, it was able to 
encapsulate (~51% w/w) the high molecular weight macromolecule (Table 4.2). Overall, 
the application of high molecular weight of PB copolymers ensured a higher EE and DL 
of large molecules encapsulated in NPs. 
 
Table 4.2 Characterization of Lyz, Fab and IgG loaded NPs 
 PB 
Copolymers 
Large 
molecule 
Particle 
size (nm) 
Poly-
dispersity 
index 
Entrapment 
efficiency 
(% w/w) (n=3) 
Loading 
(% w/w) 
(n=3) 
 
PB-A Lysozyme 
(15 kDa) 
221.4 0.392 42.85 ± 1.57 6.31 ± 0.79 
 IgG-Fab (50 
kDa) 
266.1 0.432 45.41 ± 1.30 5.46 ± 0.51 
PB-B  IgG-Fab (50 
kDa) 
238.5 0.398 49.28 ± 1.86 11.28 ±1.13 
 IgG (150 
kDa) 
201.8 0.360 51.19 ± 1.52 9.69 ± 0.46 
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In vitro release studies    
In vitro release profile of different MW of macromolecules Lyz (14.5 kDa), Fab 
(50 kDa) and IgG (150 kDa) were evaluated for both formulations; (A) PB-A and PB-B 
based NPs and (B) PB-A and PB-B NPs embedded in 15 wt% thermosensitive gelling 
copolymer (PBG-2).vBoth PB-A NPs formulations of Lyz and Fab demonstrated 
biphasic release profile i.e., initial burst release followed by sustained release as 
described in figures 4.5 and 4.6 respectively. Lyz exhibited significantly higher burst 
release (~21%) relative to Fab (~19%). It may be due to the fact that NPs have a certain 
amount of surface adsorbed drug, resulting into burst effect during the initial time period. 
Approximately, 80% of cumulative drug release was found in ~13 and ~35 days from 
Lyz and Fab PB-A NPs respectively. Therefore, to overcome this problem, hydrogels 
have been utilized to develop a formulation which can eliminate or minimize burst effect 
and offer zero-order drug release throughout the release period.  
 
Figure 4.5 In vitro release of Lyz encapsulated in PB-A NPs and Lyz encapsulated in PB-
A NPs suspended in PB-C thermosensitive gels (Composite nanoformulation). Results 
are given as mean ± SD, n = 3.   
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Figure 4.6 In vitro release of Fab encapsulated in PB-A NPs and Fab encapsulated in PB-
A NPs suspended in PB-C thermosensitive gels (Composite nanoformulation). Results 
are given as mean ± SD, n = 3  
 
Lyz and Fab encapsulated PB-A NPs were suspended in an aqueous solution of 
thermosensitive gelling polymer (PBG-2) termed as composite nanoformulation. 
Aqueous solution of PBG-2 copolymer remains in liquid state around room temperature 
but immediately transition from solution to hydrogel at the physiological temperature of 
37°C (sol-gel transition) entrapping NPs throughout the polymeric matrix. From 
composite nanoformulation, 80% cumulative release of Lyz was for ~27 days whereas 
Fab prolonged the release for ~49 days from PB-A NPs as illustrated in figures 4.5 and 
4.6 respectively. Such behavior is a result of NPs suspended into the gel matrix which 
served an additional diffusion barrier due to surface adsorbed drug. It also resulted in a 
zero-order release pattern of the encapsulated drug throughout the release period. The 
enzymatic activity of Lyz was analyzed by the lysozyme assay kit. The integrity or 
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stability of the protein molecules was not addressed in this work and an assessment of the 
compatibility of the polymers with the macromolecule remains to be elucidated in future 
studies.  
In addition, the effects of the MW of the PB copolymers (PB-A and PB-B) on Fab 
have been studied. Composite nanoformulation of Fab prepared from PB-A and PB-B 
copolymer demonstrated biphasic release. However, sustained release was observed from 
both of formulations as illustrated in figure 4.7. Although PB-A copolymer promises 
longer duration relative to PB-B but composite formulation of PB-B shows faster release 
compared to PB-A. It might be due to the high drug loading because of higher MW of the 
PB copolymer in addition to the reduced crystallinity of PB-B compared to PB-A. 
 
 
Figure 4.7 In vitro release (n=3) of Fab-encapsulated in PB-A NPs and PB-B NPs 
suspended in PBG-2 thermosensitive gels (Composite nanoformulation). Results are 
given as mean ± SD, n = 3.  
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Further, higher MW of PB copolymer (PB-B) was used to prepare NPs with Fab 
and IgG.  In vitro release profile of both NPs formulations of Fab (Fig. 4.8) and IgG (Fig. 
4.9) showed similar profiles as mentioned above. Fab (~21% w/w) and IgG (~18% w/w) 
exhibited higher burst release from the NPs alone. Similarly, composite nanoformulation 
minimizes the burst release (~9.78% w/w) and (~8.21% w/w) for Fab and IgG as 
described in figures 4.8 and 4.9 respectively. IgG composite nanoformulation sustained 
release for more than 8 weeks with high MW PB-B. 
 
 
 
Figure 4.8 In vitro release of Fab encapsulated in PB-B NPs and Fab encapsulated in PB-
B NPs suspended in in PBG-2 thermosensitive gels (Composite nanoformulation). 
Results are given as mean ± SD, n = 3 
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Figure 4.9 In vitro release of (n=3) IgG encapsulated in PB-B NPs and IgG encapsulated 
in PB-B NPs suspended in in PBG-2 thermosensitive gels (Composite nanoformulation). 
Results are given as mean ± SD, n = 3.  
 
In vitro release profiles of Lyz and Fab from PB-A copolymer and Fab and IgG 
from PB-B copolymer suggest that the hydrodynamic diameter of macromolecules may 
exert effect on drug release pattern as depicted in figures 4.10 and 4.11 respectively. The 
results suggest higher burst release and shorter release duration for Fab relative to IgG 
from their respective NPs. Lyz has smaller hydrodynamic diameter compared to Fab 
which may lead to rapid diffusion through both polymeric matrices of NP and from 
composite nanoformulation. Figure 4.12 represents the comparative release pattern of all 
the composite nanoformulations studied in this work.   
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Figure 4.10 In vitro release (n=3) of Lyz and Fab-encapsulated in PB-A NPs suspended 
in in PBG-2 thermosensitive gels (Composite nanoformulation). Results are given as 
mean ± SD, n = 3. 
 
Figure 4.11 In vitro release (n=3) of Fab and IgG-encapsulated in PB-B NPs suspended 
in in PBG-2 thermosensitive gels (Composite nanoformulation). Results are given as 
mean ± SD, n = 3. 
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Figure 4.12 In vitro release (n=3) of Lyz PB-A, Fab PB-A, Fab PB-B and IgG PB-B NPs 
suspended in in PBG-2 thermosensitive gels (Composite nanoformulation). Results are 
given as mean ± SD, n = 3.  
Release kinetics 
In order to evaluate the release mechanisms of NPs, in vitro drug release data 
were fitted in First-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas kinetic 
models. Results presented in Table 4.3 indicated that Korsmeyer-Peppas was the best fit 
model for all the formulations with R
2
 values ranging between 0.985-0.998. Moreover, n 
values in Korsmeyer-Peppas model for the release of Lyz, Fab and IgG from NPs were 
below 0.40 indicating the diffusion controlled release pattern. Interestingly, n values for 
composite nanosystem (NPs suspended in thermossensitive gel) of Lyz (0.402), Fab from 
PB-A (0.549), Fab from PB-B (0.582) and IgG (0.541) were suggested an anomalous 
diffusion controlled release mechanism. Hence, the release of macromolecules from 
composite nanosystem was controlled by diffusion as well as degradation of copolymer.  
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Table 4.3: Coefficient of determination (R
2
) for various kinetic models for in vitro 
release of Lyz, Fab and IgG from composite nanoformulation 
Block copolymers 
Korsmeyer-
Peppas 
Higuchi 
First-
Order 
Hixon 
Crowell 
Best fit 
model 
R
2
 n R
2 R2 R2 
Lyz NPs PB-A  
0.991 0.314 0.867 0.883 0.797 
Korsmeyer-
Peppas 
Lyz NPs PB-A suspended 
in thermosensitive gel 
0.985 0.402 0.961 0.947 0.883 
Korsmeyer-
Peppas 
Fab NPs PB-A 
0.996 0.492 0.996 0.945 0.911 
Korsmeyer-
Peppas 
Fab NPs PB-A suspended 
in thermosensitive gel 
0.997 0.582 0.988 0.972 0.995 
Korsmeyer-
Peppas 
Fab NPs PB-B 
0.994 0.974 0.951 0.866 0.794 
Korsmeyer-
Peppas 
Fab NPs PB-B suspended 
in thermos-sensitive gel 
0.990 0.569 0.983 0.959 0. 947 
Korsmeyer-
Peppas 
IgG NPs PB-B 0.998 0.388 0.965 0.863 0.781 
Korsmeyer-
Peppas 
IgG NPs PB-B suspended 
in thermosensitive gel   
0.998 0.541 0.995 0.980 0.955 
Korsmeyer-
Peppas 
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Enzymatic activity of lysozyme   
The biological activity of Lyz in the released samples taken at different time 
points was displayed in Table 4.4. It was observed that the enzyme activity in the 
released samples diminished with time due to the reason that macromolecules remained 
in the release medium for a long time interval. In addition, hydrophobic residues caused 
the protein adsorption on polymer surface that resulted in the loss of biological activity of 
the entrapped protein. A decrease in enzymatic activity can be attributed to storage 
conditions which may not be the expected case under in vivo conditions. It is anticipated 
that during the NP preparation (W1/O/W2 double emulsion), PEG (hydrophilic block) 
may have oriented at aqueous-organic interface. Hence, PEG may have reduced the 
interaction of Lyz with the hydrophobic polymer segments (PCL and PLA) which 
avoided the denaturation of large molecules. Therefore, it was concluded that enzyme 
activity of the entrapped Lyz was lower due to longer exposure in the release medium.  
 
Table 4.4 Enzymatic activity of lysozyme estimated in the released samples (n=3) 
Time (days) Specific enzyme activity (U/mg) x 10
3
 
Release samples Controls 
1 50.3 ± 1.9 55.1 ± 3.2 
7 41.2 ± 4.5 48.3 ± 3.8 
14 33.6 ± 4.1 40.2 ± 4.3 
21 24.5 ± 2.7 31.7 ± 3.8 
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Conclusion 
The presented study discussed the synthesis and characterization of PB copolymers for 
the preparation of the composite nanosystem to achieve a controlled and long-term drug 
release profile of macromolecules. In order to eliminate the burst release phase, a novel 
composite nanosystem comprised of Lyz, Fab and IgG-encapsulated PB-A and/or PB-B 
NPs suspended in PB-C thermosensitive gel was successfully formulated. It was observed 
that the hydrodynamic diameter of macromolecules exerted its effects on drug release. 
The peppas model was the best fit model, suggesting that the release rate was controlled 
by diffusion and degradation of copolymers.  
Results confirmed that the PB copolymer based composite delivery system are 
able to minimize the side effects associated with repeated every month intravitreal 
injections by lowering the injection frequency. In addition, the synthesized PB 
copolymers are biocompatible in nature and can be considered excellent biomaterials for 
ocular delivery. The enzyme activity of Lyz was observed up to three weeks. The 
integrity or stability of the protein molecule was not addressed in this work and an 
assessment of the compatibility of the polymers with the macromolecule remains to be 
elucidated in the future studies. However, the nanoformulations were optimized to 
achieve a high drug loading. This was essential so that a small volume of intravitreal 
injection containing a higher dose can be injected. This was also targeted in order to 
achieve a long-term delivery up to 3-6 months with an amount release of 2-10 µg/day. 
Overall, the outcomes from this study clearly suggested that the PB copolymers based 
control drug delivery system may serve as a promising platform not only for the back of 
the eye complications.  
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CHAPTER 5 
(89)
 
COMPOSITE NANOFORMULATION FOR LONG TERM OCULAR DELIVERY OF 
IGG-FAB AND RANIBIZUMAB 
 
Rationale  
The back of the eye diseases such as macular edema (ME), diabetic macular 
edema (DME), diabetic retinopathy (DR) and age related macular degeneration (AMD) 
result in functional deficits and huge global costs. These diseases are major concerns for 
elderly patients and involve several side effects.(20) AMD is a major cause of central 
vision loss affecting the retinal pigment epithelium (RPE), Bruch‘s membrane, and 
choriocapillaris in the macular region of the neural retina. The disease is typically 
manifested in two forms; dry and wet AMD and is responsible for more than 80% of 
cases of severe visual loss and impairment (187). The hallmark of wet AMD is the 
formation of new anomalous blood vessels that typically arise from the choroidal 
vasculature that grow into the sub-retinal space. These neovascular vessels commonly 
hemorrhage and ultimately compromise vision (188). The degenerating tissues begin to 
release angiogenic growth factors that bind to specific receptors located on endothelial 
cells of preexisting blood vessels (189). 
Vascular endothelial growth factor (VEGF) is a rate-limiting factor in 
angiogenesis and responsible for the growth of blood vessels. VEGF is associated with 
various pathophysiological processes affecting the eye including AMD and other retinal 
diseases such as DME, DR, retinal vein occlusion and vitreous hemorrhage. Elevated 
VEGF levels have been reported in AMD and DME patients (190). Similarly, VEGF is a 
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key mediator of blood-retinal barrier breakdown that leads to fluid leakage and the 
development of macular edema. Therefore, it is hypothesized that alternative or adjunct 
therapies using VEGF inhibitors (anti-VEGF) could be beneficial in reversing vision loss 
from DME and AMD (42). VEGF may also stimulate release of inflammatory cytokines, 
which can further reinforce the inflammation cycles and angiogenesis.  
Currently, the first line therapies for these diseases include the intravitreal (IVT) 
injection of FDA approved anti-VEGF agents such as bevacizumab (Avastin), 
ranibizumab (Lucentis), and aflibercept (Eylea) (191). Although, beavcizumab a FDA 
approved drug is used only off label for back of the eye diseases. In general, IVT 
injection is the most common and effective route for delivery of anti-VEGF therapeutics 
as it can provide and maintain a high concentration of the therapeutic agents near the 
target tissues (RPE, Bruch‘s membrane). However, one of the major disadvantages of 
IVT injection is its poor patient compliance due to discomfort and inconvenience 
associated with frequent injections (192). Clinical trials for anti-VEGF agents further 
supported the need of frequent injections (monthly) for Lucentis (193), Avastin (194), 
and Eylea (188). This can further increase the cost of the therapy. Pharmacokinetic 
studies (195) suggested very short half-lives, of anti-angiogenic proteins in vitreous 
humor after IVT injections (9.82 days for bevacizumab(196), 10 days for ranibizumab in 
human subjects (197), and 5-6 days for aflibercept) (191). Retinal penetration of anti-
VEGF agents after IVT administration has also been reported (198). Therefore, frequent 
IVT injections are required to inhibit capillary growth and leakage to maintain the clear 
vision. However, frequent IVT injection is not well tolerated by patients and 
 113 
 
 
accompanied by numerous side effects such as endophthalmitis, retinal hemorrhage, and 
retinal detachment (199). 
Several biodegradable polymeric nanoformulations have been extensively 
investigated for controlled delivery of protein therapeutics. Biodegradable polymers such 
as polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly lactide-
co-glycolide (PLGA), and polyethylene glycol (PEG) have been comprehensively studied 
for the preparation of protein encapsulated NPs (200),
 
(201). Recently, many 
investigators have applied several block copolymers such as PLGA-PEG-PLGA, PEG-
PCL-PEG, PLGA (202), and PEG-PLA (203) for the development of sustained release 
protein formulations. However, some reports indicated that protein/peptide molecules 
suffer from rapid loss of biological activity during formulation preparation, storage 
and/or release. Acylation with polymer degradation products (lactic acid and glycolic 
acid) (204, 205) further accelerates the hydrolysis of macromolecules due to lower pH 
induced by polymer degradation products. One of the possible causes for the loss of 
activity and/or irreversible aggregation of protein therapeutics is caused by the presence 
of hydrophobic interfaces in PLA, PGA, and PLGA based delivery systems. It is 
noteworthy that changes in protein/peptide structure, either physically or chemically, may 
cause immunogenicity and toxicity issues (182). As a result, there is an urgency to 
develop a biocompatible and biodegradable polymeric system which can provide 
sustained release of macromolecule therapeutics at near zero-order rate for longer 
durations without compromising the stability and functional activity of macromolecules. 
Based on the above mentioned facts, the objective of this work is to synthesize a 
novel tailor-made PB copolymer based composite nanoformulation for the controlled and 
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sustained delivery of protein therapeutics for the treatment of the back of the eye 
diseases. Here, the composite nanoformulations were anticipated to minimize the burst 
release of macromolecule therapeutics to achieve a continuous zero-order drug release for 
longer duration. 
 
Materials and methods 
 
Materials 
Poly (ethylene glycol) (PEG, 4 kDa), methoxy-PEG (550 Da), stannous octoate, 
ε-caprolactone, poly (vinyl alcohol) (PVA), lipopolysaccharide were procured from 
Sigma-Aldarich (St. Louis, MO). L-lactide and hexamethylene diisocynate (HMDI) were 
purchased from Acros organics (Morris Plains, NJ). Micro-BCA
TM 
assay kit was obtained 
from Fisher Scientific Inc., (Rockford, IL). Mouse TNF-α, IL-6 and IL-1β ELISA kits 
were obtained from e-Bioscience Inc. (San Diego, CA). Lactate dehydrogenase (LDH) 
estimation assay and CellTiter 96® AQueous non-radioactive cell proliferation assay 
(MTS) kits were obtained from Takara Bio Inc., (Otsu, Japan) and Promega Corp., 
(Madison, WI), respectively. RAW 264.7 cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and TrypLE™ Express was from Invitrogen, 
Carlsbad, CA. All other reagents utilized in this study were of analytical grade and used 
as obtained from suppliers. 
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Methods 
Synthesis of PB Copolymers 
Novel PB copolymers, poly(caprolactone)-poly(lactic acid)-poly(ethylene glycol)-
poly(lactic acid)-poly(caprolactone) (PCL-PLA-PEG-PLA-PCL i.e., PB-1) and methoxy-
poly(ethylene glycol)-poly(caprolactone)-poly(lactic acid)-poly(caprolactone)-
poly(ethylene glycol)-methoxy (mPEG-PCL-PLA-PCL-PEGm i.e., PB-2) were 
synthesized by ring-opening bulk polymerization method.(183, 206) PB copolymer for 
the preparation of NPs i.e., PB-1 was synthesized in two steps by sequential ring-opening 
polymerization reaction (Figure 5.1). PEG (4 kDa) was utilized as macroinitiator and 
stannous octoate as catalyst. In the first step, triblock (TB) copolymer PLA-PEG-PLA 
(Figure 1, Step 1) was synthesized by polymerization of L-lactide on two open hydroxyl 
ends of PEG. L-lactide and stannous octoate (0.5% w/w) were added to anhydrous PEG 
and temperature was raised to 130°C. After 24 h, reaction mixture was dissolved in 
dichloromethane (DCM) followed by precipitation in cold petroleum ether. The 
precipitated polymer was filtered and dried under vacuum at room temperature for 24 h.  
In the second step, PLA-PEG-PLA (TB copolymer) was reacted with ε-
Caprolactone to synthesize the PB-1 copolymer (Figure 1, Step 2). Briefly, TB 
copolymer and ε-Caprolactone were added and the temperature was raised to 130°C 
under inert atmosphere. To the above mixture, stannous octoate (0.5% w/w) was added 
and the reaction was continued for 24 h. PB copolymer was then purified by cold ether 
precipitation method as described in the first step. The final PB-1 copolymer product was 
dried under vacuum and stored at -20°C until further use. 
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To synthesize the thermosensitive gelling copolymer (PB-2) (mPEG-PCL-PLA-
PCL-PEGm), intermediate copolymer (mPEG-PCL-PLA) was synthesized by ring-
opening bulk copolymerization as described in chapter-3. ε-Caprolactone was 
polymerized at the hydroxyl terminal of mPEG (550 Da) followed by second 
polymerization with L-lactide. The resulting intermediate copolymer was coupled using 
HMDI as a linker. The coupling reaction was continued for 8 h at 70°C. The synthesized 
PB-2 copolymers was purified by cold ether precipitation followed by drying under 
vacuum and stored at -20°C until further uses. A reaction scheme was illustrated in 
Figure 5.2. 
 
Characterization of TB and PB copolymers 
Proton nuclear magnetic resonance (
1
H-NMR) spectroscopy 
The 
1
H-NMR spectra of TB and PB copolymers were acquired on a 400 MHz 
NMR instrument (Varian Inc., Palo Alto, CA). The chemical shift values were reported 
as δ in parts per million (ppm). The NMR samples were prepared by dissolving each 
copolymer in deuterated chloroform in a 5-mm outer diameter NMR tubes (Wilmad-Lab 
Glass, Vineland, NJ). 
Gel permeation chromatography (GPC) analysis 
The purity, MWs and PDI of PB copolymers were confirmed by GPC analysis. 
Polymeric samples were analyzed with a Waters 410 refractive index detector (Waters, 
Milford, MA). Briefly, samples were prepared by dissolving 5 mg of polymeric material 
in tetrahydrofuran (THF) whereas, THF was utilized as eluting agent at the flow rate of 1 
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mL/min. Separation was carried out on Styragel HR-3 column (Waters, Milford, MA). 
Polystyrene samples with narrow MW distribution were considered as standards.  
Fourier transform infrared (FT-IR) spectroscopy 
The FT-IR analysis of TB and PB copolymers was performed using Nicolet iS10 
Spectrometer (Thermo Scientific, West Palm Beach, FL). The instrument was controlled 
by OMNIC™ Spectra™ software. The analysis was performed at 600 to 4000 cm-1 wave 
numbers. The spectra were automatically corrected with a linear baseline. No specific 
sample preparation method was used before the analysis. 
X-ray diffraction (XRD) analysis 
To analyze the crystallinity of copolymers, XRD analysis was performed using 
Rigaku MiniFlex automated X-ray diffractometer (Rigaku, The Woodland, TX) equipped 
with Ni-filtered Cu-Kα radiation (30 kV and 15 mA). The analysis was performed at 
room temperature at the scanning rate of 5°/min. 
 
Phase transition (gelation) Study of PB-2 thermosensitive gelling copolymer 
The sol-gel transition behavior of PB-2 copolymer was examined by test tube 
inverting method. The copolymer was dissolved in phosphate buffer saline (PBS, pH 7.4) 
at different concentrations ranging from 15-30wt% and incubated for 12 h at 4°C. 
Afterwards, 1 ml of PB-2 copolymer solution was taken in 4 ml glass vial with an inner 
diameter of 12 mm and placed in a water bath. The temperature of the water bath was 
raised slowly from 10 to 60°C at the rate of 1°C increment/min. The gel formation was 
observed visually by inverting the glass vials. A physical state of flow was characterized 
as sol phase whereas, a state of no flow was considered as gel phase. 
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In Vitro cytotoxicity of PB copolymers 
Cytotoxic effects of PB copolymers on corneal and retinal cell lines were 
analyzed using Lactate Dehydrogenase (LDH) and cell viability (MTS) assays according 
to the supplier‘s instructions. The Human Corneal Epithelial (HCEC) cells were cultured 
were cultured at 37°C, humidified 5% CO2/95% air atmosphere in a culture medium 
containing DMEM/F-12 supplemented with 10% (v/v) FBS (heat inactivated), 15 mM 
HEPES, 22 mM NaHCO3, 100 mg of penicillin and streptomycin each, 5 μg/mL insulin, 
and 10 ng/mL of human epidermal growth factor following a previously published 
protocol.(207, 208) Cells of passage numbers between 20 and 22 were utilized for all the 
experiments. 
The Retinal Pigment Epithelium (D407) cells were grown at 37°C, humidified 5% 
CO2/95% air atmosphere in a culture medium containing DMEM supplemented with 
10% (v/v) FBS (heat inactivated), 29 mM NaHCO3, 20 mM HEPES, 100 mg of penicillin 
and streptomycin each, and 1% nonessential amino acids at pH 7.4. Cells of passage 
numbers between 67 and 70 were employed for all the experiments.(207) The growth 
medium was changed every other day. Both HCEC and D407 cells were cultured in a 
flask, harvested at 80–90% confluency with TrypLE™ Express (a superior replacement 
for trypsin).  
LDH (cytotoxicity) assay 
LDH assay was performed using previously published protocol with some minor 
modifications.(209, 210) Briefly, 100 µL of 1, 5 and 20 mg/mL of PB copolymers (PB-1 
and PB-2) dissolved in acetonitrile (ACN) were aliquoted in 96-well plate. Plates were 
exposed overnight under UV light (laminar flow) for polymer sterilization as well as 
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evaporation of ACN. HCEC and D407 cells at the density of 1.0 x 10
4
 were seeded in 
each well and incubated at 37°C, 5% CO2 in humidified atmosphere for 48 h. After 
completion of incubation period, cell supernatants were analyzed for quantification of 
LDH using LDH assay kit as per supplier instructions. Absorbance of each well was 
measured at 450 nm using a DTX 800 multimode microplate reader (Beckman Coulter, 
Brea, CA). The LDH release (%) was calculated according to Eq. 5.1 and more than 10% 
of LDH release was considered as cytotoxic. 
 
 …Eq (5.1) 
 
MTS (cell viability) assay 
Safety of PB copolymers was further established by performing in vitro cell 
viability (MTS) assay. The MTS (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide) tetrazolium reduction) assay was performed according to a previously reported 
protocol with minor modifications.(209) As described earlier, PB copolymer solutions at 
the concentration of 1, 5 and 20 mg/mL were prepared, aliquoted and sterilized. After the 
sterilization, D4O7 and HCEC cells were seeded in 96-well plate at the cell density of 1.0 
x 10
4
, and incubated at 37°C and 5% CO2 in humidified atmosphere for 48 h. At the end 
of incubation period, cell culture medium was aspirated and cells were incubated for 4 h 
(37°C and 5% CO2) in the presence of 100 µL of serum free medium containing 20 µL of 
MTS solution. Absorbance of each well was measured at 450 nm using the above 
microplate reader. The percent cell viability was calculated according to Eq. 5.2 and PB 
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copolymers exhibiting more than 90% of cell viability were considered non-toxic and 
suitable for ocular applications. 
 
 …Eq (5.2) 
 
In Vitro biocompatibility studies 
Mouse macrophage (RAW-264.7) cells were maintained according to ATCC 
guidelines at 37°C, 5% CO2 and 95% humidity. Cells were plated in 96-well plates at a 
density of 1.0 x 10
4
cells/well. Macrophage cells were grown in a similar way as 
explained for D407 and HCEC cells and utilized for further studies. PB copolymers were 
dissolved in ACN at the concentration of 1, 5, 10 and 20 mg/mL. Two hundred 
microliters of this solution were aliquoted in each well of 48-well cell culture plates and 
incubated for overnight under UV lights (laminar flow) for ACN evaporation and 
sterilization of resulting polymer film. After the sterilization, RAW-264.7 cells (5.0 x 
10
4
) were seeded in each well of cell culture plate and incubated for 24 h at 37°C and 5% 
CO2. Cell supernatants were analyzed for the presence of cytokines i.e., TNF-α, IL-6 and 
IL-1β. Lipopolysaccharide (LPS) was used as positive control whereas, cells without any 
treatment were considered as negative control. Cytokines levels (in pg/mL) were 
measured by ELISA method according to manufacturer‘s (e-Biosciences, San Diego, CA) 
instructions. Standard calibration curves for TNF-α, IL-6 and IL-1β were prepared in the 
concentration range of 10-750 pg/mL, 5-500 pg/mL and 10-500 pg/mL, respectively.  
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Formulation of PB-1 copolymer based NPs (PB-1 NPs) 
IgG-Fab loaded PB-1 NPs were prepared by water in oil in water (W1/O/W2) 
double emulsion solvent evaporation method. Briefly, IgG-Fab containing aqueous 
solution (W1 phase) was emulsified in organic phase (DCM) comprising PB copolymers 
using probe sonication to form a W1/O primary emulsion. The primary emulsion was 
further emulsified in aqueous phase containing 2% polyvinyl alcohol (PVA) using probe 
sonication to prepare a W1/O/W2 double emulsion. The resulting double emulsion was 
diluted with 2% PVA (W3) under continuous stirring. Organic phase (DCM) was then 
evaporated under vacuum using a rotatory evaporator (BUCHI Labortechnik AG, Flawil, 
Switzerland). The NPs were separated by ultracentrifugation at 20,000 rpm for 30 min at 
4C. The NPs were washed twice with distilled deionized water (DDW), and centrifuged 
to remove the traces of PVA and unentrapped IgG-Fab. The purified NPs were freeze-
dried with mannitol (3% w/v) and stored at -20°C until further uses. Similarly, 
Ranibizumab encapsulated NPs were prepared using above mentioned method.   
 
Physicochemical characterization of PB-1 NPs 
Size distribution analysis 
The PB-1 NPs were analyzed for their particle mean diameter (PMD: in nm) and 
size distribution by Nanoparticle Tracking Analysis (NTA) using a Nanosight LM10 
instrument (Nanosight, Salisbury, UK). To determine the particle size distribution of NPs 
in different media (PBS, DMEM without and with serum, RAW without and with serum), 
NPs samples at the concentration of 1 mg/mL were incubated at 37°C. The samples were 
analyzed at 0 h, 4 h, day 1, day 2, day 3, day 7, and day 10, at ambient temperature (22-
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23°C) conditions using NTA analysis software. Basically, NTA determines the particle 
diffusion coefficient Dt by measuring the Brownian motion movement of the particle and 
then this employs the Stokes-Einstein equation (Eq. 5.3) to determine the particle size 
distribution in each sample (211). 
d3
TK
D Bt

          …Eq (5.3) 
Here, T is the sample temperature, KB is the Boltzmann's constant, and η is the 
solvent viscosity. Using Dt, the sphere-equivalent hydrodynamic diameter (d) of the 
particles was determined using Eq. 5.3. 
Percent entrapment efficiency (%EE) and drug loading (%DL) 
The %EE was estimated by the amount of protein in the supernatants obtained 
from NP preparation. Micro BCA
TM
 protein estimation kit (Thermo scientific, IL) was 
employed for the estimation of total protein content. To analyze the %DL, 2 mg 
equivalent protein-loaded NPs were dissolved in 200 µL of dimethyl sulphoxide 
(DMSO). The resulting solution was analyzed by UV absorbance spectroscopy. Standard 
curve of IgG-Fab and Ranibizumab ranging from 31.25 to 2000 µg/mL was prepared in 
DMSO. The Eq. (5.4) and (5.5) were utilized for the calculation of %EE and %DL 
respectively.  
 
% Encapsulation efficiency = (Initial amount of drug – Amount of drug in supernatant) *100    …Eq. 5.4    
 Initial amount of drug 
 
 
% Drug loading =  Amount of drug in nanoparticle     * 100                 …Eq. 5.5 
     Total amount of drug and polymer 
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In vitro drug release profile and kinetics of composite nanoformulations 
In order to analyze the in vitro drug release profile of NPs, 1 mg of IgG-Fab 
equivalent freeze-dried NPs were suspended in 100 µL of aqueous solution of 
thermosensitive gelling polymer (PB-2) (15wt% and 20wt%). The resulting suspension 
was incubated at 37°C for 30 min. Once gel was formed, an aliquot (1 mL) of PBS (pre-
incubated at 37°C) was added slowly. At predetermined time intervals, 200 µL of clear 
supernatant was collected and replaced with same volume of fresh PBS (preincubated at 
37°C). Release samples were analyzed by Micro BCA
TM
 assay for total protein content. 
In vitro release data were expressed as cumulative drug released (%) with time. Similarly, 
1 mg equivalent Ranibizumab equivalent freeze-dried NPs were suspended in 100 µL of 
aqueous solution of thermosensitive gelling polymer (PB-2) (15wt%, 17 wt%, and 
20wt%) and in vitro drug release profile was determined by above mentioned protocol.    
The drug release kinetics of IgG-Fab and Ranibizumab loaded NPs was analyzed 
by using zero order, first order, Higuchi, and Korsmeyer-Peppas models as given by Eq. 
(5.6), (5.7), (5.8) and (5.9), respectively(96, 212). 
 
tK+QQ 00t          …Eq (5.6) 
t/2.303K+QlogQlog 10t         …Eq (5.7) 
5.0
Ht tKQ           …Eq (5.8) 
k log+tlogn/QQlog t         …Eq (5.9) 
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In these Equations, Qt is the amount of drug released at time t, Q0 is initial amount 
of drug in solution, K0 is zero order release constant, K1 is first order release constant, KH 
is Higuchi dissolution constant, Qt/Q∞ is the fraction of drug released at time t, Q∞ is the 
total amount of drug released, k is a kinetic constant and n is the exponent explaining the 
drug release mechanisms.(212) The exponent n is classified as Fickian diffusion (n ≤ 
0.5). 
 
Evaluation of Anti-VEGF activity of ranibizumab released from composite 
nanoformulation 
At predetermined time points, release samples were withdrawn and replaced with 
similar amount of PBS buffer to continue in vitro release study. Concentration of released 
drug in supernatant was estimated using micro BCA assay. After protein estimation, the 
released samples were subjected for indirect ELISA assay. For this Samples and 
standards were diluted to achieve 20ng/mL, 10ng/mL and 5ng/mL protein concentration. 
An indirect ELISA assay, developed and validated in our lab, was used for estimating 
anti-VEGF activity of ranibizumab from the released sample. Briefly, wells of flat-
bottomed microtiter plates were coated with 100 μL of 0.5μg/mL VEGF in 50 mM 
carbonate buffer (pH 9.6) and incubated overnight at 4°C. Then, wells were washed with 
washing buffer (0.05% Tween 20 in PBS) and blocked with 1% BSA in PBS for 2 h at 
room temperature by gentle shaking. Serial dilutions of reference ranibizumab and 
samples were plated at 100 μL per well and incubated for 2 h at room temperature. 
Following incubation, wells were washed and incubated with secondary antibody 
solution (1:8000 dilutions in 1% BSA in PBS) for 45 min at room temperature. Finally, 
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100 μL of color developing agent was added to each well for the enzymatic reaction to 
occur. Color was allowed to develop, and the absorbance was measured at 450 nm. 
Subsequent to each incubation, plates were washed 3 times with 200 μL of a washing 
solution (0.05% Tween 20 in PBS). 
 
Results and discussion 
 
Synthesis and characterization of PB copolymers 
PB copolymers (PB-1 and PB-2) were successfully synthesized by ring-opening 
bulk copolymerization of ε-Caprolactone, and L-lactide as given in Figure 5.1 and 5.2, 
respectively. The characterization of synthesized PB copolymer was performed as 
explained below. 
 
Figure 5.1 Reaction scheme for the synthesis of PB-1 (PCL-PLA-PEG-PLA-PCL) 
copolymer (Reproduced from Ref. 89). 
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Figure 5.2 Reaction scheme for the synthesis of thermosensitive copolymer PB-2 
(mPEG-PCL-PLA-PCL-PEGm). (Reproduced from Ref. 89). 
 
The purity and molecular weight (Mn) of PB copolymers were calculated by 
1
H-
NMR spectroscopy (Figures 5.3). The 
1
H-NMR spectra of TB copolymer was given in 
Figure 3A. The typical 
1
H-NMR characteristic peaks of PB-1 were observed at 1.40, 
1.65, 2.30 and 4.06 δ ppm represented the methylene (–CH2–) protons of -(CH2)5-, -
OCO-CH2-, and -CH2OOC- of PCL units, respectively, (Figure 3B). A sharp peak at 3.65 
δ ppm was attributed to methylene protons (-CH2CH2O-) of PEG. Typical signals at 1.50 
(-CH3) and 5.17 (-CH-) ppm were assigned for PLA blocks. Figure 3C of 
1
H-NMR 
spectra of PB-2 copolymers (thermosensitive gel), depicted peaks a, b and c as methylene 
protons of the PCL block, while peaks e and f represent methyl and -CH- groups of PLA 
block, respectively. The ratio of mPEG and ε-Caprolactone was computed through proton 
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integration ratio of –CH2– proton peak at 3.65 (d) and 2.3 (c), respectively, and for L-
lactide it was computed through –CH– proton peak at 5.10 (f). 
 
 
Figure 5.3 
1
H-NMR spectra of: (A) TB (PLA-PEG-PLA); (B) PB-1 (PCL-PLA-
PEG-PLA-PCL); and (C) PB-2 (mPEG-PCL-PLA-PCL-PEGm) copolymers (Reproduced 
from Ref. 89).  
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The molecular weights (Mw and Mn) and PDI of copolymers was determined by 
GPC analysis (Figure 5.4). A single peak of each polymer was observed describing 
unimodal MW distribution and absence of any other homo-copolymer block such as 
PEG, PCL or PLA. Moreover, MWs were very close to the feed ratio. The low PDI 
values of < 1.5 described the narrow distribution of MWs calculated by 
1
H-NMR and 
GPC analyses (Table 5.1). 
 
 
Figure 5.4 GPC chromatograms for PB-1 (PCL-PLA-PEG- PLA-PCL) and PB-2 (mPEG-
PCL-PLA-PCL-PEGm) copolymer (Reproduced from Ref. 89). 
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Table 5.1 PB copolymer utilized for the preparation of composite nanoformulation (PB-1 
NPs suspended in the thermosensitive gelling copolymer PB-2). 
Name Structure Total Mn
a
 
(theoretical) 
Total Mn
b
 
(calculated) 
Total Mn
c
 
(calculated) 
Mw
c
 
(GPC) 
PDI
c
 
PB-1 PCL10000-PLA6000-
PEG4000-PLA6000-
PCL10000 
 
36,000 
 
32,400 
 
39,425 
 
38,232 
 
1.39 
PB-2 PEG550-PCL825-
PLA550-PCL825-
PEG550 
3,300 3,255 4,390 6,082  
1.41 
a
 Theoretical value, calculated according to the feed ratio. 
b
 Calculated from 
1
H-NMR.  
c
 Determined by GPC analysis. 
 
 
The FT-IR spectra for the TB, PB-1, and PB-2 copolymers were presented in 
Figure 5.5. The C-H stretching band of PEG was observed at ~2876 cm
-1 
in TB 
copolymer (Figure 5.5A). However, the C-H stretching bands of PCL were observed at 
~2942 cm
-1 
in PB-1 (Figure 5.5B) and PB-2 (Figure 5.5C) copolymers. The strong band 
in the region around 1730-1750 cm
–1 
was due to the stretching bands of the carbonyl 
groups present in the PLA, PCL, and PEG monomers. Overall, the FTIR spectra 
confirmed the functional groups of TB and PB copolymers.  
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Figure 5.5 FT-IR spectra of: (A) TB (PLA-PEG-PLA); (B) PB-1 (PCL-PLA-PEG-PLA-
PCL); and (C) PB-2 (mPEG-PCL-PLA-PCL-PEGm) copolymers (Reproduced from Ref. 
89).  
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In order to assess the crystallinity and phase composition, the PB copolymers 
were analyzed for their XRD patterns (Figure 5.6). Interestingly, TB (PLA-PEG-PLA) 
copolymer exhibited a crystalline peak at 2θ = 16° and 19° but, in PB-1 crystalline peaks 
of PCL shifted to 2θ = 21.5°. A peak at 2θ = 24° was observed in both PB-1 and PB-2 
copolymers. XRD patterns of TB and PB-1 indicated that PLA blocks retained their semi-
crystalline structure even after covalent conjugation with the PCL blocks. Conjugation of 
PCL blocks at the terminals of TB copolymers exhibited shift in the intensity of the 
crystalline peak indicated the semi-crystalline structures of PB-1. Thus, the crystallinity 
of copolymers was easily controlled by the arrangement of polymer blocks in structural 
backbone. PB-2 (Figure 5.6) copolymer was devoid of any crystalline peak suggested its 
amorphous nature. Previously published reports(186) showed that a decrease in 
crystallinity significantly enhanced the degradation of block copolymers. 
 
Figure 5.6 XRD patterns of TB (PLA-PEG-PLA), PB-1(PCL-PLA-PEG-PLA-PCL) and 
PB-2 (mPEG-PCL-PLA-PCL-PEGm) copolymers (Reproduced from Ref. 89).  
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Phase transition (gelation) of PB-2 thermosensitive gel 
 The thermosensitive gelling copolymers was amphiphilic in nature containing 
hydrophilic block (PEG) and hydrophobic block(s) of PCL and/or PLA. The aqueous 
solution of PB-2 was observed clear due to self-assembly of polymeric chains into 
micellar structure which showed aggregation upon increasing the temperature and 
resulted in the gel formation. However, upper gel-sol conversion was due to increased 
molecular motion of the hydrophobic chain of PCL and PLA. The aqueous solution of PB 
copolymers exhibited a sol-gel transition response upon increasing the temperature in a 
concentration range of 15wt%. The phase diagram (Figure 5.7) revealed the critical gel 
concentration (CGC) from the solution to gel state conversion at 37°C.  
 
 
 
Figure 5.7 Phase transition (gelation) of thermosensitive gelling copolymer PB-2 (mPEG-
PCL-PLA-PCL-PEGm) (Reproduced from Ref. 89). 
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In vitro cytotoxicity studies 
LDH assay 
 In order to investigate the toxicity of PB copolymers with biological system, 
ocular cell lines (HCEC and D407 cells) were treated with 1, 5, 20 mg/mL of PB-1 and 
PB-2 for 48 h. LDH is a cytoplasmic enzyme, secreted in cell culture medium following 
cell-membrane damage. Less than 10% of LDH release was observed after 48 h exposure 
indicated a negligible toxicity with HCEC (Figure 5.8A) and D407 (Figure 5.8B) cell 
lines. Noticeably, results were comparable with negative controls whereas, significant 
differences were observed compared to the positive control (Triton-X). Triton X is one of 
the most widely used nonionic surfactants to analyze the cell cytotoxicity and viability. 
The toxicity of Triton-X arises because of the disrupting action of its polar head group on 
the hydrogen bonding present within the cell‘s lipid bilayer leading to a disruption of 
cellular structure. 
MTS assay 
 To further confirm the cytotoxicity of PB copolymers, MTS cell viability assay 
was performed using a similar protocol as described above. In MTS assay, only 
metabolically active cells converted the tetrazolium compound to a formazan product. 
Hence, the concentrations of formazan products provided a direct estimation of cell 
viability. Results in Figure 5.9A and 5.9B demonstrated more than 90% cell viability for 
HCEC and D407 cell lines, respectively, after 48 h exposure to copolymer materials. The 
results suggested an excellent safety profile of block copolymers for ocular applications. 
No significant difference in the cell viability of copolymers was observed compared to 
the negative control. However, no toxicity was found with the in vitro cell-based (LDH 
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and MTS) assays as cultured cells can only address the ocular toxicity to certain extent 
especially when the exposure time was shorter (in a couple of hours only), and further in 
vivo evaluation will be needed. 
Figure 5.8 In vitro cytotoxicity (LDH) assay of PB-1 and PB-2 copolymers at different 
concentrations on: (A) HCEC cells, and (B) D4O7 cells. Results are given as mean ± SD, 
n = 3 (Reproduced from Ref. 89). 
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Figure 5.9 In vitro cell viability (MTS) assay of PB-1 and PB-2 copolymers at different 
concentrations on: (A) HCEC cells, and (B) D4O7 cell. Results are given as mean ± SD, 
n = 3 (Reproduced from Ref. 89). 
 
 136 
 
 
In Vitro biocompatibility studies 
 Many investigators have utilized the in vitro cell culture model using RAW-264.7 
cells for the estimation of biocompatibility of polymeric materials intended for human 
applications. In this study, we examined the cytokines (TNF-α, IL-6 and IL-1β) release in 
culture supernatant following 24 h exposure to PB-1 and PB-2 copolymers. Samples were 
analyzed via a sandwich ELISA assay. Results depicted in Figure 5.10A and 5.10B 
indicated that there was no significant release of TNF-α, IL-6 and IL-1β in both groups 
i.e., PB-1 and PB-2 compared to the negative control (cells without treatment). These 
results suggested that PB copolymers are safe for their clinical applications in humans.  
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Figure 5.10 In vitro release of TNF-α, IL-6, and IL-1β from RAW 264.7 cells on 
exposure to: (A) PB-1, and (B) PB-2 copolymers. Results are given as mean ± SD, n = 3 
(Reproduced from Ref. Ref. 89). 
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Formulation and characterization of PB-1 NPs 
Size distribution analysis 
 IgG-Fab encapsulated PB-1 NPs were prepared by W1/O/W2 double emulsion 
solvent evaporation method. The mean particle size distribution of NPs in PBS was found 
in the range of ~150 nm (Figure 5.11A) and was consistent throughout the study in 
different media analyzed up to 10 days (Figure 5.11B). These results confirmed the 
higher stability of NPs in different media. The NPs particle size distribution graphs were 
provided in PBS (Figure 5.11A & 5.11B), DMEM-with serum (Figure 5.11C & 5.11D), 
RAW-with serum (Figure 5.11E & 5.11F), DMEM-without serum (Figure 5.11G & 
5.11H), RAW-without serum (Figure 5.11I & 5.11J), analyzed at 0 day and 10 days, 
respectively. 
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Figure 5.11 (A) Particle size distribution graph of PB-1 NPs in PBS. (B) Particle size 
distribution of PB-1 NPs in PBS, DMEM-with serum, RAW-with serum, DMEM-
without serum, RAW-without serum, at 0 hr, 4 hr, day 1, day 2, day 3, day 7, and day 10, 
analyzed by NTA measurements. Results are given as mean ± SD, n = 3 (Reproduced 
from Ref. 89). 
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Figure 5.12 PB-1 NPs particle size distribution graphs in: PBS (A & B), DMEM-with 
serum (C & D), RAW-with serum (E & F), DMEM-without serum (G & H), RAW-
without serum (I & J), at 0 day and 10 days, respectively, analyzed by NTA 
measurements (Reproduced from Ref. 89). 
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% EE and % DL 
 The %EE and %DL for IgG-Fab encapsulated in PB-1 copolymers were 66.64% 
± 1.75 and 18.17% ± 0.39, respectively, (n = 3). Similarly, %EE and %DL for 
Ranibizumab encapsulated in PB-1 copolymers were 61.45% ± 2.89 and 16.99% ± 0.66, 
respectively, (n = 3).  PB-1 NPs demonstrated a higher %DL relative to previously 
published results(182) which may be attributed to relatively high hydrophobicity of PB-1 
copolymer synthesized in this study. During the solvent evaporation step, high 
hydrophobicity of PB-1 copolymer may allow more rapid polymer precipitation to form 
the NPs. This has been prevented the diffusion of IgG-Fab in external aqueous (W2) 
phase. The lower volume of phase ratios (W1, W2 and O) compared to previously 
published method(182) diminished the protein partitioning in aqueous phase, thus, 
improved the drug loading efficiency In addition, reduction in organic phase volume had 
raised the polymer concentration that led to rapid polymer precipitation and thus, NP 
formation.  
 
In vitro drug release profile and kinetics of composite nanoformulations of IgGFab 
The composite nanoformulations comprised of IgG-Fab-loaded (1 mg IgG-Fab 
equivalent) PB-1 NPs were suspended in thermo-sensitive gelling copolymer (PB-2) 
(15wt% and 20wt% gelling solution) and evaluated for the release profile. The solution 
then brought to 37°C which immediately transitioned the solution to solid hydrogel 
entrapping NPs throughout the polymeric matrix. The aqueous solution of PB-2 
copolymer remained in a liquid state at room temperature but immediately transformed to 
hydrogel at physiological temperature of 37°C (sol-gel transition). 
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As depicted in Figure 5.13, burst release of IgG-Fab from composite 
nanoformulation was negligible relative to the burst release observed from PB-1 NPs 
alone (Data not shown here).(182) Moreover, with NPs alone, the release profile reached 
to > 90 % compared to composite nanoformulations (~20% with 20wt%, and ~40% with 
15wt %) in ~35 days. In this study, the composite nanoformulation of IgG-Fab exhibited 
negligible burst release followed by a zero-order release as analyzed up to 80 days. This 
behavior may be due to the fact that when the NPs were suspended into the gel matrix, 
the matrix served as an additional diffusion barrier for the surface adsorbed drug. It also 
led to a zero-order release pattern of the encapsulated drug throughout the release period. 
The integrity or stability of the protein molecule was not addressed here and an 
assessment of the compatibility of the polymers with the protein is remains to be 
elucidated in future studies. 
 
Figure 5.13 In vitro release of IgG-Fab from composite nanoformulation (15 wt% and 20 
wt%). Results are given as mean ± SD, n = 3 (Reproduced from Ref. 89). 
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The release on day-1 was followed to be 4.6%, and 1.8% w/w for 15wt%, and 
20wt%, PB-2 gel, respectively. PB-1 copolymer maintained ~4 µg/day for more than 2 
months in both the gel concentrations of 15wt% and 20wt%. Theoretically, for 15wt% 
gel ~430 µg of drug remained in formulation after 80 days with projected release for an 
additional 120 days. For 20wt% gel, ~600 µg of drug remained in formulation after 80 
days. Therefore, it can be projected that release could be sustained for additional 150 
days. The wt% of gelling copolymer had a significant effect on the initial burst release 
and higher the gel concentration, minimal burst release was observed. Overall, the release 
profile was slower with 20wt % gel compare to 15wt % gel. 
The drug release kinetics from the PB-1 Fab NPs in thermosensitive gels (15wt 
%) and (20wt %) was analyzed using various in vitro kinetic models. The parameters 
obtained were given in Table 5.2. Based on the r
2
 values observed, 15wt% and 20wt% 
composite nanoformulations followed the Peppas model. To determine the drug release 
mechanism, the Korsmeyer-Peppas model was further applied. It was observed that the 
drug release from 15wt% composite nanoformulation occurred through Fickian diffusion 
(n ˂ 0.5), whereas, 20wt% composite nanoformulation followed anomalous (non-
Fickian) transport (diffusion and erosion controlled release) mechanism since 0.5 < n < 
1. 
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Table 5.2 In vitro IgG-Fab release kinetic models of composite nanoformulation (PB-1 
NPs suspended in the thermosensitive gelling copolymer PB-2). 
Composite 
nanoformulations 
Zero order 
release 
model  
First order 
release 
model 
Higuchi 
release 
model 
Korsmeyer-
Peppas model 
r
2 a
 r
2 a
 r
2 a
 r
2 a
, (exponent n) 
PB-1 NPs 
suspended in 
thermosensitive gels 
PB-2 (15wt %) 
 
0.939 
 
0.967 
 
0.987 
 
0.993, (0.351) 
PB-1 NPs 
suspended in 
thermosensitive gels 
PB-2 (20wt %)  
 
0.986 
 
0.988 
 
0.984 
 
0.989, (0.609) 
a 
Correlation coefficient.  
 
In vitro drug release profile of composite nanoformulations of ranibizumab 
 In vitro release studies were performed by suspending 1 mg equivalent 
ranibizumab equivalent NPs prepared from PB-I in 100 µL solution with 15 wt%, 17 
wt% and 20 wt% gelling polymer. The release study was performed as described earlier. 
The steady state sustained release was observed with zero order as shown in Figure 5.14. 
The release was found to be 7%, 4.51%, and 2.52% for 15 wt%, 17 wt% and 20 wt%, 
respectively for day 1. PB-I copolymer maintains ~ 4 µg/day for more than 2 months with 
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all three studies. For 15 wt% gel ~350 µg of drug remained in formulation after 84 days 
with release rate, release that can be sustained for 106 days. For 17 wt% gel ~ 460 µg of 
drug is remaining in formulation after 74 days and release is sustained for ~215 days 
more. For 20 wt% gel, ~ 480 µg of drug is remaining in formulation after 74 days and 
release is sustained for further 221 days. Wt% of gelling polymer had effect on release 
rate. Higher the concentration of gel, minimal burst release was observed. (Release 
kinetics of ranibizumab not shown here). 
 
 
Figure 5.14 In vitro release of ranibizumab from NPs prepared with PB-1 suspended in 
gelling polymer of different wt %. Results are given as mean ± SD, n = 3. 
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Evaluation of anti-VEGF activity of ranibizumab released from composite 
nanoformulation 
Indirect ELISA was used to examine anti-VEGF activity of ranibizumab 
following release from composite nanoformulation. Results of anti-VEGF activity are 
given in Table 5.3, results are given as mean ± SD, n = 3. Ranibizumab released from 
composite nanoformulation retained its VEGF binding activity. Results of both the 
studies clearly indicate that ranibizumab was stable thorough out the process of NP 
preparation. The plausible explanation is that drug remains inside the PEG core by less 
exposing the drug at the oil/aqueous interphase provided shielding effect to ranibizumab 
against sonication. It is plausible that PB copolymer possess lower mass of lactic acid and 
no glycolic acid block which produce very low amounts of lactic acid, thereby 
eliminating or reducing the possibilities of protein degradation.  
 
Table 5.3 Anti-VEGF activity form released sample 
Days Concentration (µg/mL) 
Micro BCA 
 
Indirect ELISA 
 
1 25.25 ± 4.81 20.1 ± 5.29  
7 9.98 ± 1.89 8.1 ± 2.63 
15 5.72 ± 0.71 4.88 ± 2.56 
30 4.31 ± 0.82 4.54 ±2.07 
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Conclusion 
This study discussed the synthesis and characterization of novel PB copolymers 
for the formulation of NPs and thermosensitive gelling copolymer to achieve the long 
term, zero order release of both Fab fragments of similar MW. A novel composite 
nanoformulation comprised of IgG Fab and Ranibizumab-loaded PB-1 NPs suspended in 
PB-2 thermosensitive gelling copolymer was successfully formulated and characterized. 
IgG-Fab and Ranibizumab encapsulated NPs suspended in thermosensitive gelling 
copolymer demonstrated a continuous zero-order release, thus avoiding the potential 
toxicity in the target tissues due to burst release effect. The synthesized PB copolymers 
were non-cytotoxic and biocompatible in nature attributes to superior biomaterials for 
ocular delivery. The NPs possess higher stability in the cell culture (DMEM and RAW 
with and without serum) and PBS medium. In addition, indirect ELISA confirmed 
retention of physical stability, VEGF binding activity and antigen binding capacity of 
ranibizumab. Such a copolymer based delivery system can minimize the side effects 
associated with frequent IVT injections. These outcomes clearly suggested that a PB 
copolymer based controlled drug delivery system developed here may serve as a 
promising platform for back of the eye complications.  
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CHAPTER 6  
SUMMARY AND RECOMMENDATIONS 
 
Summary 
Developing a nanoformulation to provide a long term release of macromolecules 
for back of the eye diseases is a challenging task. The ideal characteristics to obtain such 
formulation are; (a) minimal burst effect and biphasic drug release profile (b) high drug 
loading in a small injection volume (≤ 100 μL) (c) syringibility: easy to administer 
through 27G needle, (d) ensure a higher stability of macromolecules, (e) provide 
controlled/sustained drug release profile throughout the release period at least for 4-6 
months, and (f) the time required for the biodegradation of formulation should not be 
more than 1.5 times the drug release profile. Considering the above objectives, the 
rationale behind developing a novel biodegradable and biocompatible PB copolymer 
based biomaterial was to achieve controlled drug delivery over a period of several weeks 
from a single IVT injection.  
In chapter 1, a brief overview of back of the eye diseases and available treatment 
was provided. Ocular drug delivery to back of the eye, ocular barrier, routes of 
administration has also been highlighted. A concise discussion on FDA approved 
polyester biodegradable polymer was provided that has been utilized to improve 
ophthalmic drug delivery. Nanotechnology based drug delivery systems for the posterior 
segment of eye diseases with their advantages and limitations are discussed. Moreover, 
the ideal characteristics, therapeutic potential, advantage and limitations of 
macromolecule for ocular drug delivery have been summarized.     
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In chapter 2, the objective and rationale of developing NPs and composite 
nanoformulations have been discussed. In order to achieve the aforementioned goal, 
biodegradable and biocompatible PB copolymers for thermosensitive gel and NPs have 
been synthesized. PB copolymers are composed of FDA approved polymeric blocks such 
as PEG, PCL, and PLA/PGA. Each block plays an important role such as presence of 
PEG helps to improve stability of NPs by reducing NP aggregation. PCL is a slow 
degrading semi-crystalline polymer which improves the loading of large molecules in 
NPs and sustains the drug release for a longer duration. It is important to synchronize 
polymer degradation profiles with the drug release in order to avoid accumulation of the 
formulation in the limited vitreous cavity. Previous reports suggested that poor 
degradation of the PCL is attributed to its crystalline nature; hence reduction in the 
crystallinity of PCL may improve its hydrolytic and enzymatic degradation. Covalent 
conjugation of PCL to PLA chains can reduce crystallinity resulting in faster degradation 
of PCL. In addition, to minimize the burst effect and to extend the duration of drug 
release; a composite nanoformulation approach has been introduced. 
In chapter 3, synthesis and characterization of PBG-1 (PLA-PCL-PEG-PCL-
PLA) and PBG-2 (PEG-PCL-PLA-PCL-PEG) copolymer based thermosensitive gelling 
polymers have been discussed. Arrangement of polymer blocks exhibited significant 
effect on the sol-gel transition curve and kinematic viscosity of respective aqueous 
solutions. PBG-2 copolymer demonstrated noticeably lower kinematic viscosity of 
aqueous solution at 25°C than PBG-1 copolymers. Cell viability and biocompatibility 
studies suggested that PCL, PLA and PEG based block copolymers were compatible with 
D407 ocular cell lines. Octreotide, IgGFab, IgGFab‘ and IgG-loaded PBG-1 and PBG-2 
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thermosensitive gels exhibited sustained release profile. The release profile was depended 
on the hydrophilic and hydrophobic nature of the gelling polymer in addition to the MW 
of the macromolecules. Results of release kinetics modeling suggested that the 
Korsmeyer-Peppas model was best fitted and the exponent values (n value) were ranging 
from 0.272-0.386, indicating diffusion controlled release of macromolecules. It is 
anticipated that a further longer release profile can be obtained by altering block 
composition or change in hydrophobicity and/or hydrophilicity of the gelling polymer. 
The drug release pattern was in conjunction with approved facts that amorphous and 
hydrophilic polymers degrade fast. CD spectroscopy results revealed no changes in 
secondary structure of IgG. Further, the degradation of hydrophilic gelling PBG-2 
copolymers was performed at four different conditions. The gelling polymer was 
degraded at a faster rate initially, due to its amorphous and hydrophilic nature. The rate of 
degradation was faster in borate buffer (pH 9.0) incubated at 37°C. Accelerated 
conditions such as pH 9.0 (37°C) and high temperature (40°C) exhibited MW loss of 
~45% and ~40% w/w, respectively, which were significantly higher compared to the MW 
loss observed under the normal conditions (pH 7.4, 37°C) i.e., ~35% w/w. No significant 
effect of enzymes was observed on polymer degradation. Approximately 50% MW loss 
was noticed in 5 days and a similar degradation pattern was observed under all four 
conditions. After the initial hydrolytic degradation of mPEG, PCL was exposed at the 
terminal. Therefore, the degradation was slower and the MW was fairly constant till 45 
days of analysis. The in vivo assessment of PBG-2 provided a safe environment and was 
well tolerated in the rabbit eyes analyzed up to 33 weeks. Over all, a biocompatible and 
biodegradable polymeric gel formulation was developed to sustain the drug release 
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profile. However, thermogelling system exhibited the sustained drug release upto only 
~20 days, which was shorter than the desired target profile (4-6 months). Moreover, it 
also demonstrated a significant burst drug release effect.    
In chapter 4, a composite nanoformulation has been designed to study the effect 
the in vitro release of macromolecule [(Lyz (14 kDa), Fab (48kDa) and IgG (150 kDa)] 
encapsulated PB-NPs suspended in PBG thermosensitive gelling polymer. The dual 
approach had successfully diminished the burst release effect and exhibited nearly zero-
order release throughout the release period. This behavior may be due to the fact that 
when NPs were suspended in a gel matrix, entangled polymer chains of thermosensitive 
gel may have served as an additional diffusion barrier for the surface adsorbed drug. The 
polymer matrix had prevented the dumping of surface adsorbed dose, thus eliminating 
burst drug release effect and avoiding any possibility of dose dependent toxicity. A series 
of PB copolymers from low to high MWs have been synthesized and evaluated for the 
preparation of NPs. PB copolymers were successfully synthesized by ring-opening bulk 
polymerization reaction and characterized by 
1
H-NMR, gel permeation chromatography 
(GPC) and X-ray diffraction (XRD) spectroscopy analyses. IgG, IgG-Fab and Lysozyme-
loaded PB-NPs were studied to analyze the effects of MW, polymer composition on 
various formulation parameters such as %EE, %DL and in vitro drug release profile. 
Results demonstrated that crystallinity of PB copolymers was easily modulated by 
altering the ratio of PLA/PCL. Moreover, MW, crystallinity and copolymer composition 
exhibited significant effect on EE, DL and in vitro release profile. The PB copolymers 
composed of high MW demonstrated a high EE (~63%), and DL (~8%) with sustained 
drug release profile up to ~60 days which was significantly higher than PBG copolymers 
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(Chapter-3). It may be possible that IgG-Fab, IgG and catalase have very less diffusivity 
through polymer matrix owing to large MW and hence their release was mainly 
controlled by degradation of polymers. Enzymatic activity of released Lyz from PB-NPs 
and control was compared upto one month. The enzyme activity in the released samples 
diminished with time. In vitro cell culture study on macrophage cell lines (RAW-264.7) 
established a higher biocompatibility of PB copolymers for ocular applications. It was 
hypothesized that the in vitro release of macromolecules with similar MWs behaves very 
identical in the same polymer matrix. Although, several positive results were observed, a 
poor DL has been observed in this study. Therefore, the objective of the next study was to 
optimize several formulation parameters to achieve a high drug loading. In addition, the 
effect of in vitro release of similar MW of macromolecules was investigated. 
  In chapter 5, high MW hydrophobic PB copolymers to sustain the drug release 
for a significantly longer duration have been synthesized. Hydrophobic PB copolymers 
were synthesized with high MW of PLA and PCL but keeping the MW of the PEG 
similar. The NP preparation method was successfully optimized with respect to polymer 
hydrophobicity, drug to polymer ratio, and phase volumes to achieve a high DL. With 
optimized NP preparation methods, more than 15% w/w of loading for IgG-Fab and 
ranibizumab in PB NPs was achieved. PB NPs encapsulating IgG-Fab and ranibizumab 
were also evaluated for their sustain release behavior. The NPs depicted negligible burst 
release phase. According to our results, proteins with similar MWs behave very similar 
during NP preparation with same PB copolymers. Hence, they exhibited very similar 
%EE, %DL and in vitro release profile. IgG-Fab and Ranibizumab encapsulated NPs 
suspended in thermosensitive gelling copolymer demonstrated a continuous zero-order 
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release, thus avoiding the potential toxicity in the target tissues. In addition, indirect 
ELISA method confirmed retention of physical stability, VEGF binding activity and 
antigen binding capacity of ranibizumab. Such a copolymer based delivery system can 
minimize the side effects associated with frequent IVT injections. Moreover, cell 
viability, cytotoxicity and biocompatibility studies revealed non-toxic and biocompatible 
nature of PB copolymers. As per the result obtained and with the projected release 
profiles for IgG-Fab, and ranibizumab, a sustain drug release for more than 6 months can 
be achieved from these novel systems. In summary, the composite formulation approach 
can serve as a delivery platform of siRNA, peptides, proteins and antibodies in the 
treatment of ocular diseases. This technology is limited to ocular applications but may 
also be used for any chronic diseases where sustained delivery of macromolecules is 
required. 
 
Recommendations 
Despite being successful in attempting high drug loading and long term release, 
these polymeric systems were not useful to release the desired amount of drug for a long 
period of time. The target drug dose of 4µg/day was observed up to 11 weeks of analysis 
however, after that the release amount was decreased and reached to a level of 
~3.5µg/day in 12 weeks of analysis. Therefore, there is a need to develop the 
formulations that can provide the desired amount of drug release per day for a longer 
period (targeted for 3-6 months). According to the results observed, the release of IgG-
Fab and ranibizumab from the composite nanoformulations was mainly governed by the 
degradation of polymers. Hence, it is hypothesized that by improving the hydrolytic 
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degradation of PB copolymers, a higher rate of macromolecule release can be achieved. 
This can be obtained by changing the order of block copolymers to random block 
arrangements or tetrablock copolymer.    
The PB copolymer (PCL-PLA-PEG-PLA-PCL) investigated in this work showed 
reduced crystallinity; however, there was a reduction in the amount of drug release in the 
later phase. It may be plausible due to the fact that the polymer degrades rapidly due to 
the amorphous nature of PB copolymer. It was anticipated that after the degradation of 
the terminal flank i.e. PCL, PB copolymer may generate the TB copolymer (PLA-PEG-
PLA) which may be slow in degradation resulting in the slower release. Therefore, newer 
arrangements of the block copolymers i.e. random block or tetrablock copolymers may be 
useful for further study. It is anticipated that new arrangement polymer degrades rapidly 
while leaving a small fragment comprised of homopolymers (PCL or PEG), or diblock 
copolymers (PCL-PLA or PLA-PEG). In addition, it is of prime importance to investigate 
the stability of proteins in presence of excipients such as sugars (sucrose, trehalose, and 
glucose), tweens and other supplemental additives such as retinol.  
It has been well documented that the proteins at elevated concentration in aqueous 
solution undergoes irreversible aggregation (formation of trimers and tetramers) resulting 
in degradation. Hence, many of the in situ gel systems with high loading have reported 
incomplete release of protein in vitro.  Therefore, to develop the next generation delivery 
systems for macromolecules, it is obvious to understand the interaction of protein 
molecules with polymer surfaces, protein-excipient interaction/compatibility and in vitro 
-in vivo correlation of released profile to understand the complete release.  
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  HIP complexation is another approach may be useful to enhance the 
encapsulation of various macromolecules and to develop sustained release delivery 
systems using PB copolymers. It was well documented that freeze dried protein may be 
generated using HIP complexation approach without aggregation. HIP complexation can 
be tailored by changing several parameters such as size, structure, pKa, pH of 
complexation, ion pairing agents and number of charges of protein/peptides. HIP 
complexation may protect macromolecule against stress conditions such as presence of 
organic solvents, sonication and may improve protein stability during formulation and 
storage.  
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PART II: DEXAMETHASONE NANOPARTICLE TO DEVELOP AN IN VITRO 
MODEL FOR GLAUCOMA 
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CHAPTER 7 
INTRODUCTION 
 
Statement of problem 
Glaucoma is a leading cause of blindness and visual impairment worldwide. It is a 
group of progressive optic neuropathies and characterized by the degeneration of retinal 
ganglion cells related to the level of intraocular pressure and other factors (213). Several 
types of glaucoma have been broadly classified as acute and chronic, secondary and 
primary. In general, glaucoma in humans is classified into three major types: Primary 
Open Angle Glaucoma (POAG), Primary Angle Closure Glaucoma (PACG), and Primary 
Congenital Glaucoma (PCG) and POAG being the most common type (214). Although, 
the common pathway of tissue damage in all three types of glaucoma is the axonal 
damage that manifests as optic nerve atrophy, causing progressive visual field defects 
that eventually lead to blindness. Elevated intraocular pressure (IOP) is a common thread 
that connects most forms of glaucoma and is a major risk factor for the disease. IOP is a 
function of aqueous humor moving into and out of the eye.  Elevated IOP in glaucoma is 
a result of disease in the primary efflux route, the conventional outflow pathway, 
affecting the proper drainage of aqueous humor (215). The research in the field of 
glaucoma is substantial, may be because of the fact that the pathophysiologic 
mechanisms causing the disease are not completely understood (216). 
Controlling IOP in glaucoma patients is important because large clinical trials 
involving tens of thousands of patients repeatedly demonstrate that significant, sustained 
IOP reduction slows or halts vision loss. Unfortunately, current daily medical treatments 
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do not target the diseased conventional pathway and do not lower IOP sufficiently in 
most people with glaucoma. Therefore, finding new, more effective ways to medically 
control IOP by targeting the conventional pathway is a central hypothesis of this project. 
Using cellular and organ-based model systems, this study seeks to identify and validate 
novel drug targets in the conventional outflow pathway such that novel treatment of 
ocular hypertension and glaucoma can be developed.      
  To understand the mechanism of glaucoma, a wide variety of agents such as 
Ginkgo biloba extract (217), topical corticosteroids (218), dexamethasone (DEX) (219), 
intracameral injection of polystyrene microbeads (220), and benzalkonium chloride (221) 
have been employed to achieve acute and short-term IOP elevation. However, IOP 
elevation was poorly controlled and frequently led to a loss of vision. Several researchers 
have attempted to develop the in vivo (222), ex vivo (223), and in vitro glaucoma models 
(224). A wide variety of animal models including monkeys, dogs, cats, and rodents have 
been used to study glaucoma (222), (225). These animal models not only helped to 
identify targets for therapeutic drugs, but also improved the understanding of the causes 
and progression of glaucoma. Due to their inherent advantages, rodent animals, including 
mice and rats, have been widely applied as models to study various aspects of glaucoma 
and to evaluate possible novel therapies (226). Although these models have provided 
valuable information about the disease, there is still no ideal model available for studying 
glaucoma due to its complexity. Moreover, ex vivo models (227) are limited by the 
absence of survival factors supplied by blood or axonal transport, in addition to the 
incubation period is time limited (225).  
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   In comparison with in vivo and ex vivo models, in vitro cell-based models (228), 
(224) offer the advantages of being simple, quick to construct, relatively inexpensive, and 
reproducible. In addition, it is easy to maintain the environment of in vitro cell-based 
models, small volumes of samples required, control on experimental settings, and 
reduction of the number of animals in in vivo studies. Therefore, use of in vitro models 
for the study of glaucoma opened the possibility of a better understanding of cellular and 
molecular mechanisms that may contribute to disease onset and progression. These 
models can be used in a wide variety from of cell cultures (cell lines) to more complex 
models such as tissue cultures. The opportunity to investigate whole tissue cultures poses 
clear advantages compared to a monolayer of cultured cells, allowing the study of cell-to-
cell interactions and maintaining an anatomical structure. Therefore, there is a need to 
develop an in vitro model that can be advanced to develop glaucoma animal model based 
on the experimental needs.    
 Glucocorticoids (GC) have been a mainstay of therapy in reducing systemic and 
ocular inflammation. GC-induced ocular hypertension (due to the steroid response) has 
long been associated with the pathophysiology of glaucoma (229). Several clinical 
observations suggested that there is a link between GCs and glaucoma (230). A subset of 
the general population (steroid responders) experiences a significant elevation of IOP in 
response to GC administration. Extended periods of steroid-induced ocular hypertension 
resulted in glaucomatous optic atrophy and visual field loss that persist after the drug 
therapy is discontinued and the IOP has returned to normal. With the extensive clinical 
use of GCs for the treatment of various ocular diseases, GC-related ocular hypertension 
has attracted much attention. GCs cause a plethora of changes to the trabecular meshwork 
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(TM) including cytoskeletal, cell junction, extracellular, and functional changes (231). 
GCs alter the expression of several genes in the TM, likely responsible in impairing the 
outflow facility and elevating the IOP.      
TM is porous connective tissue with complex 3D structure (232). Resident TM 
cells are responsible for maintaining its unique architecture and extracellular matrix 
(ECM) constituents (233). ECM is a dynamic structure composed of a number of 
different matrix proteins those are constantly remodeled by a new deposition and 
proteolysis (234). Three secreted ECM-related proteins: matrix metalloproteinase-2 
(MMP-2); myocilin (MYOC); and fibronectin whose expression is altered by 
dexamethasone (DEX: a GC) have shown to play important roles in ECM formation and 
remodeling (235). Morphological examination of the TM in patients having GC-induced 
glaucoma shows an increased deposition of extracellular materials, specifically ECM 
content in the juxtacanalicular tissue. It has been proposed that reduction in MMP activity 
led to enhancing deposition of ECM material in the TM and thus induces an elevated 
juxtacanalicular outflow resistance (234). Other common features of GC treated eyes are 
MYOC induction, cytoskeletal rearrangement, which all may contribute to increased 
outflow resistance. Recently, it was noted that both humans and mice on prolonged GC 
treatment display increased deposition of basement membrane materials below the inner 
wall of Schlemm's canal (SC), possibly contributing to increased barrier function resulted 
in fluid flow resistance (236). The function of MYOC is unknown, however mutations in 
MYOC are a cause of hereditary open-angle glaucoma with ocular hypertension (237). 
Overall, an exact pathogenesis of glaucoma is not known, and current therapeutic options 
are not sufficient to prevent or recover vision loss in glaucoma patients. 
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Animal models are essential to elucidate the natural course of the glaucoma and to 
develop novel therapeutic approaches. However, glaucoma has a complicated 
pathogenesis that is far from being completely understood (45). Since the mechanisms of 
glaucoma differ among animal models, data obtained from a particular model should not 
be generalized and should be interpreted within the context of that model. Therefore, the 
selection of in vitro or in vivo models should be based on experimental needs and the 
hypothesis being tested. Experimentally, induced in vivo models have the advantage of 
studying certain changes in glaucoma in a living animal. However, the duration of IOP 
elevation in these models is transient without sequential treatments. In addition, precise 
control over IOP is difficult, and the timing of induction and progression of glaucoma is 
often unpredictable. Also, in vivo experiments include the involvement of undefined and 
uncontrollable factors. All these limitations associated with in vivo models have 
encouraged development and validation of in vitro models derived from human primary 
and immortalized cells.  
 
Rationale of investigation 
 
Based on the above stated problems of in vivo animal models, it was made clear 
that the exploitation of an appropriate in vitro model is crucial for the development of 
new approaches to overcome ocular barriers. In vitro models can be used to evaluate 
combinations of several experimental parameters; those are often not achievable with 
animal models. In addition to being much less complexed than animal models, in vitro 
models offer the advantage of having controlled experimental conditions, clarifying 
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individual cell responses to stress and allowing preliminary targeting of a specific cell 
type or pathway involved in the progression of glaucoma. Due to the lack of model 
systems to study glaucoma, the use of cultured TM cells provides means to evaluate their 
biological properties when challenged with conditions linked to glaucoma (233), (238). 
TM of the eye that is composed of cells and matrix is thought to regulate aqueous humor 
outflow to control IOP (239). TM and aqueous humor outflow pathway has a wide 
anatomical variation from one species to another; however, TM of humans, rat and 
mouse all contain extracellular meshwork organized into a network of beams covered 
with endothelial cells. Human TM (HTM) cells are usually obtained from whole donor 
eyes or from corneal buttons and ideally, one would like to compare HTM cells from 
glaucomatous tissue to normal HTM cells. Aspects of the different HTM in vitro models 
can be combined and developed to create more accurate representations of TM cell 
behavior in vivo. Ultimately, a more complete understanding of the cellular properties of 
HTM cells will provide new treatment options for glaucoma.   
In order to understand the pathophysiology of glaucoma, HTM cell lines can be 
selected to develop an in vitro model of ocular hypertension. To elevate and maintain the 
IOP, a long-term release of GC drug is required which should be biocompatible to HTM 
cell lines. DEX is one of the effective GC that has been widely indicated in the clinical 
practice of ophthalmology. With the development of nanotechnology, slow, sustained, 
and controlled-release of DEX could be achieved. Polymeric nanocarriers such as 
nanoparticles (NPs) of biodegradable materials are useful in the development of such 
kind of delivery systems. FDA approved biodegradable polymers such as 
polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polyethylene 
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glycol (PEG) and poly lactide-co-glycolide (PLGA) have been comprehensively studied 
for the development of sustained release formulations of the GC.  
 
Objective  
 
The objective of this study is to design the optimized block copolymer based 
delivery system to provide long-term delivery of DEX with minimal burst release effect. 
In this approach, the in vitro drug release profile was optimized by adjusting the block 
length, arrangement and ratios of the PCL/PLA/PGA with PEG. These arrangements may 
be further optimized by changing the MW of each polymeric block. The PB copolymer 
displayed a unique block arrangement, ratio and MW, which can significantly influence 
the drug release profile of hydrophobic molecules. Considering these facts, a PB 
copolymer (PGA-PCL-PEG-PCL-PGA) has been synthesized to encapsulate DEX in PB 
based NPs. The purpose of the present study is to examine the long-term DEX release 
profile of PB copolymer based NPs in physiological solution and culture media. In 
addition, the activity and safety over time in ocular cell culture were examined using 
primary cultures of HTM cells. Current study investigated the possible association 
between MYOC expression and the steroid response on HTM cell. This approach will be 
followed to generate an animal model for GC induced ocular hypertension in a glaucoma 
model. The above mentioned hypothesis was studied with the aim of ‗development and 
characterization of PB copolymer based NP formulations of GC model drug (DEX) to 
develop a glaucoma model‘. This aim is experimentally performed by the following 
methods.   
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(A) Synthesis and characterization of PB copolymers: Novel PB copolymer [PGA-
PCL-PEG-PCL-PGA] was synthesized in two steps by sequential ring-opening 
polymerization reaction. The synthesized PB copolymers were characterized for their 
MW, PDI, and purity by (
1
H) nuclear magnetic resonance (
1
H-NMR) spectroscopy, gel 
permeation chromatography (GPC), and powder X-ray diffraction (PXRD).  
(B) Development, and optimization, and characterization of DEX loaded PB-NPs: 
DEX-loaded PB copolymer NPs were prepared by oil in water (O/W) single emulsion 
solvent evaporation method. DEX-encapsulate PB-NPs were optimized to achieve a high 
entrapment efficiency and drug loading. 
(C) Cytotoxicity evaluation of PB copolymers and PB-NPs: The cytotoxic effects of 
PB copolymers and PB-NPs on corneal, conjunctival and retinal cell lines, cell 
cytotoxicity (Lactate Dehydrogenase: LDH) and cell viability (MTT) assays were 
performed. 
(D) Characterization of DEX loaded PB-NPs: NPs were analyzed for their particle 
mean diameter and size distribution by Nanoparticle Tracking Analysis (NTA). The EE 
(%) and DL (%) of NPs were estimated by the ultra-fast liquid chromatography (UFLC) 
assay. The UFLC assay was used for quantitative estimation of in vitro drug release of 
DEX from NPs. 
(E) Cytotoxicity evaluation of NPs in HTM cell line by WST-1 and LDH assays. 
(F) MYOC level estimation: The long-term secretion of MYOC from HTM cells 
triggered from nanoformulation was analyzed by Western Blot analysis. 
(G) In vivo study: IOP measurement and histology study in C57BL/6 (C57) mice model 
using DEX-PB-NPs to examine the changes in the tissue morphology of the eye.   
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CHAPTER 8 
PENTABLOCK COPOLYMER BASED DEXAMETHASONE 
NANOFORMULATIONS ELEVATE MYOC: IN VITRO LIBERATION, ACTIVITY 
AND SAFETY IN HUMAN TRABECULAR MESHWORK CELLS AND MICE 
MODEL 
(240)
 
 
Rationale 
Glucocorticoids (GCs) have been a mainstay of therapy in reducing systemic and 
ocular inflammation since 1950s (241). However, GC uses often induces ocular 
hypertension, optic nerve head damage, and visual field defects if left untreated. 
Elevation of intraocular pressure (IOP) usually occurs weeks to months after GC 
administration, and happens in ∼40% of patients without glaucoma, called ―steroid 
responder‖. Glaucoma, a group of diseases characterized by progressive optic nerve 
degeneration resulting in visual field loss and irreversible blindness, is a leading cause of 
permanent vision loss worldwide. The death of retinal ganglion cells (RGCs) is a major 
element in the pathophysiology of these diseases, relating to the level of IOP and other 
factors. The exact mechanism for the GC-induced IOP elevation is uncertain, but due to 
its time course likely involves at least two cellular processes in the resistance-generation 
region of the conventional outflow pathway: increased barrier function at the inner wall 
of Schlemm's canal (SC) and alterations in cell contractility and extracellular matrix 
(ECM) turnover in the trabecular meshwork (TM). Morphological examination of the TM 
in patients having GC-induced glaucoma shows increased deposition of extracellular 
materials, specifically, increased ECM content in the juxtacanalicular tissue (cribriform 
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region). Moreover, GC treatment results in decreased intra-trabecular spaces as a result of 
increased collagen, fibronectin and elastin deposition and an imbalance in ECM enzymes. 
Other common features of GC treated eyes are myocilin (MYOC) induction, cytoskeletal 
rearrangement, which all may contribute to increased outflow resistance.  
Recently, it was noted that both humans and mice on prolonged corticosteroid 
treatment display increased deposition of basement membrane materials below the inner 
wall of SC, possibly contributing to increased barrier function. This was modeled in vitro 
by Alvarado showing that Dexamethasone (DEX) increased the junction complexes in 
both SC and TM cells, which resulted in increased transendothelial fluid flow resistance. 
TM is a porous connective tissue with complex three-dimensional structure. The resident 
TM cells are responsible for maintenance of its unique architecture and their ECM 
constituents. The ECM is a dynamic structure composed of a number of different matrix 
proteins that is constantly remodeled by new deposition and proteolysis. In the current 
study, we focused on MYOC whose expression is altered by DEX and shown to play 
important roles in ECM formation in normal physiological processes. The function of 
MYOC is unknown, however, mutations in MYOC is a cause of hereditary open-angle 
glaucoma with ocular hypertension. Since exact pathogenesis of glaucoma is not known, 
and current therapeutic options are not sufficient to prevent or recover vision loss in 
glaucoma patients. Functional, repeatable, and easy-to-use in vitro and animal models are 
therefore needed. Because of their inherent advantages, rodent animals, including mice 
and rats, have been widely developed as models to study various aspects of glaucoma and 
to evaluate possible novel therapies. However, no single model has been shown to 
 167 
 
 
emulate all aspects of glaucoma to understand its pathology and physiological 
mechanism.    
Nanocarriers offer several benefits in ocular drug delivery (1, 242). DEX, one of 
the most effective GCs, has been widely indicated in the clinical practice of 
ophthalmology as an anti-inflammatory and immunosuppressive agent. It can be 
administrated via topical, periocular (i.e. subconjunctival) or intraocular (i.e. intravitreal) 
routes. Topical DEX has proven efficacious for the management of postoperative 
inflammation in the anterior segment after cataract surgery, treatment of anterior uveitis 
(iritis) and dry-eye disease symptoms (243-245). Intravitreal administration of DEX has 
been effective in the treatment of macular edema following retinal vein occlusion, 
diabetic macular edema (246-248), and non-infectious uveitis (249), particularly when 
other therapeutic agents have failed to provide treatment benefits. However, DEX has a 
short half-life (250), and requires multiple applications. As a consequence, technologies 
that achieve slow, sustained, and controlled-release of DEX may prevent frequent 
administrations or multiple invasive treatments (251, 252). In this regard, FDA approved 
biodegradable polymers such as polycaprolactone (PCL), polylactic acid (PLA), 
polyglycolic acid (PGA) polyethylene glycol (PEG) and poly lactide-co-glycolide 
(PLGA) have been comprehensively studied for the sustained delivery of the 
corticosteroid (253, 254). These polymers have been widely tested, preparing various 
diblock (DB) (255), and triblock (TB) copolymers (255) for drug delivery technologies. 
Investigators have applied various block copolymers combinations such as 
PLGA-PEG-PLGA (256), PEG-PLA-PEG (257, 258), for the development of sustained 
release formulations. Several of these polymers are incorporated in microparticle (259), 
 168 
 
 
NP (254), and liposomal preparations (260) for long term release. Recently, the FDA has 
approved a DEX intravitreal implant for the treatment of macular edema following retinal 
vein occlusion, diabetic macular edema, or non-infectious uveitis (249, 261). Several 
attempts have been made to overcome initial burst release by using DB or TB 
copolymers. It has been observed that lipophilic drugs can be trapped in the hydrophobic 
core of the NPs causing no or limited release in later time intervals. Therefore, there is an 
unmet need of designing the optimized block copolymer based delivery system to provide 
continuous delivery of corticosteroids for longer duration with minimal burst release.   
In this regard, PB copolymers have been designed in this study to overcome the 
limitation of the burst release associated with the NP and to provide long term delivery of 
therapeutic molecules (90, 154). In this approach, the in vitro drug release profile was 
optimized by adjusting the block length, arrangement and ratio of the PCL/PLA/PGA 
with PEG. The arrangements may be further optimized by changing the MW of each 
polymeric block. Considering these facts, we have developed a novel PB copolymer 
(PGA-PCL-PEG-PCL-PGA) to encapsulate DEX in PB-NPs attempting to achieve long 
term delivery. The PB copolymer displays unique block arrangement, ratio and MW, 
which can influence drug release profile of hydrophobic molecules. The purpose of the 
present study is to examine the DEX release profile of PB copolymer in physiological 
solution and culture media. In addition, the activity and safety over time in ocular cell 
culture were examined using primary cultures of HTM cells. This approach will be 
followed to generate an animal model for corticosteroid induced ocular hypertension.  
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Materials and Methods 
 
Materials 
Poly (ethylene glycol) (PEG 1 kDa), poly (vinyl alcohol) (PVA), and DEX were obtained 
from Sigma Aldrich, USA. The ε-caprolactone, glycolide and L-lactide were procured 
from Acros Organics, USA. Stannous octoate, HPLC solvents and other reagents utilized 
in this study were of analytical grade. 
 
Methods  
Synthesis of PB copolymers   
Novel PB copolymer, (PGA-PCL-PEG-PCL-PGA) was synthesized in two steps 
by sequential ring-opening polymerization reaction (90). PEG (1 kDa) was utilized as the 
macroinitiator and stannous octoate act as the catalyst. In the first step, triblock (TB) 
copolymer PCL-PEG-PCL was synthesized by polymerization of ε-caprolactone on two 
open hydroxyl ends of PEG. Ε-caprolactone and stannous octoate (0.5% w/w) were 
added to anhydrous PEG and temperature was raised to 130°C. After 24 h, the reaction 
mixture was dissolved in methylene chloride followed by precipitation in cold ether. 
Purified TB copolymer was then used for the preparation of the PB copolymer. Stannous 
octoate (0.5% w/w) was added as a catalyst in the reaction mixture containing a 
predetermined quantity of the TB copolymer. The synthesis of PB copolymer was carried 
out at 130C for 24 h under inert atmosphere. After 24 h, the reaction mixture was 
dissolved in methylene chloride followed by precipitation in cold petroleum ether. The 
purified PB copolymer was vacuum-dried and stored at -20C until further analysis. 
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Reaction schemes for the synthesis of TB and PB copolymers were depicted in Figures 
8.1A and 8.1B, respectively.   
 
Characterization of copolymers 
The synthesized TB and PB copolymers were characterized for their MW, PDI, 
and purity by 
1
H-NMR spectroscopy, GPC, and PXRD. The structures and MWs of 
copolymers (TB and PB) are described in Table-8.1. 
1
H-NMR spectroscopy 
1
H-NMR spectra of TB and PB copolymers were acquired on a 400 MHz NMR 
instrument (Varian Inc., Palo Alto, CA, USA). The chemical shift (δ) values were 
reported in parts per million (ppm). NMR samples were prepared by dissolving TB and 
PB copolymers in deuterated chloroform in a 5-mm outer diameter NMR tubes (Wilmad-
LabGlass, Vineland, NJ, USA). 
GPC analysis 
The purity, MW and PDI of TB and PB copolymers were further analyzed by 
GPC analysis. Polymer samples were analyzed with Waters 410 refractive in DEX 
detector (Waters, Milford, MA, USA). Briefly, samples were prepared by dissolving 1 
mg of copolymers in tetrahydrofuran (THF) (THF was utilized as eluting agent at the 
flow rate of 1 mL/min). Separation was carried out on Styragel HR-3 column (Waters, 
Milford, MA, USA). The internal and external temperatures of the SEC column was 
maintained at 35°C using Waters column heater module controlled by 410 RI detector. 
The data were acquired and processed with Waters Millenium
32
 software (version 3.2). A 
calibration curve was prepared by using Dextran SEC standards (Polymer Standards 
 171 
 
 
Service-USA, Amherst, MA, USA) in the MW range of 5.2 to 410 kDa. A volume of 200 
µL was injected into the SEC system in each analysis. 
PXRD analysis 
To analyze the crystallinity of copolymers, PXRD analysis was performed using 
RigakuMiniFlex automated X-ray diffractometer (Rigaku, The Woodland, TX, USA) 
equipped with Ni-filtered Cu-Kα radiation (30 kV and 15 mA). The analysis was 
performed at room temperature at the scanning rate of 5°/min. 
 
Formulation of PB copolymer based DEX NPs (DEX-PB-NPs) 
DEX-loaded PB copolymer NPs were prepared by oil in water (O/W) single 
emulsion solvent evaporation method. Briefly, DEX (5 mg) and PB copolymer (25 mg) 
were dissolved in methylene chloride copolymers to make the organic phase. The 
aqueous phase was comprised of 5 mL of 2% PVA. The O/W emulsion was formed using 
probe sonication. The organic phase was then evaporated by stirring the emulsion 
overnight. NPs were separated by ultracentrifugation at 20,000 rpm for 45 min at 4C. 
NPs were washed twice with distilled deionized water (DDW), and centrifuged to remove 
traces of PVA and unentrapped DEX. The purified NPs were freeze-dried with mannitol 
as a cryoprotectant and stored at -20°C until further uses.  
 
Physicochemical characterization of NPs 
Size distribution measurements 
DEX-PB-NPs were analyzed for their particle mean diameter: nm, and size 
distribution by Nanoparticle Tracking Analysis (NTA) using a Nanosight LM10 
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instrument (Nanosight, Salisbury, UK). Freeze dried DEX-PB-NPs (1 mg/mL) suspended 
in DDW were subjected to particle size analysis at room temperature and 90° scattering 
angel. All the samples were analyzed in triplicate (n=3). 
Entrapment efficiency (EE) and drug loading (DL)  
The EE (%) and DL (%) were estimated by the ultra-fast liquid chromatography 
(UFLC) assay for the amount of DEX in the supernatants obtained from the NP 
preparation. Equations 8.1 and 8.2 were utilized for the calculation of EE (%) and DL 
(%), respectively. 
 
% Encapsulation efficiency = (Initial amount of drug – Amount of drug in supernatant) *100    …Eq. 8.1   
     Initial amount of drug 
 
  % Drug loading =  Amount of drug in nanoparticle     * 100            …Eq. 8.2 
     Total amount of drug and polymer 
 
           
In vitro drug release profile of DEX-NPs 
To analyze the in vitro drug release profile, 1 mg of DEX equivalent freeze-dried 
NPs were suspended in a dialysis tube. DEX-loaded NPs were suspended in 25 mL of 
phosphate buffer saline (PBS) pH - 7.4 at 37°C. The tube containing dialysis bag was 
placed in a water bath at 37°C (GFL 3032 Shaker, LABOTEC, Germany). At 
predetermined time intervals, 1 mL of clear supernatant was collected and replaced with 
same volume of fresh PBS (preincubated at 37°C). Drug concentrations were measured 
by UFLC analysis. All experiments were conducted in triplicate (n = 3). In vitro release 
data were expressed as cumulative drug released (%) with time.  
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Ultra-fast liquid chromatography (UFLC) assay 
Reversed phase UFLC assay was employed to analyze the entrapment efficiency, 
drug loading and in vitro release profile of DEX-PB-NPs. A Shimadzu UFLC system 
(Shimadzu Scientific Instruments, Columbia, MD, USA) coupled with pumps (LC-
20AT), degasser (DGU-20A3R), DAD detector (SPD-20AV) and autosampler (SIL-
20AHT) was used. A Phenomenax column (Phenomenex C18 kinetex column (100×4.6 
mm, 5 mm) was used at total flow rate of 0.5 mL/min. An isocratic elution method was 
employed for separation with mobile Phase A (water with 0.1% formic acid) at 60% and 
mobile phase B (ACN with 0.1% formic acid) at 40% were ran for 8 min. Concentration 
of DEX standards ranged from 250 ug/mL to 0.488 ug/mL prepared in the mobile phase. 
All solvent fractions were in %v/v ratio. Injection volume of 30 uL was used for each 
analysis and the DAD detector was set at 254 nm for quantification.  
 
In vitro tolerability studies of PB copolymer and PB-NPs 
To analyze the cytotoxic effects of PB copolymers on corneal, conjunctival and 
retinal cell lines, cell cytotoxicity (Lactate Dehydrogenase: LDH) and cell viability 
(MTT) assays were performed according to the supplier‘s instructions. SV-40 (Human 
Corneal Epithelial transfected with a recombinant SV40-adenovirus vector Cell), 
CCL20.2 (Human Conjunctival Epithelial Cell/ Chang's Conjunctival Cell Line) and 
D407 (Human Retinal Pigment Epithelium Cell) cells are immortalized and can be sub-
cultured many times, while maintaining their physiological properties. SV40 cells were 
cultured in DMEM/F-12 medium supplemented with 15% (v/v) heat-inactivated fetal 
bovine serum (FBS), 22 mM NaHCO3, 15 mM HEPES and 5 mg/L insulin, 10 μg/L 
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human epidermal growth factor, 100 mg penicillin, and 100 mg streptomycin each. The 
cells were incubated at 37°C, 5% CO2, and 98% humidity. CCL20.2 cells were 
maintained in a cell culture flask containing Minimum Essential Medium (MEM), Earle‘s 
Balanced Salt Solution (BSS) medium supplemented with 10% FBS, 100 U/L of 
penicillin, 100 mg/L of streptomycin, sodium bicarbonate (2.2 mg/mL), and 2 mM l-
glutamine. D407 cells were grown at 37°C, humidified 5% CO2/95% air atmosphere in a 
DMEM culture medium supplemented with 10% (v/v) FBS (heat inactivated), 29 mM 
NaHCO3, 20 mM HEPES, 100 mg of penicillin and streptomycin each, and 1% 
nonessential amino acids at pH 7.4. The cells were harvested at 80–90% confluency with 
TrypLE™ Express (a superior replacement for trypsin). (96, 255) 
 
Human trabecular meshwork (HTM) cell culture  
Five strains of TM cells (HTM120, 136, 126, 134 and 141) were isolated from 
eyes of human donors of ages11- and 3-month-old (HTM120 and 136), 88-, 51-, and 38-
year old (HTM126, 134 and 141), respectively, with no documented history of eye 
disease. The genders for the HTM cells were HTM126, 136: females; HTM134, 141: 
males; HTM120: unknown, no records from the Eye Bank. Cells were isolated and 
characterized as previously described (262, 263). Human eye tissues were sourced 
ethically from Miracles in Sight (Winston Salem, NC, USA), accredited by the Eye Bank 
Association of America. The research uses of eye tissues were in accordance with the 
terms of the informed consents of the donors and/or donor family. HTM cells (passages 
3-6) were seeded into 24- or 96-well culture plates in DMEM containing 10% fetal 
bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) until cells reached confluency. As 
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a differentiation step, the cells were then switched to DMEM medium containing 1% 
FBS for at least 7 days prior to the experiments.   
 
Dexamethasone NP (DEX-PB-NPs) treatment  
HTM cells were treated with DEX-PB-NPs (1 mg/mL) containing a total of 23 µg 
DEX (DEX-PB-NPs) or Con-NPs (without DEX), DEX (39.25 ng/mL) or control (Con: 
0.1% ethanol) in fresh 1 mL DMEM containing 1% FBS (1% DMEM). Two days after 
initial treatment, cell culture supernatant was removed and replaced with fresh 1% 
DMEM medium containing either 0.1% ethanol vehicle or DEX (39.25 ng/mL in 0.1% 
ethanol). Similarly, medium in Con-NPs or DEX-PB-NPs treated wells was replaced with 
fresh 1% DMEM. Then, cell culture supernatant was collected and replaced with fresh 
1% DMEM once/week for a total of 12 weeks for DEX-NP or Con-NP treatment wells. 
Other wells were replaced with fresh 1% DMEM medium containing either Con or DEX 
once/week. After 4 weeks, all wells were replaced with fresh 1% FBS medium once in a 
week for additional 8 weeks and stored at -80°C until further analysis.   
 
Western blot analysis 
Secreted MYOC levels in cell culture supernatant was detected and normalized 
following our previously published method (264). Briefly, cell culture supernatants were 
collected from wells of culture plates after 2 days of treatment, and then once/week for 12 
weeks. At the end of 12 weeks, cells were harvested, and rinsed twice with cold PBS. 
Cells were scraped into 80 µL of lysis buffer (25% glycerol, 0.0625M Tris.HCl, 2% 
SDS) containing 5% beta mercaptoethanol. Cell culture media at each time point was 
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mixed with 4 × loading buffer (50% glycerol, 0.125M Tris.HCl, 4% SDS) containing 5% 
beta mercaptoethanol and boiled for 10 min before storing at -20°C. For Western 
blotting, 24 µL of solubilized proteins in the cell culture supernatant containing 4 × 
loading buffer were loaded into 8% polyacrylamide gel slabs; and 10 µL of cell lysates 
were loaded to 10% polyacrylamide gel slabs. The proteins were separated via SDS-
PAGE. Fractionated proteins were then transferred electrophoretically to nitrocellulose 
membranes. Non-specific binding of antibodies to membranes containing transferred 
proteins was reduced by incubating with Tris-buffered saline with 0.1% Tween 20 (TBS-
T) containing 5% nonfat dry milk (blocking buffer).  
Rabbit polyclonal antibodies against MYOC or a mouse monoclonal antibody 
against beta-actin (Sigma, St. Louis, MO, USA) in blocking buffer were incubated 
overnight with membranes at 4°C. The next day, membranes were first washed in TBS-T 
(3 times for 10 minutes) and then were incubated in blocking buffer containing 
horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) for 1 hour. After incubation, membranes were 
washed with TBS-T. Protein-antibody complexes were visualized using a 
chemiluminescent HRP antibody detection reagent spray (HyGLO; Denville Scientific, 
Inc., Metuchen, NJ, USA) and exposure to x-ray film (Phonix Research Company, 
Candler, NC, USA). The protein abundance in each band was quantified by densitometry 
using ImageJ image analysis software (GeneSnap/GeneTools; Syngene, Frederick, MD, 
USA).  
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Cell cytotoxicity (LDH) assay  
The LDH assay was performed using supplier‘s instructions. Briefly, 5, 25 and 50 
mg/mL of PB copolymer were dissolved in acetonitrile (ACN) and 100 µL was aliquoted 
in each well of the 96-well plate. Plates were exposed overnight under UV light (laminar 
flow) for polymer sterilization as well as evaporation of ACN. Similarly, 5, 25 and 50 
mg/mL of PB-NP was dispersed in culture media and filtered through 0.22 µM filter. One 
hundred microliter of this solution was added to the 96-well cell culture plate. D407, SV-
40 and CCL.20.2 cells at the density of 1.0 x 10
4
 were seeded in each well and incubated 
at 37°C, 5% CO2 in humidified atmosphere for 48 h. After completion of the incubation 
period, cell supernatants were analyzed for the quantification of LDH release using LDH 
assay kit (Takara Bio Inc., Otsu, Japan). Absorbance of each well was measured at 450 
nm using a DTX 800 multimode microplate reader (Beckman Coulter, Brea, CA). The 
LDH release (%) was calculated according to Eq. 8.3 and more than 10% of LDH release 
was considered as cytotoxic.     
                                                                                                                                            
         … Eq. 8.3 
 
To test the cytotoxicity in HTM cells, three strains of confluent HTM cells 
(HTM141, HTM126 and HTM136) kept in 1% DMEM media for 1 week were treated 
with Con vehicle (0.1% ethanol), DEX (39.25 ng/mL in 0.1% ethanol), Con-NPs (1 
mg/mL) or DEX-PB-NPs (1 mg/mL) in 1% DMEM media. The treatment protocol was 
the same as for collecting media for MYOC analysis as explained before. At the end of 
12 weeks of incubation, cytotoxicity was determined by measuring LDH release from 
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cells using LDH assay kit (Roche, Indianapolis, IN, USA). Briefly, the supernatant was 
carefully removed, centrifuged, and transferred to a 96-well plate. The cells were lysed 
and then transferred to a 96-well plate. A reaction mixture consisting of catalyst/dye 
combination was prepared, and 100 μL was added directly to each of 100 μL of the cell 
supernatant, cell lysates, plain media and lysate solution. After incubation at 25°C for 30 
min, absorbance was measured using a spectrophotometer at 490 nm with a reference 
wavelength at 690 nm. Released LDH in the cell supernatant was calculated by 
subtraction of media background and then normalized by total LDH in cell lysates from 
each treatment group. 
 
Cell viability assay 
The safety and biocompatibility of PB copolymers was further established by 
performing an in vitro cell viability assay (MTS; (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) tetrazolium reduction) (Promega Corp., Madison, WI, 
USA), according to suppliers instructions. PB copolymer solutions at the concentration of 
5, 25 and 50 mg/mL in ACN were prepared, aliquoted and sterilized. Following 
sterilization, D407, SV-40 and CCL20.2 cells were seeded in each well of 96-well plate 
at a cell density of 1.0 x 10
4
, and incubated at 37°C and 5% CO2 in humidified 
atmosphere for 48 h. Similarly, 5, 25 and 50 mg/mL of PB-NP solution were prepared in 
culture media and filtered through 0.22 µM filter. From this, 100 µL was added to the 96-
well plate. At the end of incubation period, cell culture medium was aspirated and cells 
were incubated for 4 h (37°C and 5% CO2) in the presence of 100 µL of serum free 
medium containing 20 µL of MTS solution. The fluorescence intensity was measured at 
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the excitation and emission wavelengths of 560 nm and 590 nm, respectively, using the 
above microplate reader. Percent cell viability was calculated using Eq. 8.4. The PB 
copolymers exhibiting more than 90% of cell viability were considered suitable for ocular 
applications.   
 
                       … Eq. 8.4 
 
To test the cell viability of HTM cells with DEX, Con-NPs or DEX-PB-NPs, a 
colorimetric assay was performed based on the cleavage of the tetrazolium salt WST-1 
(4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1.3-benzene disulfonate) by 
mitochondrial dehydrogenases in viable cells (Roche, Mannheim, Germany). Twelve 
weeks after the initial treatment, WST-1 solution (10μL/well) was added to each well 
containing 100 µL of cell culture supernatant. Cells were further incubated for 30 min at 
37°C. The plate was read on a spectrophotometer at 440 nm with a reference wavelength 
of 690 nm.  
 
Extraction method of DEX from cell culture media 
Cell culture medium samples were analyzed using an UFLC method as described 
earlier. Sample preparation was carried out using liquid–liquid extraction technique. 
Hydrocortisone, a corticosteroid, similar in structure to DEX was employed as an internal 
standard. Briefly, samples were thawed at room temperature and 50 µL of internal 
standard was added to the samples (300 µL). The solutions were vortexed for 30 sec, 100 
µL of ACN was added, and vortexed again for 30 sec to deactivate the serum proteins 
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and enzymes. Each sample was mixed with 300 µL of organic solvent and vortexed again 
for another 2.5 min to allow equilibration between the phases. For efficient separation of 
the aqueous and organic layers, samples were extracted twice and centrifuged at 10,000 
rpm for 7 min. Aliquots (500 µL) were collected and dried under reduced pressure for 45 
min. The residue was reconstituted with 300 µL of mobile phase [ACN (40%) & water 
(60%)], vortexed for 30 sec and transferred into a pre-labeled UFLC autosampler vial 
with silanized inserts. A 30 µL of the resulting solution was injected onto the UFLC 
system and analyzed for DEX quantification. 
 
Statistical analysis 
The experimental values were generally presented as mean ± standard deviation 
(SD) of triplicate determinations (n = 3). Mann–Whitney U test was used to analyze 
statistical significant difference between groups. A P value of ≤ 0.05 was considered 
statistically significant. 
 
In vivo study in C57BL/6 mice  
Mice were handled in accordance with animal care and use guidelines of Duke 
University and in compliance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. C57BL/6 mice were from the Jackson Laboratory (Bar 
Harbor, Maine, USA), bred/housed in clear cages and kept in housing rooms at 21 °C 
with a 12 h: 12 h light-dark cycle. Mice were examined at ages between 3 and 4 months 
old. There were 7 mice (14 eyes) in the ghost group and 6 mice (12 eyes) in the DEX 
treated group. DEX-PB-NPs or Con-NPs were diluted in PBS at concentrations of 0.5 
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mg/µL, vortexed for 10 min and then sonicated for 10 min. Mice were anesthetized with 
Ketamine/Xylazine 100mg/10mg/kg. IOPs were measured right after mice stop moving. 
NPs (20 µL from 1mg/mL containing ~23ug of DEX or no DEX) were slowly injected 
into superior subconjunctival fornix on both eyes using 30-gauge needle with a Hamilton 
glass microsyringes (50 µL volume; Hamilton Company, Reno, NV, USA). After 
withdrawing the needle, antibiotic ointment was applied to the eyes and mice were 
recovered on the warm pad.   
 
Intraocular pressure (IOP) measurement  
IOP was measured in both eyes for control and treated groups (Group # 1, 1A, 2, 3 and 
4). The mice were anesthetized with ketamine (60 mg/kg) and xylazine (6 mg/kg). IOP 
was immediately measured just as the mice stopped moving (light sleep) using rebound 
tonometry (TonoLab) between 10am to 1pm (265). Each IOP recorded was the average 
of six measurements, giving a total of 36 rebounds from the same eye. Post-treatment and 
pre-treatment IOPs were measured during the same time of the day. 
 
Histology Study in C57BL/6 mice  
Mice were euthanized at the predefined time intervals by decapitalization under 
anesthesia condition following the approved animal study protocol. Immediately after 
euthanasia, eyes were enucleated and processed for histopathology. Following eye 
removal, carcasses were discarded without necropsy. Three weeks after DEX-PB-
NPs/Con-NPs injection in both eyes, eyes were collected and immerse fixed in 4% 
paraformaldehyde, and kept at 4 °C overnight.  The eyes were then bisected and the 
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posterior segments and lenses were removed. The anterior segments were cut into four 
quadrants and each quadrant was embedded into Epon (Electron Microscopy Sciences, 
ON, Canada). The blocks were cut into 0.5 µm semi-thin sections and stained with 1% 
methylene Blue. The images were captured digitally using light microscopy. 
 
Results and Discussion 
 
Synthesis of PB copolymer  
PB copolymer designed for the preparation of NPs was successfully synthesized by ring-
opening bulk copolymerization as represented in Figure 8.1A and 8.1B.  
 
Figure 8.1 Synthesis scheme for (A) triblock (TB: PCL-PEG-PCL) copolymer and (B) 
pentablock (PB: PGA-PCL-PEG-PCL-PGA) copolymer by ring opening bulk 
copolymerization method. (Reproduced from Ref. 240).  
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Characterization of PB Copolymer  
A typical 
1
H-NMR peaks comprised of glycolic acid which displayed a series of singlets 
between 4.6 to 4.9 ppm confirming the methylene protons of PGA block as depicted in 
Figure 8.2. The MWs of copolymers were calculated from the integration values of 
1
H-
NMR peaks of individual blocks. Moreover, absence of any additional peaks in 
1
H-NMR 
spectrum confirmed the purity of PB copolymers. The MWs calculated from 
1
H-NMR 
are reported in Table 8.1. 
 
 
Figure 8.2 Characterizations of pentablock (PB) copolymer by proton nuclear magnetic 
resonance spectra (
1
H NMR) spectroscopy. (Reproduced from Ref. 240). 
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Table 8.1 Characterization of triblock and PB copolymers  
Co-
polymers 
Structure Total Mn
a
 
(theoretical) 
Total Mn
b
 
(calculated) 
Total Mn
c
 
(calculated) 
Mw
c
 
(GPC) 
PDI 
c
 
TB PCL7000-
PEG1000-PCL7000  
15000 14278 12289 17562 1.83 
PB PGA3000-
PCL7000-
PEG1000-
PCL7000-PGA3000 
21000 20264 17952 23158 1.36 
a: Theoretical value, calculated according to the feed ratio.  
b: Calculated from 
1
H-NMR. 
c: Determined by GPC analysis.  
 
 
The purity, molecular weights (Mn and Mw) and PDI were further evaluated by 
GPC and represented in Figure 8.3. The PDI values of PB copolymers were below 1.5 
suggesting a narrow distribution of MWs. Moreover, PB copolymers depicted a single 
peak in GPC chromatogram indicating mono distribution of MW. Calculated MWs 
appear to be very similar to the theoretical MWs obtained from feed ratio. Therefore, 
theoretical MWs were considered instead of calculated MWs subsequently.  
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Figure 8.3 Gel permeation chromatograms (GPC) of pentablock (PB) copolymer 
depict a single peak indicating mono distribution of MW. (Reproduced from Ref. 240).  
 
XRD spectra revealed the crystallinity of block copolymers as represented in Figure 8.4. 
Interestingly, TB and PB copolymers exhibited crystalline peaks of PCL at 2θ = 21.5° 
and 23.9°. XRD patterns of TB and PB indicated that PCL blocks have retained semi-
crystalline structure even after covalent conjugation with PGA blocks. Conjugation of 
PGA blocks at the terminals of TB copolymers slightly affected the intensity of 
crystalline peak. Previously published reports suggested that decrease in crystallinity 
significantly enhances the degradation of block copolymers (183). Hence, it is anticipated 
that PB copolymer can display a slower rate of degradation due to its semi-crystalline 
nature.    
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Figure 8.4 X-ray diffraction patterns (XRD) of triblock (TB) and PB copolymers. 
(Reproduced from Ref. 240). 
Formulation and Characterization of DEX-PB-NPs 
Particle size 
The particle size of NPs was found to be 109 ± 3.77 (n = 3) as analyzed by nanoparticle 
tracking analysis (NTA) reported in Figure 8.5. 
 
Figure 8.5 Particle size distributions of DEX-PB-NPs by Nanoparticle Tracking Analysis. 
(Reproduced from Ref. 240). 
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Entrapment efficiency (EE %) and drug loading (DL %) 
The percent EE and DL was calculated as 63.23 (±2.31) and 10.53 (±0.38) respectively, 
(n = 3). 
 
In vitro DEX release study 
The release study was performed by suspending 1 mg of DEX equivalent PB-NPs in PBS 
at 37°C and sampling from dialysis chamber. Burst release (20%) was observed for the 
first two days possibly due to the release of surface bound drug of NPs. Cumulative 
%DEX released vs. time profile was illustrated in Figure 8.6. DEX release from the PB-
NPs was continuous over three months. About 50% of DEX was released within six 
weeks which appeared to be responsible for interactions with PGA chains resulting in 
relatively faster release pattern. A bi-phasic release pattern of DEX was evidented from 
NPs with initial burst release, followed by a sustained release phase. DEX demonstrated 
slow release rate from NP because of the hydrophobicity and low crystallinity of PB 
copolymer. Hence, PB copolymer based NPs were considered to be more effective 
relative to existing PLGA and other polymers based systems. The advantages associated 
with this sustained release formulation (DEX loaded NPs) offered a higher drug residence 
at the site of absorption.  
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Figure 8.6 In vitro release of Dexamethasone (DEX) from DEX-PB-NPs. Results are 
given as mean ± SD, n = 3. (Reproduced from Ref. 240). 
 
In vitro tolerability of PB copolymer and PB-NP on ocular cells 
In order to investigate the toxicity of PB copolymer and PB-NPs with biological system, 
transformed ocular cell lines (SV-40, CCL.20.2 and D407 cells) were treated with 5, 25 
and 50 mg/mL of PB copolymer and PB-NPs for 48 h (Figures 8.7). Primary cultures of 
HTM cells were treated with 1 mg/mL of PB copolymer and DEX-PB-NPs for 12 weeks 
(Figure 8.8 A). LDH is a cytoplasmic enzyme, secreted in cell culture medium following 
cell-membrane damage. Estimation of LDH concentration in culture supernatant was 
used to provide PB copolymer toxicity information. Less than 10% of LDH release was 
observed after 48 h and 12 weeks exposure indicated a negligible toxicity. Noticeably, 
results were comparable with negative controls.   
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Figure 8.7 In vitro cytotoxicity assay (LDH) of: (A) pentablock (PB) copolymers; (B) 
Blank PB-NPs at different concentrations on D407, SV-40, and CCL20.2 cells. Results 
are given as mean ± SD, n = 5. (Reproduced from Ref. 240).  
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Figure 8.8 Effect of DEX-PB-NP on HTM cytotoxicity over time. Confluent HTM 
cells were treated with a single application of con-NPs or DEX-PB-NPs (1 mg/mL). Cell 
viability was determined by (A) WST-1 and cytotoxicity was examined by (B) LDH 
release after 12 weeks. (Reproduced from Ref. 240).  
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To further confirm the cytotoxicity of copolymers, MTS or WST-1 cell viability 
assays were performed. The WST-1 assay is a rapid and sensitive colorimetric assay 
based on the cleavage of the tetrazolium salt WST-1 (4-[3-(4-lodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1.3-benzene disulfonate) by mitochondrial dehydrogenases 
in viable cells (Roche, Mannheim, Germany). In MTS assay, only metabolically active 
cells convert tetrazolium compound to formazan. Hence, the concentrations of formazan 
products provide a direct estimation of the cell viability. Results in Figure 8.9 
demonstrated that we observed more than 90% cell viability (for all the cell lines) after 
48 hours and 12 weeks exposure to PB copolymer and PB-NPs (Figure 8.8 B). This 
suggested an excellent safety profile of PB copolymer and nanoformulation for ocular 
applications.  
 192 
 
 
 
Figure 8.9 In vitro cell viability assay (MTS) of: (A) PB copolymers; (B) blank PB-NPs 
at different concentrations on D407, SV-40, and CCL20.2 cells. Results are given as 
mean ± SD, n = 5. (Reproduced from Ref. 240).  
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MYOC secretion from cultured HTM cells 
The expression and secretion of MYOC from primary cultures of TM cells was 
robustly enhanced following DEX treatment (264, 266-270). Previous studies (264) 
suggested that MYOC was continually upregulated following prolonged 4 weeks DEX 
treatment and its expression declines over time in the absence of DEX. Thus, the 
secretion of MYOC can be used as a surrogate read out of biological activity of DEX 
released from DEX-PB-NPs. A single application of DEX-PB-NPs (1 mg/mL) or control 
NPs were given to HTM cells. Cell culture supernatant was collected and replaced with 
fresh 1% DMEM once/week for 12 weeks. DEX or Con vehicle serves as controls to 
compare MYOC secretion levels by Western blot, being applied once/week for 4 weeks, 
and then switched to fresh 1% DMEM media for the last 8 weeks. Four HTM cell strains 
showed similar MYOC secretion patterns, having robust responses for the entire 
monitoring period (Figure 8.10). In contrast, one cell strain only responded over a few 
weeks (Figure 8.11).   
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Figure 8.10 DEX-PB-NPs induced prolonged myocilin (MYOC) secretion from cultured 
HTM cells. Representative WB images showed MYOC secretion over time in response to 
DEX (39.25 ng/mL), Con-NPs and DEX-PB-NPs treatment. Cells were exposed to NP 
preparations for entire 12 week period, while only exposed to DEX for the first 4 weeks.  
Rows 1 to 12 show MYOC protein levels from week 1 to 12. Last row shows beta-actin 
from the same cells collected at end of 12 week period. Four HTM cell strains (A) HTM 
136 (B) HTM 120, HTM 126, HTM 134, showed similar MYOC secretion pattern.  
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Figure 8.11 Unique myocilin (MYOC) secretion pattern observed in a single cell strain. 
Confluent HTM141 cells were treated with single application of Con-NPs or DEX-PB-
NPs (1 mg/mL) and exposed for 12 weeks. Dex (39.25 ng/mL) treatment was repeated 
once/week for four weeks and then withdrawn. Cell culture media was collected and 
replaced with fresh 1% FBS media once/week for 12 weeks. Rows 1 to 12 show MYOC 
protein levels by Western blot from week 1 to 12. Last row shows beta-actin from the 
same cells collected at end of 12 weeks. (Reproduced from Ref. 240). 
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Quantitation of WB data from 5 HTM cell strains (Figure 8.12) showed that 
MYOC levels was increased 5.2 ± 1.3, 7.4 ± 4.3, and 2.8 ± 1.1 fold at 4, 8, and 12 weeks 
in presence of DEX-PB-NPs compared to 9.2 ± 3.8, 2.2 ± 0.5, and 1.5 ± 0.3 fold at 4, 8, 
and 12 weeks in control DEX treatment group. There were significant differences at early 
time points when DEX group is compared to the Control group (*). The DEX-PB-NP 
group was compared to ghost-NP group (#) using Mann-Whitney U Test. They did not 
reach statistical significant difference at later time points in DEX-PB-NPs compared to 
ghost-NP, primarily due to the unresponsiveness of on one cell strain HTM141(out of 
five cell strains) at later time points. The control data were consistent with our previous 
results (264) where MYOC from cells treated with DEX were significantly up-regulated 
(>4-fold) within the first 6 weeks and then gradually returned to near baseline levels at 
the end of 6 weeks. Based on the decline in MYOC levels after withdrawal of DEX from 
control wells, the data suggested that DEX-PB-NPs released the biologically active DEX 
for at least 10 weeks. Interestingly, the first measurement of MYOC levels in Con-NPs-
treated groups at week 1 showed 4-fold increase, then dramatically dropped back to near 
control levels by 2 weeks, where it remained. By comparison, MYOC levels in vehicle 
treated control wells remained unchanged. 
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Figure 8.12 Quantification of myocilin (MYOC) secretion in response to Dexamethasone 
(DEX)-loaded nanoparticles (NPs) over time from HTM cells. MYOC Western blot 
images from all five HTM cell strains treated with DEX-NPs, Con NPs or DEX (39.25 
ng/mL) for 12 time points for each strain were digitized and quantified using ImageJ 
software whereby the band intensities were normalized by beta-actin level observed for 
each individual cell strain. Cells were exposed to NP preparations for entire 12 weeks, 
while cells were only exposed to DEX for first four weeks. The relative MYOC secretion 
levels from DEX, Con-NPs and DEX-PB-NPs were compared to their individual controls 
at each time point. The combined data represent mean ± SE, N = 5. Symbols (* and 
#
) 
indicates the significant differences compared to the Control group and ghost-NP group, 
respectively, using Mann-Whitney U Test. (Reproduced from Ref. 240). 
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Modification of HTM cell morphology by the PB polymer 
Although not showing any signs of cytotoxicity, we did observe that HTM cells 
changed morphology in the presence of either NP alone or DEX-PB-NP, becoming more 
elongated (Figure 8.13), possibly due to phagocytosis of NPs. A change in morphology 
was observed as early as 6 weeks and continued upto the last observation at 12 weeks. 
Interestingly, morphology alterations did not appear to change the MYOC secretion 
response to DEX released from PB-NPs.  In contrast, cells treated with DEX looked 
similar to vehicle control treated cells during the 4 weeks of treatment, compared to 12 
weeks of Con-NPs. Regardless, changes in morphology were observed in cells treated 
with Con-NPs alone, suggesting that DEX was not responsible for morphological 
alterations.  
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Figure 8.13 Modifications of HTM cells morphology by Con-NPs and DEX-PB-NPs but 
not by Dexamethasone (DEX). Confluent HTM cells were treated with single application 
of Con-NPs or DEX-PB-NPs (1 mg/mL) for entire 12 week observation period. In 
contrast, DEX (39.25 ng/mL) treatment was repeated once/week for four weeks. At the 
end of 12 weeks, cell morphology from each treatment was recorded under phase/contrast 
light microscope with 10 × magnifications. N = 5. Arrows indicate aggregated polymers. 
(Reproduced from Ref. 240). 
 
Extraction of DEX from cell culture media 
The culture media from the different cell strains of HTM cells was thawed and 
collected from cells exposed to DEX-PB-NPs once a week. DEX was extracted from the 
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collected media to determine the amount of DEX released from the NPs. The extraction 
efficiency was found to be > 90% for both DEX and HC. Interestingly, the amount of 
DEX released from all three strains was almost equal and detectable for 12 weeks.    
 
Elevation of IOP by DEX-PB-NPs 
IOP data were collected before and twice/week after DEX-PB-NPs or Con-NPs 
injection. As shown in figure 8.14, IOP was clearly elevated in DEX-PB-NPs treatment 
group, but not in Con-NPs group. By comparing between the two groups, significant IOP 
elevation observed for 8 days to 3 weeks after initial NPs injection. If IOP was compared 
to pre-injection, significant elevation started as early as 4 days post-injection in DEX-PB-
NPs group and reached significantly different at all the time points.   
 
 
Figure 8.14 Elevation in intraocular pressure (IOP) by DEX-PB-NPs treatment group, 
compared to Con-NPs. 
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In vivo histology on C57BL/6 (C57) mice   
Histology analysis showed that neither DEX-PB-NPs nor Con-NPs modified 
gross outflowed tissues morphology after 3 weeks of initial DEX-NPs or Con-NPs 
injection as shown in Figure 8.15. The outflow tissues (TM, SC) did not show any 
abnormal phenomenon in gross morphology.   
 
 
Figure 8.15 Ocular tissue morphology of DEX-PB-NPs and Con-NPs after 
subconjunctival injection  
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Conclusion 
In the current study, a novel PB-NP loaded with DEX was developed to obtain a 
long-term slow release of DEX. The longer DEX release from the PB-NP was observed 
due to the high MW of the PB copolymer which required longer time for degradation. 
The activity of DEX-loaded PB copolymers on MYOC secretion was examined by the in 
vitro cell culture system using HTM cells. With a single application of the DEX-PB-NPs 
to cultured HTM cells, the robust upregulation of MYOC secretion by HTM cells was 
detected and maintained for more than 12 weeks. Consistent with a previous study, HTM 
cells from different donors can vary in response to DEX treatment (264). Out of five 
HTM cell strains studied, four of them showed consistent MYOC increase over the first 6 
weeks (4 weeks of treatment). The level of MYOC in the media from these four cell 
strains decreased afterwards, but was still significantly higher than control levels after the 
7 weeks. Only one cell strain (HTM141) showed an increase in MYOC secretion in 
response to DEX-PB-NPs for only three weeks before equal to or below control levels for 
the remainder of the study. The varied response to polymer treatments in different cell 
strains indicated that the polymers should be examined on various strains from multiple 
donors before it is studied in vivo.  
The individual response to DEX treatment in the clinic varies; about 40% of non-
glaucoma individuals are steroids responders. The exact mechanism for the steroids-
induced IOP elevation is uncertain, but due to its time course likely involves at least two 
cellular processes in the resistance-generation region of the conventional outflow 
pathway: increased barrier function at the inner wall of SC and/or alterations in cell 
contractility and/or ECM turnover in the TM [33]. Resident TM cells are responsible for 
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maintenance of its unique architecture and their ECM constituents. The differential 
response of individual HTM cell strains to DEX and DEX-PB-NPs treatment in our study 
may have partially explained the important role of TM cells in steroids-induced ocular 
hypertension. For these reasons, it was important that multiple cell strains were tested.  
Although, the PB copolymers didn‘t display any sign of cytotoxicity to HTM cells 
in this long-term study, it did modify the HTM cells morphology. HTM cell elongation 
was present in all strains following Con-NPs and DEX-PB-NPs treatments. 
Morphological modification of HTM cells by polymers may have accompanied 
functional changes that could not be measured in the present study, but needs further 
investigation. In addition, MYOC elevation was also observed in three HTM cell strains 
with Con-NPs treatment during the first week of the treatment. Therefore, the safety of 
copolymers must be ascertained further. This study provided the evidences that the in 
vitro system is a valuable tool for testing safety as well as the biological effects on 
steroids release from the polymers. 
 Although, the in vitro release conditions were somewhat different compared to 
DEX release study with HTM cell strains, an approximately equal amounts of DEX 
release was observed into the culture media. Under both in vitro conditions, DEX was 
released for a longer period of time. Although slow and long-term (>1 month) DEX 
release was detected in the current study, early burst release phenomenon still occurred 
with PB copolymers. This may limit the PB copolymers applications in some of the in 
vivo studies, especially in clinic. Our next goal is to develop the PB copolymers with 
different MWs, ratios, and arrangements so that the therapeutic agents could be released 
in more controlled zero-rate release fashion without initial burst release effect. At the 
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same time the PB copolymers must be biocompatible, biodegradable and should not 
modify the cellular functions and morphology.  
In this project, DEX-induced ocular hypertension in mice was investigated. 
Within 1 week of DEX-PB-NPs, IOP became elevated by 2 to 3mm Hg, and IOP 
elevation was sustained throughout the entire 3- to 4-weeks duration of the study, which 
showed the promising use of DEX-PB-NPs. However, no single model has been shown 
to recapitulate all aspects of glaucoma, and each rodent model has particular advantages 
and disadvantages that make it suited to answer specific research questions. With several 
new developments in biotechnology, basic science research tools, and better 
understanding of the pathogenesis of glaucoma, more and better animal glaucoma models 
would be developed, helping to better treat the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 205 
 
 
CHAPTER 9 
SUMMARY AND FUTURE PROSPECTIVE 
 
Summary 
In chapter 8, PB copolymer (PGA-PCL-PEG-PCL-PGA) was synthesized in two 
steps by sequential ring-opening bulk copolymerization reaction. The PB copolymer was 
characterized by NMR, GPC and XRD. 
1
H-NMR peaks comprised of glycolic acid 
displayed a series of singlets between 4.6 to 4.9 ppm confirming methylene protons of 
PGA block. PB copolymers depicted a single peak in GPC chromatogram indicating 
mono distribution of MW with PDI <1.5. XRD patterns of copolymer indicated that PCL 
blocks have retained semi-crystalline structure even after covalent conjugation with PGA 
blocks. DEX-loaded PB copolymer base NPs were prepared by oil in water (O/W) single 
emulsion solvent evaporation method. The percent EE and DL was determined as 63.23 
±2.31 and 10.53±0.38 %w/w (n = 3), respectively. The particle size of NPs was found to 
be 109 ± 3.77 nm, analyzed by NTA measurements. A long term DEX release from the 
PB-NPs was observed for over three months. A biphasic release pattern of DEX was 
evident from NPs with an initial burst release followed by a sustained release phase. 
Cytotoxic effects of PB copolymers on corneal (SV-40), conjunctival (CCL20.2), retinal 
(D407), and HTM cells indicated a negligible toxicity. In addition, more than 90% cell 
viability (for all the cell lines) after 48 hours and 12 weeks of exposure of HTM cells to 
PB copolymer and PB-NPs suggested their excellent safety profiles.   
To study MYOC elevation, five strains of TM cells (HTM120/136/126/134/141) 
were isolated from eyes of human donors of ages11- and 3-month-old (HTM120/136), 
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88-, 51-, and 38-year old (HTM126/134/141), respectively and treated with DEX-PB-
NPs. The expression and secretion of MYOC from primary cultures of TM cells was 
robustly enhanced following DEX treatment and quantitatively analyzed by Western 
Blot. Based on the decline in MYOC levels after withdrawal of DEX from control wells, 
the data suggested that DEX-PB-NPs released the DEX for at least 10 weeks. 
Interestingly, MYOC levels in Con-NPs-treated groups at week one showed a 4-fold 
increase, and then dramatically dropped back to near control levels by 2 weeks. The 
MYOC levels in vehicle treated control wells remain unchanged. The C57BL/6 mice 
were selected to develop in vivo model for glaucoma. After subcutaneous injection, IOP 
level became elevated by 2 to 3 mm and sustained throughout the entire 3- to 4-week 
duration of the study. In vivo histology was performed in the presence of control and 
DEX-PB-NP on the ocular tissues. The outflow tissues (TM, SC) did not show any 
abnormal phenomenon in gross morphology in the presence of DEX-PB-NPs and Con-
NPs, analyzed after 3 weeks of injection. 
 
Future prospective 
The ocular hypertension related to GC induced glaucoma using primary cultures 
of HTM cells has been investigated. Activity and safety of DEX-PB-NPs over time with 
HTM was excellent. Therefore, the developed system is found to be a valuable and novel 
tool for determining the safety and effects of steroids released from polymeric NPs. 
Although, the PB copolymer did not show any sign of cytotoxicity to HTM cells in this 
long-term study, it did modify the HTM cell morphology. HTM cell elongation was 
present in all cell strains after both Con-NPs and DEX-PB-NPs treatment. Morphological 
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modification of HTM cells by the copolymers may accompany functional changes those 
were not measured in the present study, but needs further investigation. Moreover, in 
future, the synthesis of PB copolymers with different MWs, ratios and arrangements will 
be studied to obtain a controlled zero-order drug release rate with minimal initial burst 
effect. In addition, several HTM cell strains will be analyzed from different donors. 
Currently, the pathogenesis of TM dysfunction, on primary cultures of HTM cells are 
under investigation. Further, this model will be evaluated for new ocular therapies aimed 
at lowering intra-ocular pressure in humans. Moreover, the IOP-lowering capabilities of 
novel rho kinase inhibitor (netarsudil), beta-blockers (timolol), Prostaglandin analogs 
(latanoprost), Alpha-adrenergic agent (brimonidine) and carbonic anhydrase inhibitors 
(dorzolamide) will be studied in a mouse model. Overall, this approach will be followed 
to generate an animal model for GC induced ocular hypertension and to evaluate the IOP-
lowering capabilities of several class of glaucoma drugs.  
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APPENDIX 
 
(A) Abbreviations 
(
1
H) NMR: proton nuclear magnetic resonance  
AMD: age related macular degeneration 
BRB: blood retinal barrier 
CD: circular dichroism spectroscopy 
CGT: critical gelling temperature  
CPT: critical precipitation temperature 
DDW: distilled deionized water 
DEX: dexamethasone 
DL: drug loading  
DLS: dynamic light scattering 
DME: diabetic macular edema  
DR: diabetic retinopathy 
EE: entrapment efficiency  
ELISA: enzyme linked immunosorbent assays 
FT-IR: fourier-transform infrared spectroscopy  
GPC: gel permeation chromatography 
HTM: human trabecular meshwork cell 
IOP: intraocular pressure 
LDH: lactate dehydrogenase  
ME: macular edema  
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MW: molecular weight 
MYOC: myocilin 
NC: nanocarrier  
NNV: non-neovascular  
NP: nanoparticle 
NTA: nanoparticle tracking analysis  
NV: neovascular 
PB: pentablock  
PBG: pentablock gelling polymer 
PBS: phosphate buffer saline 
PEG: polyethylene glycol 
PDI: Poly dispersity index 
PCL: polycaprolactone  
PGA: polyglycolic acid  
PLA: polylactic acid  
PLGA: poly lactide-co-glycolide 
RPE: retinal pigment epithelium 
SC: schlemm's canal  
TM: trabecular meshwork 
UFLC: ultra-fast liquid chromatography 
VEGF: vascular endothelial growth factor 
XRD: X-ray diffraction analysis 
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India in 2008. Following completion of her degree, she joined Acropolis Institute of 
Pharmaceutical Education and Research, Indore, India as a lecturer.     
Vibhuti Agrahari joined the interdisciplinary Ph.D. program at the University of 
Missouri-Kansas City (UMKC) School of Pharmacy in Spring 2012. She is completing 
her Ph.D. research projects under the supervision of Dr. Ashim K. Mitra where she aimed 
to develop composite nanoformulations for sustained ocular delivery of macromolecules 
and steroid induced in vitro model for ocular hypertension/glaucoma. Vibhuti has 
presented her research works at various conferences, authored several peer reviewed 
papers and book chapters. She has received Quality by Design and Product Performance 
Focus Group Award (2016), Ocular Drug Delivery Disposition Focus Group Graduate 
Student Poster Awards (2014 and 2015) and American Association of Indian 
Pharmaceutical Scientists (AAiPS) Research Award (2014) at the AAPS annual 
meetings. She is the recipient of the AAPS Biotechnology Graduate Student Symposium 
Awards (2015 and 2016) at National Biotechnology Conferences. At UMKC, Vibhuti has 
received several awards, including Women‘s Council Graduate Assistant Fund (2014, 
2015, 2016, 2017), Ronald MacQuarrie Fellowship (2015), School of Graduate Studies 
Research Grant Proposal Award (2014 and 2015), Judith Hemberger Graduate 
Scholarship (2014), PFF Fellowship (2014-2016), Best Poster Award-Community of 
Scholar Symposium (2014), Best Speaker Award Fall 2014 seminar series; division of 
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pharmaceutical sciences, Best Poster Award at UMKC Research Summit (2016), Podium 
Presentation winner at UMKC Interdisciplinary Student Conference (2017) and Tony B. 
Academic Travel Award (2017) from Society of Laboratory Automation and screening 
(SLAS).     
Vibhuti is also a playing an active role in several professional organizations. She 
has contributed her services as a Chair of the AAPS-UMKC Student Chapter, President 
of the CRS-UMKC Student Chapter and President of the Graduate Student Council in 
2015-2016. She served as a secretary of the Interdisciplinary Doctoral Student Council 
(IDSC) Executive Board, Senator at the Student Government Association, and student 
representative of the Graduate Program Committee (GPC) at UMKC. Vibhuti chaired the 
community of scholar‘s symposium (2016) and co-chaired the PGSRM 2016 meeting 
hosted by the school of pharmacy, UMKC. She was student representative of the Student 
and Postdoctoral Outreach Committee (SPOD) and Ocular Drug Delivery Disposition 
Focus Group of the AAPS in 2014-2016. She is a member of several professional 
organizations such as the American Association of Pharmaceutical Scientists (AAPS), 
Controlled Release Society (CRS), and Association for Research in Vision and 
Ophthalmology (ARVO).    
Vibhuti received Graduate Student Professional Leadership Program Certificate 
(2015) from UM system. She holds a Graduate Certificate in College Teaching and 
Career Preparation (December 2016), Designing Courses for Significant Learning 
Certificate (2016), and Effective Teaching Practices Certificate Course (2015).       
 
 
